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Abstract 
Trop2 is a type 1 transmembrane protein regulating proliferation, cell cycle progression, 
migration and anchorage independent growth (Cubas et al., 2009), which was identified as a 
cell surface marker on a subpopulation of prostate basal cells with stem cell characteristics 
(Goldstein et al. 2008). Trop2 undergoes regulated intramembrane proteolysis and cleavage 
induces self-renewal and proliferative activity of prostate cancer (PCa) stem cells 
(Stoyanova et al. 2013). This study aimed to investigate the regulation of Trop2 processing 
by Protein Kinase C (PKC) isoforms. PKCs represent a family of serine-threonine kinases 
which show altered activation or expression in various forms of cancer.  PKCζ, an atypical 
PKC, is an important tumour suppressor and loss of function mutations in PCa have been 
identified, where it may regulate growth factor availability by proteolysis (Kim et al., 2013).  
My data showed that phorbol ester-induced activation of classical and novel PKCs resulted 
in ADAM17-mediated Trop2 cleavage and the release of full-length Trop2 containing 
ectosomes directly from the cell surface. In contrast, inhibition of atypical PKCζ caused 
internalization of Trop2 and its N-terminal cleavage in the endocytic compartment by 
ADAM10 and ADAM17, resulting in exosomal release of Trop2 fragments which remain 
connected via internal disulphide bridges.  
We described for the first time the existence of two pathways that lead to Trop2 processing 
at two distinct cleavage sites and that these cleavage events are differentially regulated by 
distinct PKC isoforms. We identified PKCζ as a novel major regulator of Trop2 function and 
showed that alternative Trop2 shedding occurs in PCa cells. This allows the examination of 
possible therapeutic intervention for PCa treatment, as well as investigations into whether 
heterogeneously released Trop2 ectodomains could be used as a novel marker in PCa 
diagnosis. 
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1. Introduction 
Cancer, or its medical term “malignant neoplasma”, describes a large group of different 
diseases which are all characterized by unregulated cell growth. This uncontrolled division 
and growth of cells leads to the formation of malignant tumours. They acquire invasive 
properties and initially invade nearby body parts before the disease progresses by spreading 
of cancer cells to more distant parts of the organism through the use of the lymphatic system 
or the bloodstream. Tumours can be classified as malignant or benign. Benign tumours are 
mostly harmless to the organism because they are not growing uncontrollably and lack the 
ability to spread and metastasize throughout the body. However, many benign tumours have 
the potential to become malignant. The development of cancer is a highly complex multistep 
process in which somatic cells obtain several biological abilities to transform into cancer 
cells. These hallmarks of cancer include sustained proliferative signalling, evasion of growth 
suppressors, apoptosis resistance, replicative immortality, inducible angiogenesis, 
reprogramming of energy metabolism, evading immune destruction and activation of 
invasion and metastasis (reviewed by Hanahan & Weinberg 2011). 
1.1 Prostate cancer 
Prostate cancer is the second most frequently diagnosed cancer in males worldwide and the 
sixth leading cause of cancer death in men. Incidence rates vary by more than 25-fold across 
the world showing the highest rates in developed countries, compared with developing 
countries (Parkin & Pisani 1999). According to data from Cancer Research UK, nearly 
36.000 men are diagnosed with prostate cancer in the United Kingdom every year, 
representing about one quarter of all new male cancer cases. The risk to develop prostate 
cancer is strongly related to age, with three-quarters of cases diagnosed in men aged 65 
years or older. The incidence rates rise sharply in men around the age of 50, with its peak in 
men aged 75 or older. Although many men may never have symptoms, post-mortem data 
showed that more than 80 % of males have developed prostate cancer at the age of 80 
(Bostwick, David, Eble 2008). Due to the fact that prostate cancer is in most cases slowly 
growing and symptom-free many men rather die with the disease than from it. Next to age, 
there are also considerable racial disparities in prostate cancer risk. In the United States 
African-American men have the highest risk to develop prostate cancer with a 60 % 
increased incident rate and a 2.4 fold higher mortality rate compared to Caucasian men 
(Jemal et al. 2008). In the Caribbean, males of African descent show the highest prostate 
cancer mortality rates in the world. The reason for this could be additional African-ancestry 
associated regions on chromosomes harbor potential prostate cancer susceptibility loci 
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(Bock et al. 2010). Another significant known risk factor is family history. Men with first-
degree family members diagnosed with prostate cancer seem to have a 2-fold higher risk of 
getting the disease compared to men without any cases in the family. Furthermore, the risk 
for men with an affected father is lower than with an affected brother (Zeegers et al. 2003). 
The human prostate itself is a small gland located within the lower pelvis surrounding the 
urethra, the tube that connects the bladder to the genitals. Its primary function is the 
secretion of an alkaline fluid as part of the ejaculate, which provides motility and 
nourishment to sperm (Turner 2010). The prostate gland is anatomically divided into four 
distinct glandular regions (peripheral, central, transition and fibromuscular zone) with the 
peripheral zone comprising 75 % of the gland. In high age, the prostate can grow in size 
leading to benign prostate hyperplasia (BPH), which is one of the most common conditions 
in men associated with ageing (Verhamme et al. 2002). It can cause urinary hesitancy, 
painful urination and increased risk of urinary tract infections, but does not lead to cancer or 
increases the risk of cancer. BPH originates usually in the transition zone of the gland, 
whereas 70-80 % of prostate cancers arise from the peripheral zone (Applewhite et al. 2001).  
One critical component of the ejaculate is the prostate-specific antigen (PSA). PSA is a 
serine protease of the Kallikrein protease family and is primarily produced in the prostate. Its 
main function is the cleavage of semenogelin I and II in the seminal coagulum, in order to 
liquefy the semen which allows sperm cells to swim freely (Balk, 2003). However, the major 
relevance of PSA is its use as a biomarker in prostate cancer diagnosis. Although prostate 
cancer cells produce smaller amounts of PSA than normal cells, elevated PSA levels can be 
associated to cancer. The reason for this is thought to be found in the disruption of the 
prostate architecture in tumours, resulting in the release of PSA into the bloodstream to 
increase serum PSA levels up to 10
5
 fold (Lilja et al. 2008). The PSA test was introduced 
into clinical practice in the early 1980s, in order to allow earlier detection of the asymptotic 
disease. In healthy men, PSA is present in the blood at very low levels in a range from 0 to 4 
ng/ml. PSA levels above 4 ng/ml might suggest the presence of prostate cancer and it is 
recommended that an additional prostate biopsy should be performed to aid diagnosis 
(Catalona 1991). Unfortunately, prostate cancer is not  always associated with an increased 
concentration of PSA leading to false negative test results (Chochrad et al. 2010). In 
addition, elevated serum PSA can also be caused by other nonmalignant conditions, such as 
prostatitis, irritation, BPH and chronic inflammation (Nadler et al. 1995). Other factors 
influencing PSA levels are ejaculation, body weight, carbohydrate intake and insulin 
resistance (Herschman et al. 1997; Parekh et al. 2008). This leads to the conclusion, that the 
PSA test is still useful tool in prostate cancer diagnosis, but due to several disadvantages and 
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flaws indicated above there is urgent need of more accurate molecular markers (Bradford et 
al. 2006).  
Additional to PSA testing, screening for prostate cancer is often performed by digital rectal 
examination (DRE). Size, shape and texture of the prostate are checked manually by an 
examiner inserting a gloved and lubricated finger into the rectum of the patient. Irregularities 
like hard or clumpy areas, could indicate the presence of tumours and prompt a 
recommendation for further evaluation. DRE only examines the back of the prostate where 
85 % of prostate cancers arise and therefore, can lead to false negative results in some cases 
(Chodak & Keller 1989). 
Detection of elevated PSA levels or abnormal DRE results is typically followed up by a 
prostate biopsy to assess the potential presence of cancer. This is performed with special 
biopsy gun which is inserted into the rectum using hollow-core needles to remove a small 
tissue sample from the gland. The sample is then histopathologically graded. In prostate 
cancer diagnosis, the Gleason Scoring system developed in the 1960s (Mellinger, Gleason 
1967) is used most commonly. It grades the two largest areas in the biopsy specimen based 
on the most prevalent histological pattern of arrangement of carcinoma cells. There are five 
basic grades in the Gleason system (Figure 1.1) ranging from 1 to 5, with 1 being the least 
aggressive and 5 representing the most aggressive. To generate a histological score, the 
primary grading pattern (predominant in the area) and the secondary grade pattern (second 
the most common) are added together. Patients with high Gleason scores show mostly more 
aggressive tumours with a poor prognosis, whereas men with low-grade diseases are more 
likely to live with a symptom-free prostate adenocarcinoma. Being directly related to the 
pathological stage of the cancer, the Gleason score represents a strong predictor of clinical 
outcome (Humphrey 2004). 
In order to work properly, the male prostate gland is highly dependent on circulating male 
hormones, known as androgens, which include both testosterone and dihydrotestosterone. 
Proliferation and differentiation of prostate cells requires the presence of androgens and their 
absence leads to apoptosis (Colombel et al. 1992). Androgens are lipid-soluble and can 
diffuse freely from the blood into the cytoplasm of target cells. After passing the cell 
membrane, they bind to the androgen receptor (AR), a steroid-hormone binding protein 
which is part of the nuclear receptor superfamily. Nuclear receptors have three functional 
domains which are the N-terminal transactivation domain, the central DNA-binding domain 
and the C-terminal ligand binding domain (LBD) (Lu et al. 2006b). The main function of the 
AR is the regulation of gene expression as a transcription factor (Mooradian, Morley 1989). 
In the absence of ligands, AR is sequestered in the cytosol where bound to chaperons 
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stabilize and protect the receptor from degradation. Ligand binding induces a conformational 
change leading to dissociation from the chaperons, formation of a homodimer and 
phosphorylation of several serine residues. The androgen-AR complex then translocates into 
the nucleus and binds to specific androgen-response elements in the promoter regions of 
target genes (Edwards & Bartlett 2005). One of the target genes which are transcriptionally 
regulated by androgens is PSA (Riegman et al. 1991). 
 
Figure 1.1: Gleason grading patterns. Original drawing (Mellinger, Gleason 1967) 
Prostate adenocarcinoma also depends strongly on androgens, due to their interaction with 
the AR and the resulting activation of signalling pathways. One treatment of prostate cancer 
is the deprivation of androgens by surgical or chemical castration, leading to cancer 
regression. However, androgen depletion is often followed by the development of hormone-
refractory prostate cancer, where tumour cells have gained the ability to grow in the absence 
of androgens. Interestingly, these androgen-independent tumours are still expressing AR as 
well as target genes like PSA (Gregory et al. 1998), which implies an adaption to an 
alternative restoration of the pathway. Apparently, castration-resistant cancer cells seem to 
stay dependent on AR signalling even without its ligand. The activation of AR in the 
absence of androgens could be caused by several mechanisms, i.e. amplification of the AR 
gene copy number (Visakorpi et al. 1995), hypersensitivity of the AR (Gregory et al. 2001), 
expression of a constitutively active AR variant lacking LBD (Guo et al. 2009), or mutation 
of the LBD changing the receptor substrate specificity (Fenton et al. 1997). Other studies 
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have shown that alternative AR activation could occur through activation by non-steroidal 
growth factors, like insulin growth factor (IGF1), epidermal growth factor (EGF), human 
epidermal growth factor receptor 2 (HER2) and mitogen activated protein kinase MEKK1 ( 
Culig et al. 1994; Abreu-Martin et al. 1999). Therefore, development of castration-resistant 
prostate cancer cells may depend on different factors in each case, as several additional 
existing mechanisms have been described above which explain androgen-independent 
growth (Vis & Schröder 2009).  
As already mentioned, androgen ablation therapy leads with high frequency to emerging 
androgen-independent tumours and subsequently to widespread metastasis into other body 
parts, particularly bones and lymph nodes. The exact mechanisms responsible for the 
development of castration resistance remain unclear. One theory addressing this issue is the 
concept of a small subpopulation of cancer cells with stem-cell like abilities, which are able 
to maintain the tumour and give rise to a progeny of androgen-refractory cancer cells. 
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1.2 Cancer stem cells (CSC) 
The CSC model evolved over the last years and proposed the concept that tumours are 
sustained by their own stem cells. This is one of two main theories (Figure 1.2A) that try to 
explain cancer growth and maintenance that are still poorly understood. Based on 
histological observations of a high degree of phenotypic heterogeneity among tumours 
(Roudier et al. 2003), this model describes a hierarchical organization of cancer cells with 
CSCs on top of the lineage hierarchy, as the CSCs have the ability of indefinite self-renewal. 
It is argued that CSCs behave like normal stem cells and undergo an epigenetic program into 
differentiation, resulting in the phenotypically diverse mass of cells which form the tumour 
bulk. As the vast majority of these cells are not contributing to cancer progression, it is 
thought that with the epigenetic changes comes an irreversible (or rarely reversible) loss of 
tumourigenicity (Reya et al. 2001; Marotta & Polyak 2009; Rosen & Jordan 2009; 
Shackleton et al. 2009). If this is the case, it would make these rare CSC subpopulations a 
promising target for new effective cancer treatments.   
In the stochastic (clonal) evolution model (Figure 1.2B), tumour growth is explained in a 
different way. It argues that most of the cells within a tumour have different epigenetic 
properties, with each cell choosing randomly between self-renewal and differentiation. This 
would result in an unorganized system in which any cell would have the same intrinsical 
potential to contribute to tumour progression. Clones with therapy resistances or distinct 
growth advantages could randomly arise in the population promoting the malignant 
evolution of the tumour (Marotta & Polyak 2009; Rosen & Jordan 2009; Shackleton et al. 
2009). Therefore, it would be essential to eliminate almost all cancer cells to achieve a 
successful treatment. These two models are not necessarily mutual exclusive and could 
apply to different stages of tumour development or to different kinds of cancers. Co-
existence of more than one type of CSCs could imply that tumours can follow the CSC 
model and might as well undergo clonal evolution through environmental selection of CSCs 
(Barabé et al. 2007; Marotta & Polyak 2009). 
To this day, the CSC model is controversial because definite proof of CSCs in human 
tumours has not been found. Insofar, CSCs are defined in practical terms through the use of 
functional assays. The most established method includes the isolation of primary tumour 
cells by flow-sorting and the subsequent xenotransplantation of these populations into 
immunodeficient mice. If these subpopulations are then able to initiate tumour formation in 
the animal, they are classified as CSCs. The first identified CSCs were CD34
+ 
/CD38
-
 cells 
in acute myeloid leukemia (Lapidot et al. 1994) and subsequent examination of solid 
tumours led to the identification of candidate CSC populations in breast(CD44
+
 CD24
-
 Lin
-
), 
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brain (CD133
+
) and colon cancers (CD133
+
) (Al-Hajj & Wicha 2003; Singh et al. 2004; 
Ricci-Vitiani et al. 2007; O’Brien et al. 2007). Although these results suggest the existence 
of CSCs in solid tumours, the scientific community still remains unconvinced. It is argued 
that it is not possible to exactly mirror natural cancer growth in the complex 
microenvironment of solid tumour cells using the xenotransplantation system (Hill 2006). 
 
Figure 1.2: Concept of CSC and clonal evolution model 
 (A) CSC model: The tumour population is phenotypically heterogeneous, but new tumour 
formation as well as heavy proliferation is restricted to cancer stem cells. (B) Clonal 
evolution model: The tumour population is phenotypically heterogeneous and most cells 
proliferate extensively with the ability to form new tumours. 
It is important to distinguish the concept of CSC from cells of origin (CO) for cancer, which 
are normal tissue cells that undergo events that initiate tumourigenesis. A logical candidate 
for a CO is a normal adult stem cell maintaining its capability to self-renew and the ability to 
initiate a lineage hierarchy. However, COs could also arise from downstream progenitor 
cells or even terminally differentiated cells, through acquirement of stem cell-like properties 
over the course of oncogenic transformation. Leukemia, for example, can be initiated 
through hematopoietic stem cells, as well as progenitor cells (Cozzio et al. 2003; Huntly et 
al. 2004). 
Stem cells have long been implicated in prostate gland formation. Cycling of the prostate 
between regression and regeneration, following androgen deprivation or testosterone 
replacement, can occur more than 30 times and implies the existence of a long-term resident 
pool of putative castration-resistant prostate stem cells (Isaacs 1986; Sugimura et al. 1986). 
These stem cells are capable to differentiate into at least three distinct types of prostate cells 
(Figure 1.3), which can be distinguished by function, location and cellular markers. 
Localized in the basal layer of the prostate are basal cells that express high molecular-weight 
cytokeratins (CKs) 5 and 14, p63 which is involved in stem cell maintenance and 
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differentiation (Grisanzio 2008), as well as bcl-2 and c-Met, which are known to be 
regulators of cell survival and invasive growth (van Leenders et al. 2003). Neuroendocrine 
cells are also localized in the basal layer and represent the rarest cell type in the prostate 
epithelium. They show an irregular expression pattern with some cells expressing basal cell 
CKs and others co-expressing PSA and endocrine markers, such as synaptophysin and 
chromogranin A. Column-like luminal cells are located in the luminal layer of the prostate 
and are characterized by expression of low-molecular weight CKs 8 and 18, as well as AR 
and PSA (Abate-Shen 2000; Shen & Abate-Shen 2010). 
 
Figure 1.3: Schematic of the prostate epithelium consisting of three different cell types 
Prostate epithelium harbours basal, luminal and neuroendocrine cells. The luminal layer 
consists of column-like luminal cells atop of basal and neuroendocrine cells, which are in 
direct contact with the basement membrane forming the basal layer of the epithelium. 
In androgen deprivation studies, basal cells showed preferential survival and therefore, it is 
believed that the basal layer most likely harbours prostate stem cells (Isaacs 1986). This is 
supported by the fact that knockout mice lacking the basal cell marker p63 are not 
developing a prostate (Signoretti et al. 2000) and that luminal secretory cells originate from 
p63
+
 basal progenitor cells (Signoretti et al. 2005). It was also recently shown that basal cells 
could be potential COs of prostate cancer indicating the cellular origin must not necessarily 
correlate with histological characteristics of the tumour (Goldstein et al. 2010). Implantation 
of fetal urogenital sinus tissue from p63
-/-
 mice into immunodeficient mice led to formation 
and regeneration of prostate tissue in the absence of basal cells, outlining that not all basal 
cells might be stem cells (Kurita et al. 2004). 
It is possible that stem cells contribute to castration-resistant prostate cancer due to similar 
characteristic properties, such as low expression levels of AR. Androgen ablation therapy 
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reduces the bulk of differentiated prostate cancer cells, which consists of androgen-sensitive 
luminal cells. This often leads to the progression to hormone-refractory prostate cancer. The 
development of androgen-insensitive cancer cells is widely considered to be achieved by 
cancer cells through inheritance, rather than to be acquired as a new trait (Isaacs et al. 1982; 
Gingrich et al. 1997; Craft et al. 1999). The hypothesis is further supported through the 
identification of castration-resistant prostate cancer cells within the basal layer that express 
stem cell genes (Signoretti et al. 2005).  This could implicate a model in which AR
-
 prostate 
stem cells located in the basal layer of the tumour are able to resist androgen ablation 
therapy. These cells would remain active in castration-resistant forms of prostate cancer and 
drive regrowth of an AR resistant tumour. 
To date, it is not fully proven that prostate CSCs arise from normal stem cells. One way to 
investigate this matter is through purification of CSCs using markers from normal stem 
cells, as both cell populations should share common marker proteins. This approach was 
successful for brain, breast, lung and other cancer types by identification of CSC 
subpopulations with stem cell phenotypes (Al-Hajj & Wicha 2003; Singh et al. 2004; Kim et 
al. 2005). Analysis of primary human prostate cancer led to the identification of a population 
of putative CSCs through stem cell markers (CD44
+/α2β1high/CD133+), that are used to 
describe prostate epithelial stem cells. These cells displayed a AR
-
 basal cell phenotype, in 
combination with a high proliferation potential and the ability to differentiate into AR
+
 cells 
(Collins et al. 2005). Furthermore, the Tang laboratory identified a population of 
CD44
+/α2β1high cells in prostate cancer with higher intrinsical tumourigenicity than their 
CD44
-
 counterparts. Small fractions of these cells showed the ability of asymmetric division, 
which is an attribute of slow-cycling stem cells (Patrawala et al. 2007).  
Another yet unanswered question is the origin of prostate cancer. It has so far been shown 
that prostate tumours can arise from both luminal and basal cells. Tumours with basal 
origins were consistently more aggressive than those who had a luminal progenitor. The 
Cre-induced inactivation of the phosphatase and tensin homolog (PTEN) tumour suppressor 
gene in prostate basal stem cells resulted in the development of neoplasia (Wang et al. 2006) 
whereas PSA-driven deletion of PTEN in luminal cells only led to hyperplasia (Korsten et 
al., 2009). In an experiment performed by the Witte group, distinct subpopulations of 
prostate luminal cells, stromal cells and basal stem cells were isolated using flow cytometry. 
These cells were exposed to various oncogenic stimuli, such as fibroblast growth factor 
(FGF) activation, ETS-related gene-1 expression or phosphoinositid-3 kinase (PI3K) 
signalling, with the result that prostate basal stem cells showed a greater capacity for tumour 
initiation than luminal cells. Additionally, basal stem cells were also able to create luminal-
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like disease. Luminal cells on the other hand were unable to initiate basal stem cell-like 
disease (Lawson et al. 2010). 
In conclusion, it is highly likely that basal cells of the prostate epithelium, due to their stem 
cell-like regenerative abilities, might play an important role in the development and 
maintaining of prostate cancer. It is not fully understood if the majority of basal cells show 
stem cell characteristics or if it is only represented by a small subset of cells in the basal 
layer. Recent studies from the Witte laboratory identified tumour-associated calcium signal 
transducer 2 (TACSTD2/Trop2), as a marker which can functionally discriminate two 
subpopulations of basal cell (Goldstein et al. 2008). Prostate specific microarray analysis 
showed a 20-fold enrichment of Trop2 in the murine prostate after castration and a 12-fold 
enrichment in prostate sphere cells, compared with the total epithelium (Wang et al. 2007). 
Localization in the region of the gland proximal to the urethra and its accumulation in 
sphere-forming cells labels, Trop2 is a cell surface marker candidate gene for cells with 
stem-like characteristics. Goldstein et al. showed that only a small proportion of basal cells 
are Trop2 positive and that the high Trop2 expression level of a subpopulation of basal cell 
correlates with elevated stem cell like activity in vitro and in vivo. They also showed that 
Trop2 expression was significantly increased during tumourigenesis (Goldstein et al. 2008). 
Epithelial cell adhesion molecule (EpCAM), a Trop2 paralogue, is already known as a 
cancer stem cell marker (Dalerba et al. 2007) and is a therapeutic target in a variety of 
epithelial cancers. Therefore, it is likely that Trop2 and EpCAM share similar functions in 
tumours. So there is evidence that Trop2 could either be a novel marker for potential 
prostate CSCs or play another important role in the development and progression of prostate 
adenocarcinoma. Both would point out Trop2 as a promising target for further 
investigations. 
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1.3 The TACSTD gene family: EpCAM and Trop2 
The TACSTD gene family is composed of two genes, TACSTD1 encoding EpCAM and 
TACSTD2 encoding Trop2, which are closely related and highly conserved with 
approximately 50% of sequence identity (Linnenbach et al. 1993; Sewedy et al. 1998). Gene 
mapping revealed the location of TACSTD1 on chromosome 2p21, whereas TACSTD2 is 
located on chromosome 1p32 (Calabrese et al. 2001). TACSTD1 consists of nine exons and 
introns (Linnenbach et al. 1993) and although large numbers of carcinoma cell lines were 
screened for splice variants of the genes, none were found (Balzar et al. 1999). In contrast, 
TACSTD2 encodes an intronless gene product which originates from exon shuffling and the 
retrotransposition of the TACSTD1 gene through an mRNA intermediate (Linnenbach et al. 
1993).  
 
Figure 1.4: Schematic domain comparison of Trop2 with EpCAM 
EpCAM and Trop2 are both type I surface glycoproteins, with a hydrophobic signal 
sequence (EpCAM AAs: 1-24; Trop2 AAs: 1-26), an extracellular domain (EpCAM AAs: 1-
265; Trop2 AAs: 1-274), one transmembrane domain (EpCAM AAs: 266-288; Trop2 AAs: 
275-297); and a short cytoplasmic tail (EpCAM AAs: 289-314; Trop2 AAs: 298-323). 
Localized in their ECD, both proteins possess a EGF-like domain (EpCAM AAs: 27-59; 
Trop2 AAs: 34-66) and a TY-repeat domain (EpCAM AAs: 66-135; Trop2 AAs: 73-145). 
Abbreviations used: SS = signal peptide, TM = transmembrane domain, ICD = intracellular 
domain. 
EpCAM and Trop2 are both type I transmembrane glycoproteins localized at the cell 
surface, with nearly the same size (EpCAM: 314 amino acids (AAs); Trop2: 323 AAs). 
They share homologous sequence elements and show the same domain organization of a 
hydrophobic signal peptide, a long extracellular domain (ECD), one transmembrane domain 
(TM) and a short cytoplasmic tail (Figure 1.4). Both proteins contain an EGF-like repeat 
localized in the ECD. The EGF-like domain is defined by six cysteine residues spread over a 
sequence of 35 to 45 AAs and can be subclassified into three major groups of type I, II and 
III repeats (Appella et al. 1988; Davis 1990). They are shared by many functually different 
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proteins, such as growth factors, extracellular matrix components, plasma proteins and cell 
adhesion molecules (CAMs) (Appella et al. 1988; Davis 1990; Artavanis-Tsakonas et al. 
1995). EpCAM harbours a type II EGF-like domain responsible for the formation of 
EpCAM mediated homophilic adhesions, such as the accumulation of EpCAM molecules at 
cell-cell boundaries (Balzar et al. 2001). It remains unknown, if the type II EGF-like repeat 
of Trop2 has the same function.  
Another domain localized in the ECD of the TACSTD family is a thyroglobulin (TY) type-
1A repeat domain. TY-repeats were originally identified as cysteine-rich motifs, organized 
into 10 tandem repeat units in the N-terminal part of thyroglobulin (Mercken et al. 1985; 
Parma et al. 1987). They are divided into two subgroups, type-1A repeats with six cysteine 
residues and type-1B repeats with four conserved cysteine residues (Molina et al. 1996). TY-
repeats in several functionally unrelated proteins have been shown to act as diverse 
inhibitors of cathepsins, a family of cysteine proteases frequently expressed by tumour cells. 
The exact mechanism remains elusive, but it is speculated that amino acid residue insertions 
of variable length at the contact regions of TY-repeat may determine the ability to bind and 
inhibit a cathepsin (Mihelic & Turk 2007). Therefore, a conceivable role of the EpCAM or 
Trop2 TY-repeat might be the protection of tumour cells from their own secreted cathepsins 
during metastasis. 
1.3.1 EpCAM 
EpCAM function and its role in cancer cells were intensively studied over the last decade. 
Healthy individuals express EpCAM in their epithelium, except squamous epithelium and 
some specific epithelial cell types, such as hepatocytes and keratinocytes (Winter, 
Nagtegaal, et al. 2003). Originally EpCAM was discovered in colon cancer (Herlyn et al. 
1979) but most human carcinomas overexpress this protein to varying degree (Went et al. 
2004). The prognostic and diagnostic significance of EpCAM has been shown in many 
independent studies (reviewed by Went et al., 2004 and 2008) and its characteristic 
overexpression in tumour cells led to several promising antibody- or vaccine-based clinical 
trials (Baeuerle & O Gires 2007). In addition, EpCAM has been recently identified as a 
marker for cancer-initiating stem cells (Visvader & Lindeman 2008). All in all, EpCAM 
represents one of the most frequently and most intensely expressed tumour-associated 
antigens known. 
As for its role as an oncogene, several EpCAM involving mechanisms have been described 
so far, including the loosening of cell-cell adhesions through interference of E-cadherin 
mediated adhesion, by disrupting  the link between α-catenin and F-actin (Winter, 
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Nagelkerken, et al. 2003). EpCAM association with claudin-7 leads to abrogation of 
EpCAM-mediated homophilic cell-cell adhesion and results in increased cell proliferation, 
motility, survival, carcinogenesis and formation of metastasis (Nübel et al. 2009). 
Intramembrane proteolysis of EpCAM releases its ICD into the cytoplasm, where it becomes 
part of a transcriptional complex inducing expression of cell cycle progression genes, such 
as c-myc and cyclins A and E (Maetzel et al. 2009). The role of EpCAM as an oncogene is 
further supported by the fact that its overexpression in different types of cancer is highly 
associated with reduced overall patient survival (Spizzo et al. 2004; Brunner et al. 2008; 
Fong, Steurer, et al. 2008;). 
Surprisingly EpCAM can also act as a tumour suppressor which is thought to be based on 
his ability to not only disturb but also promote homophilic adhesive interactions (Litvinov et 
al. 1994). Therefore EpCAM could act as an inhibitor of cell scattering and invasion due to 
its adhesive properties (Basak et al. 1998; Litvinov et al. 1994). Indeed, other studies 
showed that in colorectal carcinoma loss of membranous EpCAM  led to increased 
migratory potential (Gosens et al. 2007) and that metastatic renal epithelial cancers were 
expressing lower amounts of EpCAM, compared to the primary tumour (Went et al. 2005). 
This is additionally supported by the findings that for esophageal, gastric and squamous cell 
carcinoma EpCAM overexpression was associated with improved patient survival (Ensinger 
et al. 2006; Hwang et al. 2009; Kimura et al. 2007; Songun et al. 2005). 
1.3.1.1 EpCAM signalling mechanism 
One important step towards clarification of the direct promoting role of EpCAM in 
carcinogenesis was its discovery as a signal transducer, after undergoing regulated 
intramembrane proteolysis (RIP). RIP represents a mechanism that cells have developed to 
communicate with their environment and to adapt to changes in the extracellular space 
(Brown et al. 2000; Lichtenthaler & Steiner 2007). It is required for signal transduction and 
influences several cellular processes, such as cell adhesion, differentiation, stress response, 
transcriptional regulation or lipid metabolism; and is crucial for the proper functioning of 
physiological processes like embryonic development, as well as for immune and nervous 
system functions (reviewed by Lichtenthaler 2011). Until now, more than 60 protein 
substrates of RIP proteases where identified including cytokines, receptors, cell adhesion 
proteins, growth factors and viral proteins (reviewed by Edwards et al. 2008; Freeman 2009; 
McCarthy et al. 2009; Willem et al. 2009). In the process of RIP, EpCAM is cleaved by 
tumour necrosis factor-α-converting enzyme (TACE/ADAM17) within its ectodomain close 
to the transmembrane domain (TM), which results in the release of EpECD from the cell 
surface (Maetzel et al. 2009). The remaining membrane-bound EpICD is then cleaved by a 
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γ-secretase complex containing presenilin 2 (PS-2) within its transmembrane domain, 
releasing the ICD into the cytoplasm, where it is either degraded or functions as a signalling 
molecule (Maetzel et al. 2009).  
However, recent studies identified several distinct cleavage sites in both transmembrane and 
ectodomain of EpCAM. Schnell et al. uncovered four novel EpECD fragments showing that 
EpCAM is cleaved at multiple positions within its ectodomain by yet unknown proteases. 
Shedding of EpCAM via different pathways may account for the multiple functions of the 
protein and could represent a novel regulatory mechanism. In addition, Hachmeister et al. 
revealed the existence of five distinct cleavage sites within the transmembrane domain of 
EpCAM. The resulting EpICDs showed differential stability and only one out of the five 
fragments was stable enough to be detected in untreated cells (Hachmeister et al. 2013). 
Similar processing was demonstrated for the Notch receptor, where the stability of Notch-
ICDs impacted on the signalling capacity of the receptor (Tagami et al. 2008). These 
findings indicate that regulation of EpCAM signalling might be more complex than 
previously assumed. 
The function of soluble EpECD released by RIP is still unknown, but treatment of cells with 
recombinant EpECD resulted in EpCAM cleavage indicating that it might provide an auto- 
and paracrine activation signal for shedding (Maetzel et al. 2009). EpICD associates in the 
cytoplasm with the adaptor protein FHL2 (four and a half LIM domain protein), β-catenin 
and the transcription factor Lef-1. This leads to the formation of a transcriptional complex, 
which translocates into the nucleus and induces the transcriptional activation of cyclin A and 
E, c-myc and other target genes involved in cell cycle progression, growth and  proliferation 
(Figure 1.5) (Münz et al. 2004; Maaser & Borlak 2008;). EpCAM has been shown to 
interfere with E-cadherin mediated cell adhesion via interaction with active PI3 kinase, but 
the exact mechanism remains unknown (Winter et al. 2007). However, it could be possible 
that EpCAM mediated E-cadherin inhibition could increase the cellular level or localisation 
of β-catenin, in order to increase its signalling capacity. Studies have shown that EpICD 
expression is turmorigenic. Immunodeficient mice injected with HEK293 cells expressing 
either EpICD or full-length EpCAM generated large tumours in 100 % of animals, whereas 
only one out of eight injected mice of the control group developed a small tumour (Maetzel 
et al. 2009).  
Furthermore, a recent publication revealed an interesting connection between EpCAM and 
members of the novel protein kinase C (PKC) family. Maghzal et al. showed that EpCAM 
acts as a potent inhibitor of PKCδ and PKCη in both embryo and cancer cells. This 
inhibition is caused by a short motif in the EpICD that resembles the pseudosubstrate 
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inhibitory domains of PKCs and binds both novel isoforms with high affinity. The study 
further revealed similar motifs in other transmembrane cell adhesion molecules, including 
EpCAM homologue Trop2; and proposes that direct inhibition of PKC by EpCAM 
represents a novel mode of signal transduction regulation (Maghzal et al. 2013). 
 
Figure 1.5: Schematic of EpCAM signalling through RIP 
EpCAM is cleaved trough RIP in two sequestered events. TACE/ADAM17 mediated 
cleavage releases EpECD into the extracellular matrix, where it may act as an auto- and 
paracrine activation signal. Subsequent cleavage by PS-2 releases EpICD into the cytoplasm, 
where it forms a multiprotein complex together with FHL2, β-catenin and Lef-1. The 
complex translocates into the nucleus and activates EpCAM target genes, such as c-myc and 
cyclins. Owing to its ability to inhibit E-cadherin-mediated adhesion, EpCAM provides itself 
with β-catenin to increase its signalling capacity. 
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1.3.2 Trop2 
Trop2 derived its name from its high expression level in trophoblasts (Lipinski et al. 1981), 
which are invasive cells of the placenta, forming the outer layer of the blastocyst. In a 
locally controlled environment, trophoblasts penetrate uterine blood vessels and stroma to 
displace endothelial and smooth muscle cells in order to establish vascular interactions with 
the maternal blood supply (Bischof et al. 2001; Knöfler et al. 2008). The biological function 
of Trop2 is not well defined and despite a high percentage of conserved sequence homology, 
it seems to have its own unique functional characteristics, compared to EpCAM. Loss of 
function mutations in Trop2 lead to gelatinous drop-like corneal dystrophy, a rare autosomal 
recessive disorder, characterized by formation of amyloid aggregates in the cornea, leading 
to blindness (Weber & Babel 1980). Most common is a Q118X stop mutation, causing 
perinuclear localization of the misfolded protein (Tsujikawa et al. 1999). There is evidence 
that at least in the cornea, Trop2 might be responsible for epithelial barrier maintenance and 
proper subcellular localization of tight junction proteins, claudin 1 and 7 (Nakatsukasa et al. 
2010). Recent in vivo studies established a functional link between Trop2 and mesenchymal 
stem cells (MSC), where Trop2 is expressed exclusively in the membrane. Yang et al. 
described that proliferation of MSCs in Trop2-deficient mice was decreased with prolonged 
cellular doubling time and reduced cell numbers entering the S Phase. Additionally, Trop2 
deficiency impaired the differentiation of MSCs by reduction of adipogenesis and 
osteogenesis (Yang et al. 2013). Other studies have suggested Trop2 as a regulator of fetal 
lung cell development through the ERK signalling pathway. Increased TROP2 gene 
expression has been associated with proliferation and motility of fetal lung fibroblasts in 
vivo and its knockdown led to altered cell morphology and abnormal localization of 
components of the cell migration apparatus (McDougall et al. 2011; McDougall et al. 2013). 
Potentially, some of these characteristics may be obtained by cancer cells overexpressing 
Trop2. 
All in all, Trop2 seems to be highly associated with cancer and tumour aggressiveness. 
Trop2 is  overexpressed in various types of human epithelial carcinomas, including ovarian 
(Bignotti et al. 2010), colorectal (Ohmachi et al. 2006), pancreatic (Fong, Moser, et al. 
2008), gastric (Mühlmann et al. 2009), lung (Jiang et al. 2013); and squamous cell 
carcinoma of the oral cavity (Fong et al. 2008). Recent publications have linked elevated 
Trop2 expression levels to bad patient outcome in non-epithelial tumours, such as gliomas 
(Ning et al. 2013) and extranodal NK/T cell lymphoma (Chen et al. 2013). Trop2 
overexpression in prostate cancer cells has been reported to correlate with their 
aggressiveness and to inhibit cell adhesion to fibronectin (Trerotola, Li, et al. 2012b). This 
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leads to increased metastatic dissemination of prostate cancer cells in vivo, which is 
promoted by Trop2 through modulation of integrin β1 functions (Trerotola et al. 2013). 
Overexpression studies identified Trop2 as an oncogene with the ability to induce oncogenic 
transformation in pancreatic or 3T3 cells, ERK1/2 phosphorylation, migration, colony 
formation and anchorage-independent growth (Wang et al. 2008; Cubas et al. 2010;). In 
patients suffering from cervical cancer, Trop2 overexpression is associated with poor 
prognosis and it was shown that proliferation and invasiveness of  cervical cancer cells is 
promoted by Trop2 through regulation of the ERK signalling pathway (Liu et al. 2013). 
Systematic screenings showed that Trop2 is upregulated in most human tumours and that 
this upregulation quantitatively stimulates human cancer growth in vitro and in vivo 
(Trerotola et al. 2012). However, Trop2 expression was also shown in most differentiated 
normal human adult tissue (Stepan et al. 2011; Trerotola et al. 2012). Therefore, 
development of therapeutic agents requires special strategies to target Trop2 only in 
tumours, in order to minimize potential toxic effects on healthy tissue. However, Trop2, like 
EpCAM, might play a dual role in cancer. Experiments with a viable Trop2
-/-
 knock-out 
mice demonstrated that Trop2 loss led to increased tumourigenesis and promoted the 
mesenchymal transdifferentiation in a subset of squamous cell carcinomas (Wang et al. 
2011). Another study showed Trop2 downregulation in lung adenocarcinoma through DNA 
hypermethylation in its promoter region. Lin et al. suggest that Trop2 could act as a tumour 
suppressor in lung cancer, through attenuation of IGF-1 receptor activation through direct 
binding of IGF-1 via its TY-domain (Lin et al. 2012). In addition, a recent study showed that 
membrane-associated Trop2 had an unfavourable impact on breast cancer patient survival, 
whereas activated intracellular Trop2 showed a positive impact on both patient survival and 
disease recurrence (Ambrogi et al. 2014).  
Little is known about the regulation of Trop2 expression. It has been shown that the 
promoter region of TACSTD2 contains TCF/Lef-transcription factor binding sites, which 
would make it likely to be regulated by Wnt signalling (Segditsas et al. 2008). Hence, a most 
recent study analysed the expression profile of Trop2-linked transcription factors in human 
cancers and revealed that Trop2 expression depends on a highly connected network of 
multiple transcription factors, which were expressed in either ubiquitous or 
histotype-specific cancer cells (Guerra et al. 2012). 
There is evidence that Trop2 is a signal transducer, but in order to identify its ligands and 
specific signalling pathways, there is need for further investigation. Trop2 might act as a 
calcium signal transducer, since clustering on the cell surface with monoclonal antibodies 
caused a rise of intracellular Ca
2+
 levels (Ripani et al. 1998). Furthermore, although the exact 
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mechanism remains unclear, it has been shown that Trop2 upregulation activates cyclin D1 
and ERK/MAPK pathways (Cubas et al. 2010) which are known to drive the expression of 
regulatory down-stream effectors of cancer growth, such as CREB, Jun, NFκB, Rb, STAT1 
and STAT3 (Haura et al. 2005; Siu & Jin 2007; Burkhart & Sage 2008; Shaulian 2010; Ben-
Neriah & Karin 2011). Despite the lack of enzymatic domains, the short cytoplasmic tail of 
Trop2 seems to play an important role in the signalling capacities of the protein. It contains a 
PIP2-binding motif (Figure 1.6), which is often present in signal transducers and can act as a 
docking site for regulatory molecules, such as G-proteins, kinases, ankyrins or kinesins 
(Alberti 1998; Alberti 1999; Segditsas et al. 2008). In addition, the Trop2-ICD contains a 
conserved serine phosphorylation site at position 303 (Ser
303
), which can be phosphorylated 
by protein kinase C (PKC) and is required for the stimulatory tumour growth capacity of 
Trop2 (Basu et al. 1995). Underlining the significance of the intracellular domain, Trop2- 
dependent NFκB, cyclin D1 and pERK growth stimulation has been shown to require the 
cytoplasmic tail (Guerra et al. 2012). 
 
Figure 1.6: Cytoplasmic domain comparison between Trop2 and EpCAM 
Both domains show similar size of 26 AAs (Trop2), respectively 25 AAs (EpCAM). 
Sequence identity can be found in 9 AA residues. The cytoplasmic tail of Trop2 contains a 
PIP2-binding motif and a phosphorylation site at Ser
303
, which are not present in EpCAM. 
It was recently confirmed that Trop2 undergoes RIP in human prostate cancer, with both 
cleavage fragments independently stimulating self-renewal and proliferation (Stoyanova et 
al. 2012). This corresponds with our findings of large amounts of Trop2-ECD in conditioned 
media of Trop2 expressing tumour initiating stem cells from prostate cancer patients 
(Knäuper, unpublished). ADAM17 was identified as the responsible metalloproteinase for 
the initial cleavage of the extracellular Trop2 domain between Ala187 and Val188. 
Furthermore, the study described the interaction of Trop2-ICD with β-catenin and that 
Trop2-driven self-renewal and prostate hyperplasia is β-catenin dependent (Stoyanova et al. 
2012). Interestingly, elevated β-catenin expression levels are associated with metastatic 
prostate cancer and abnormal β-catenin localization is found in 71% of prostate cancer 
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patients (Yardy & Brewster 2005; Yardy et al. 2009). Despite these new insights into Trop2-
ICD function, the role of its ectodomain remains unclear. Whereas EpCAMs proposed 
functional unit is a homo-oligomer (Trebak et al. 2001), a recent x-ray crystallography study 
demonstrated that recombinant Trop2-ECD forms homo-dimers in solution (Vidmar et al. 
2013). However, further investigation will be necessary to verify whether this also applies to 
endogenous Trop2 as well as to Trop2 ectodomain fragments cleaved from the cell surface.  
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1.4 The ADAM family of metalloproteinases 
Members of the ADAM (a disintegrin and metalloproteinase) family are complex multi-
domain structural proteins, with functions in cell adhesion and proteolytic cleavage of target 
substrates. The first ADAMs (ADAM1 and ADAM2) recognized were subunits of the sperm 
protein fertilin (Wolfsberg et al. 1993). As metalloproteinases, they are part of a larger 
superfamily of zinc-based proteinases, the metzincins, which have been identified in various 
species (Huxley-Jones et al. 2007). 38 members of the ADAM family were catalogued so far 
and named according to the order in which they have been discovered (reviewed by Edwards 
et al. 2008). All ADAMs are type I transmembrane proteins located on the cell surface, 
although soluble splice variants for ADAM12 (Gilpin et al. 1998) and ADAM33 (Powell et 
al. 2004) have been described.  They are involved in several biological processes, such as 
development, fertilization and diverse aspects of immunity, as well as in disease processes 
like inflammation, asthma, Alzheimer’s disease and cancer (Holgate et al. 2006; Garton et 
al. 2006; Mochizuki & Okada 2007; Deuss et al. 2008). The best established function of 
catalytically active ADAMs is the remodelling or proteolytic processing of cell surface 
proteins, such as growth factors, cytokines, receptors and adhesion molecules. This ADAM-
dependent “ectodomain shedding” is crucial for the regulation of a multitude of biological 
processes and despite substance preferences, ADAMs can have overlapping substrate 
specificity (Edwards et al. 2008). ADAMs play also an important role in the process of RIP, 
where two sequential cleavages occur, the first by an ADAM protease and  the second 
through the γ-secretase complex.  
Structural analysis by X-ray crystallography identified 8 distinct domains in the generalised 
structure of an ADAM protein (Gomis-Rüth 2003). These domains comprise a signal 
sequence, a prodomain, a metalloproteinase domain, a disintegrin or integrin-binding 
domain, a cysteine-rich region, an EGF-like domain, a transmembrane sequence and an 
intracellular C-terminus (Figure 1.7). A common feature of proteases is their synthesis as 
zymogens which are enzymatically inactive precursor proteins. For ADAMs, this inactive 
state is maintained through a so called “cysteine switch” mechanism, which describes the 
interaction of a cysteine residue in the prodomain with the zinc ion in the catalytic site. In 
order to activate the protease, the prodomain is either cleaved by autocatalysis or by a furin-
like convertase, depending on the specific ADAM (Edwards et al. 2008; Murphy 2008). 
Furthermore, the function of the prodomain is not only to hold the protein in its inactive 
state, but to act as an intramolecular chaperon to ensure proper folding.  
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Figure 1.7: Topography of a member of the ADAM family 
Generalized domain structure of a typical ADAM protein with signal sequence (SS), 
prodomain, metalloproteinase domain, disintegrin domain, cysteine rich region, EGF-like 
domain, transmembrane sequence (TM) and intracellular C-terminal tail. In its inactive 
form, prodomain and metalloproteinase domain are interacting through a cysteine switch. 
One of the domains to which ADAMs owe their name is the metalloproteinase domain. It 
contains the active site of the enzyme with a conserved HEXGHXXGXXHD sequence, 
which binds to the catalytic zinc ion in its centre through three histidine residues. Although 
the domain is present in all ADAMs, only about 50 % of them are enzymatically active. 
Consequently, only 13 of the 21 identified human ADAMs show proteolytic activity 
including ADAM9, 10, 12, 15 and 17 (Edwards et al. 2008). Catalytic inactive ADAMs lack 
one or more critical features in their zinc-binding active site. The second name giving 
domain is the disintegrin or integrin-binding domain. It is named after its homology to small 
proteins in snake venom, which have the ability to prevent platelet aggregation by binding to 
platelet integrins (Niewiarowski et al. 1994), which are adhesion proteins involved in cell 
adhesion, migration and signalling (Stupack 2007). Interestingly, the consensus motif Arg-
Gly-Asp (RGD), which is responsible for integrin binding and characteristic for snake 
venom disintegrins, is only present in ADAM15. Nonetheless, various studies have shown 
interactions between integrins and ADAMs, which are missing the RGD motif (Edwards et 
al. 2008). 
The biological functions of the remaining ADAM domains are not fully understood and need 
further investigation. There is evidence that in some ADAMs, the cysteine-rich region 
together with the EGF-like domain are involved in the regulation of protease activity and 
control of substrate recognition (Smith et al. 2002; Reiss et al. 2006). The cytoplasmic tail of 
ADAMs often contain potential phosphorylation sites or proline-rich regions, which can act 
as docking sites for intracellular effector proteins and regulate inducible ectodomain 
shedding (Blobel 2005). 
Over the last years, ADAMs are implicated more and more to play a causal or contributional 
role in cancer formation and progression (Murphy 2008; Duffy et al. 2009). Proteolytic 
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active ADAMs were shown to be specifically involved in these processes. Increased 
expression of certain ADAMs enhanced in vitro invasion, proliferation and promotion of 
tumour invasion, whereas decreased expression had the opposite effect (Borrell-Pagès et al. 
2003; Franovic et al. 2006; McGowan et al. 2007; Takamune et al. 2008; Zheng et al. 2009). 
Furthermore, various studies described a potential correlation between tumour progression 
and expression levels of specific ADAMs (O’Shea et al. 2003; Roemer et al. 2004; 
Valkovskaya et al. 2007; Fritzsche et al. 2008; Zhong et al. 2008); and it was shown that 
selective ADAM inhibitors are able to reduce or abolish tumour growth in model systems 
(Zhou et al. 2006; Fridman et al. 2007; Witters et al. 2008). Hence, the functional role of 
ADAMs in cancer seems to be diverse and can include mechanisms such as activation of 
growth stimulating pathways (Horiuchi et al. 2006; Sahin & Blobel 2007), inactivation of 
growth inhibitory pathways (Liu et al. 2009; Ikushima & Miyazono 2010), shedding of 
adhesion molecules (Najy et al. 2008; Maretzky, Reiss, et al. 2005); and mediating 
angiogenesis (Göoz et al. 2009; Zhao et al. 2001). For prostate cancer, overexpression of 
multiple proteolytic active ADAMs was shown, including ADAM9 (Peduto et al. 2005), 
ADAM10 (McCulloch et al. 2004), ADAM12 (Peduto et al. 2006), ADAM15 (Kuefer et al. 
2006) and ADAM17 (Karan et al. 2003).  
1.4.1 ADAM9 
ADAM9 is a widely expressed member of the ADAM family and was first identified 
through its interaction with the SH3 domain of the non-receptor protein tyrosine kinase Src 
via proline-rich sequences in the cytoplasmic tail (Weskamp et al. 1996). ADAM9 acts as an 
adhesion molecule, due to its ability to bind integrins like αVβ5 via the disintegrin domain 
(Zhou et al. 2001). To date, several ADAM9 substrates are known, such as pro-EGF (Peduto 
et al. 2005), laminin (Mazzocca et al. 2005) or collagen XVII (Franzke et al. 2004). 
Interestingly, another identified ADAM9 substrate is ADAM10. Cleavage of ADAM10 
results in ADAM9 activation, demonstrating ADAMs are able to activate and influence each 
other (Cissé et al. 2005). 
ADAM9 is expressed by several types of cancer, including breast (O’Shea et al. 2003), lung 
(Shintani et al. 2004) and pancreatic cancer (Yamada et al. 2007). Liver carcinoma studies 
led to the identification of ADAM9-S, a soluble and alternatively spliced variant of 
ADAM9. The splice variant is secreted by hepatic stellate cell and has been implicated in the 
promotion of tumour invasiveness (Mazzocca et al. 2005). With regard to prostate 
carcinomas, ADAM9 was detected in several prostate cancer cell lines, as well as in tissue 
samples from prostate cancer patients (Karan et al. 2003). Furthermore, overexpression of 
ADAM9 has been show to convert androgen-dependent LNCaP cells into an androgen-
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independent and metastatic phenotype (Sung et al. 2006). In a transgenic prostate cancer 
mouse model, high ADAM9 expression levels in the epithelium corresponded with well-
differentiated tumours, whereas very low or undetectable amounts of ADAM9 correlated 
with poorly differentiated carcinomas (Peduto et al. 2005). 
1.4.2 ADAM10 
ADAM10 was first identified in bovine brain myelin membrane preparations and referred to 
as mammalian disintegrin-metalloprotease (Chantry et al. 1989). As of today, more than 40 
substrates have been identified for ADAM10 (Pruessmeyer & Ludwig 2009). One of the 
most prominent substrates processed by ADAM10 is the amyloid precursor protein (APP) 
(Lammich et al. 1999), whose main biological function is still unknown. APP was identified 
as the precursor protein of short β-amyloid peptides, whose fibrillar form is the main 
component of amyloid plaques in the brain of patients with Alzheimer’s disease (Endres & 
Falk Fahrenholz 2010). 
Similar to other catalytic active members of the ADAM family, ADAM10 has been shown 
to be overexpressed in several types of cancer, such as colon (Gavert et al. 2005), ovary 
(Fogel et al. 2003) and gastric cancer (Yoshimura et al. 2002). There is evidence that 
ADAM10 can modulate tumour progression through cleavage of the cell adhesion molecules 
N- and E-cadherin (Reiss et al. 2005; Maretzky et al. 2005), leading to altered patterns of 
adhesion and migration of tumour cells. ADAM10 has been identified as the main source of 
HER2 ectodomain sheddase activity in HER2 overexpressing breast cancer cells (Liu et al. 
2006). These findings made ADAM10 an interesting target for treatment of patients with 
HER2 positive breast cancer, as it was shown that high serum levels of HER2 ectodomain is 
an indicator of poor prognosis (Christianson et al. 1998). Prostate cancer cell lines that were 
treated with androgens and growth factors responded with increased production of ADAM10 
mRNA and protein. Although, this up-regulation was not directly associated with increased 
tumour growth, ADAM10 translocation from the cell surface to the nucleus was observed, 
which would support a direct role of ADAM10 in cell signalling during tumour progression 
(McCulloch et al. 2004). 
1.4.3 ADAM12 
ADAM12, initially called meltrin α, was first identified as a transmembrane protein 
implicated in muscle cell fusion (Yagami-Hiromasa et al. 1995). Two naturally occurring 
human splice variants exist, namely ADAM12-L and ADAM12-S. The transmembrane 
associated ADAM12-L is composed of typical ADAM domains, whereas the transmembrane 
and cytoplasmic domains are replaced with a unique stretch of 33 amino acids in the C-
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terminus of soluble ADAM12-S (Gilpin et al. 1998). ADAM12-L is a proteolytically active 
member of the ADAM family and  known to process several transmembrane molecules, 
such as epithelial growth factor (EGF), heparin binding EGF (HB-EGF), betacellulin and 
Delta-like 1, a mammalian ligand for Notch receptors (Asakura et al. 2002; Kurisaki et al. 
2003; Horiuchi et al. 2006; Dyczynska et al. 2007). Soluble ADAM12-S is also 
enzymatically active and cleaves insulin-like growth factor-binding proteins, IGFBP-3 and 
IGFBP-5 (Loechel et al. 2000). Besides its catalytic activity, ADAM12 is thought to act as a 
signal transmitter, using its intracellular tail (Wewer et al. 2006). With 179 amino acids, the 
cytoplasmic tail of human ADAM12-L is relatively long and contains several proline-rich 
regions, with a number of consensus binding sites for SH3 domain-containing proteins 
(Seals & Courtneidge 2003). Studies on mouse ADAM12 have already shown interactions 
between the intracellular tail and the SH3 domains of the Src non-receptor tyrosine kinases, 
c-Src and Yes, as well as the Src substrate and adaptor protein, Grb2 (Kang et al. 2000; 
Suzuki et al. 2000). There is evidence, that the cytoplasmic tail might also play a role in 
subcellular localization of ADAM12. Although the mechanism remains unclear, it has been 
shown, that exogenous full-length ADAM12-L mainly resides in a perinuclear compartment, 
whereas an ADAM12-L mutant lacking the cytoplasmic tail translocates more readily to the 
cell surface (Hougaard et al. 2000). 
ADAM12 expression levels are elevated in several types of human cancer, such as bladder 
(Fröhlich et al. 2006), breast (Kveiborg et al. 2005), colon (Iba et al. 1999), liver (Le Pabic 
et al. 2003) and brain cancer (Kodama et al. 2004). Overexpression has been shown for both 
ADAM12 splice variants (Le Pabic et al. 2003; Fröhlich et al. 2006), although in some cases 
a specific upregulation of the long transmembrane variant ADAM12-L has been observed 
(Iba et al. 1999; Kodama et al. 2004). ADAM12 overexpression in prostate cancer was so far 
only seen in a mouse model where its knock-down led to reduced tumour growth and 
progression (Peduto et al. 2006). 
1.4.4 ADAM15 
ADAM15 was first described as metargidin, referring to its RGD-motif in its disintegrin 
domain, which is unique among ADAM proteases (Krätzschmar et al. 1996). It was shown 
that ADAM15 can bind to integrins αVβ3 and αVβ1  in a RGD dependent manner (Zhang et al. 
1998; Nath et al. 1999) and to αIXβ1 independent of the RGD motif (Eto et al. 2000). In 
addition, ADAM15 seems to be involved in cellular signalling pathways due to interactions 
of its cytoplasmic tail with Src kinases, Lck and Hck, as well as with the adaptor protein, 
Grb2, in hematopoietic cell types (Poghosyan et al. 2002). 
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The majority of studies investigating ADAM15 were directed towards its role as an integrin 
binding molecule and therefore, little is known about its catalytic activity. ADAM15 is 
proteolytic active and purified ADAM15 has been shown to process type IV collagen and 
gelatin (Martin et al. 2002). Furthermore, it was reported that ADAM15 overexpression 
resulted in increased FGF-receptor cleavage (Maretzky et al. 2009). ADAM15 mediated 
shedding and activation of HB-EGF in response to thrombin was seen in breast cancer cells 
(Hart et al. 2005), as well as in prostate cancer cells where ADAM15 was responsible for the 
cleavage of adhesion molecules E- and N-cadherin (Najy et al. 2008; Lucas & Day 2009). 
ADAM15 is overexpressed in multiple adenocarcinomas such as breast (Lendeckel et al. 
2005), lung (Schütz et al. 2005), gastric (Carl-McGrath et al. 2005) and prostate cancer, 
where its upregulation correlates with metastatic and hormone-refractory progression of the 
disease (Kuefer et al. 2006). 
So far, four different cytoplasmic domain variants of ADAM15 have been identified, named 
ADAM15A, B, C and D. ADAM15D is the shortest isoform lacking proline-rich motifs that 
are present in the C-termini of the other three variants (Zhong et al. 2008). Interestingly, 
comparison between breast cancer samples and normal tissue revealed no difference in total 
ADAM15 mRNA levels, but a change in ADAM15 isoform expression. ADAM15B and C 
expression was higher in breast cancer cells and the particular combination of splice variants 
correlated with patient prognosis. An explanation for this could be the varying ability of the 
ADAM15 isoforms to modulate cell adhesion, migration or shedding, through interaction 
with different intracellular signalling effectors (Zhong et al. 2008). 
1.4.5 ADAM17 
ADAM17 or TNF-α converting enzyme (TACE) has initially been described as the principle 
sheddase of soluble tumour necrosis factor-α (TNFα) (Black et al. 1997; Moss et al. 1997). 
Since then, it is the member of the ADAM family that has attracted the most attention. 
ADAM17 has been shown to regulate several cellular processes due to its broad diversity of 
substrates, such as TNFR1 and TNFR2, CD30, APP, interleukin 6 receptor, L-selectin and 
collagen XVII (Gooz 2010). However, ADAM17 has come forward in particular as the main 
constitutive sheddase of transforming growth factor-alpha (TGFα), amphiregulin, HB-EGF 
and epiregulin, demonstrating that it plays an essential role in EGF receptor (EGFR) 
activation via release of its ligands (Le Gall et al. 2009). This ADAM17 mediated EGFR 
signalling is crucial during mammalian embryonic development (Peschon et al. 1998). 
Despite the obvious importance of catalytic ADAM17 activity, there is little knowledge 
about other ADAM17 functions. For instance, so far the only known integrin that binds 
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ADAM17 is α5β1 (Bax et al., 2004). However, the existence of phosphorylation and SH3-
binding sites in its C-terminus propose additional signalling properties for ADAM17.  
Increased shedding of EGF ligands has been shown to contribute to the development of a 
malignant phenotype (Katakowski et al. 2007), which led to ADAM17 implication in 
carcinogenesis due to its role as a growth factor sheddase. ADAM17 upregulation has been 
observed in various malignancies, such as brain (Zheng et al. 2007), prostate (Karan et al. 
2003), breast (McGowan et al. 2007) and colon cancer (Blanchot-Jossic et al. 2005). 
Currently, ADAM17 is best studied in mammary carcinomas, where overexpression of the 
protease correlates with TGFα expression (Borrell-Pagès et al. 2003), tumour progression 
and metastasis (McGowan et al. 2007). In addition, increased ADAM17 levels were shown 
to predict reduced survival in breast cancer patients (McGowan et al. 2008); and inhibition 
of ADAM17 activity or its downregulation led to reduced growth of breast cancer cells in 
vitro and reversion of the malignant phenotype (Kenny & Bissell 2007). 
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1.5 The Protein Kinase C family 
Protein Kinase C (PKC) isoenzymes represent one of the most extensively studied families 
of signalling kinases. They are central components of various signalling pathways regulating 
cellular functions, such as proliferation, differentiation, migration, cell cycle and survival. 
Knockout studies of individual isoforms have shown that members of the PKC family often 
fulfil distinct and non-redundant functions (Leitges 2007). Originally, PKCs were identified 
as peptides involved in the signalling pathway for the carcinogenic effects of phorbol esters, 
which potently mimic the function of the endogenous activator diacylglycerol (DAG) 
(Castagna et al. 1982; Kikkawa et al. 1983). The PKC family is part of the larger AGC 
family of kinases, named for protein kinases A, G and C, which also encompasses related 
kinases, such as protein kinase N, S6 kinase and phosphoinositide-dependend kinase-1 
(PDK-1) (Newton 2010). The mammalian PKC family consists of 10 members which 
evolved from the single PKC1 in Saccharomyces cerivisiae (Watanabe et al. 1994). 
Depending on domain composition, they are grouped into three classes which are named 
classical, novel and atypical PKCs. Classical PKCs (cPKCs) are composed of PCKα, two 
splice variants of PKCβ (PKCβI and PKCβII, which differ in the last 43 amino acids in the 
C-terminus) and PKCγ. The group of novel PKCs (nPKCs) includes PKCδ, PKCε, PKCη 
and PKCθ. Closest to the point of divergence are atypical PKCs (aPKCs), which consist of 
PKCζ and PKCι (human; murine isozyme is PKCλ). All members of the PKC family share a 
basic architecture (Figure 1.8) of a catalytic C-terminal kinase domain, linked by a flexible 
hinge segment to an N-terminal region with regulatory modules (Garg et al. 2013). Classical 
PKCs hold cysteine-rich tandem C1a and C1b domains that bind to DAG or phorbol esters 
in membranes; and a C2 domain that can bind to membranes in the presence of Ca
2+
. The 
regulatory module of novel PKCs likewise possesses tandem C1a and C1b domains that bind 
to DAG or phorbol esters whereas the C2 domain of novel PKCs lacks the ability of Ca
2+
 
binding. In order to compensate for the missing contribution of the C2 domain to membrane 
recruitment, the C1b domain of novel PKCs shows a 100-fold higher affinity for DAG, 
compared to the C1b domain of classical isoforms (Giorgione et al. 2006; Dries et al. 2007). 
Due to a missing C2 domain, atypical PKCs are not regulated by Ca
2+
 and they contain a 
variant of the C1 domain that contains an impaired ligand-binding pocket without the ability 
of binding either DAG or phorbol esters (Kazanietzs et al. 1994; Sonnenburg et al. 2001). 
Their control is rather provided by protein-protein interactions mediated by an N-terminal 
Phox-Bem1 (PB1) domain, which is only present in atypical isoforms (Lamark et al. 2003). 
All PKCs undergo a series of three constitutive, ordered and tightly coupled 
phosphorylations, in order to mature into a catalytically competent, but closed and inactive 
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conformation in which an autoinhibitory pseudosubstrate segment occupies the substrate-
binding pocket. The first phosphorylation event is likely the phosphorylation of a Ser residue 
in the activation loop, performed by the upstream kinase PDK-1. The other  two 
phosphorylations then take place in the C-terminal part of the catalytic domain at two Thr 
residues, found in the turn and hydrophobic motif (Figure 1.8) (Newton 2010). 
 
Figure 1.8: Structure of PKC isozymes 
Domain structure of PKC family members, showing autoinhibitory pseudosubstrate domain 
(pink), C1 domains (orange), C2 domain (green) and catalytic kinase domain (blue); the 
activation loop, turn motif and hydrophobic motif phosphorylation sites are indicated 
(yellow). PKCs are multidomain proteins regulated by lipids and protein–protein 
interactions. DAG is generated upon receptor binding and causes the activation of cPKCs 
and nPKCs, which can be mimicked by phorbol esters. aPKCs do not respond to DAG or 
phorbol esters, but are activated through direct protein-protein interactions. PKCs induce a 
number of signal transduction pathways that regulate tumourigenesis and metastasis. 
PKC isozymes recognize five different consensus phosphorylation motifs. Each of these 
motifs possess an essential basic amino acid (Arg and/or Thr) at the -2 and/or -3 N-terminal 
position, relative to that of the Ser or Thr phosphorylation site (Kang et al. 2012). Through 
phosphorylation of target proteins, PKC isozymes are involved in several cell biological 
processes, such as cell cycle regulation (e.g. MARCKS, p53 and p21), cell adhesion (e.g. 
adducins and integrins), DNA synthesis and transcription (e.g. transcription factor C/EBP 
and GSK3β), cell motility (e.g. RhoA and integrins), apoptosis (e.g. Bad and Bcl-2), drug 
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resistance (e.g. P-glycoprotein); and cell growth and differentiation (e.g. bFGF, EGFR, Raf1 
and H-Ras) (Kang 2014). PKCs can also be activated through autophosphorylation, as well 
as transphosphorylation by other members of the PKC family. PKCε has been shown to 
phosphorylate the activation loop of PKCδ and PKCδ induces autophosphorylation and 
phosphorylation of PKCε at the hydrophobic motif (Rybin et al. 2003; Steinberg 2008). 
1.5.1 Classical PKCs 
In their fully phosphorylated “mature” form, cPKCs are localized primarily in the cytosol, 
where they are maintained by interactions with scaffolding factors (Schechtman & Mochly-
Rosen 2001). Binding of Ca
2+
 to the C2 domain leads to pre-targeting of cPKCs from the 
cytosol to the plasma membrane, where they bind to anionic phospholipids with selectivity 
for PIP2. Once localized at the membrane, the C1 domain can bind to membrane-embedded 
DAG, an interaction that is enhanced by stereospecific binding to a phosphatidylserine. 
Coordinated interaction of both C1 and C2 domains at the membrane leads to the release of 
the autoinhibitory pseudo-substrate sequence from the substrate binding pocket, finally 
activating the enzyme (Newton 2010). Inactivation of cPKCs is performed by a process 
referred to as downregulation (Hansra et al. 1999). While in matured, but inactive 
conformation the isozymes are resistant to dephosphorylation. After activation and 
transformation into an open and membrane-bound conformation, the sensitivity of the 
enzyme to dephosphorylation increases by two orders of magnitude (Dutill et al. 1994). As a 
result, prolonged activation of cPKCs results in dephosphorylation by PH-domain and 
leucin-rich repeat protein phosphatases and subsequent degradation of the unstable 
dephosphorylated species, terminating signalling.  
1.5.1.1 PKCα 
PKCα is ubiquitously expressed and associated with a variety of cellular functions, such a  
motility, proliferation and differentiation (Nakashima 2002). Several studies linked the 
isoform to anti-apoptotic signals and enhanced proliferation in cancer cells, indicating that it 
can act as a regulator of multiple aspects of tumour growth  (Nakagawa et al. 2003; Kong et 
al. 2005; Cameron et al. 2008). Cancer cell invasiveness has been linked to PKCα mediated 
regulation of the cytoskeleton, through inhibition of adherens junctions and desmosomes 
(Masur et al. 2001; Koivunen et al. 2004), inhibition of β4-integrin mediated 
hemidesmosomes (Rabinovitz 1999; Rabinovitz et al. 2004); and changes in β1-integrin 
mediated cell-matrix junctions (Ng et al. 1999; Parsons et al. 2002). Furthermore, PKCα is 
upregulated in some cancers, such as prostate and bladder cancer (Koren, Meir, et al. 2004; 
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Varga et al. 2004); and downregulated in others such as colorectal tumours and malignant 
renal cell carcinoma (Baltuch et al. 1995; von Brandenstein et al. 2012).  
For prostate cancer, high levels of PKCα expression were detected in malignant tumour 
tissue specimens (Cornford et al. 1999a; Koren, Meir, et al. 2004). Androgen-sensitive 
prostate cancer cell lines (e.g. LNCaP) show lower levels of PKCα, compared to androgen-
independent cell lines (e.g. PC3 or DU145) (Powell, Brittis, et al. 1996). PKCα is required 
for EGFR transactivation and ERK1/2 activation in PC3 cells; and it was shown that TGF-β1 
mediated reduction of membrane-bound active PKCα in these cells resulted in decreased cell 
growth (Lamm et al. 1997; Stewart & O’Brian 2005). 
Various studies have shown that PKCα can fulfil both pro- and antiapoptotic functions in 
prostate cancer. When treated with the chemotherapy drug, cisplatin, expression of oncogene 
PCPH in prostate cancer cells increased cell survival through PKCα mediated Bcl-2 
stabilization (Villar et al. 2009). Another experiment showed that p53-mediated apoptosis 
induced by resveratrol, a natural stilbene, was inhibited by EGF induced PKCα activation 
(Shih et al. 2004). In androgen-dependent LNCaP cells, PKCα promotes apoptosis through 
activation of p38 MAPK and the inhibition of the Akt survival pathway (Tanaka et al. 2003). 
A similar induction of apoptosis in LNCaPs was seen in response to stable DAG analogues, 
with preferred selectivity for PKCα (Garcia-Bermejo et al. 2002). Furthermore, an inactive 
kinase-dead PKCα mutant was described to protect LNCaP cells from radiation-induced 
apoptosis, whereas a constitutively active PKCα mutant sensitized the same cells to radiation 
treatment. In mice, the combinatorial treatment of radiation and PMA or a specific PKCα 
DAG activator induced a drastic reduction of LNCaP tumour growth and serum PSA levels, 
compared to radiation treatment only (Truman et al. 2009). 
1.5.1.2 PKCβ 
The Protein Kinase C β gene encodes two splice variants, PKCβI and PKCβII, which have 
differential tissue expression levels and a distinct involvement in cancer. Nonetheless, 
several studies have associated the isoforms with progression of lymphoma, glioblastoma, 
breast, prostate and colorectal cancer (Teicher et al. 2001; Teicher et al. 2002; Espinosa et al. 
2006; Yu et al. 2003; Kim et al. 2008a). So far, it remains unclear why both splice variants 
have different functions. It is speculated that this might be due to unique protein and lipid 
interactions via their C-termini, resulting in distinct localization properties (Stribling 1996; 
Gokmen-Polar & Fields 1998; Stebbins & Mochly-Rosen 2001). However, many studies 
using pharmacological agents do not distinguish between PKCβ subtypes. 
 31 
 
In prostate carcinomas, PKCβI expression positively correlates with high Gleason scores. 
Inhibition of the isozyme blocks xenograft growth in vivo and AR-induced cancer cell 
proliferation in vitro. Interestingly, the phosphorylation of histone H3 by PKCβI results in 
the inhibition of androgen-dependent gene transcription (Metzger et al. 2010). Inhibition of 
centrosomal PKCβII in PC3 cells led to the normalisation of previously disturbed 
microtubule organisation and a significant reduction of angiogenesis and proliferation (Kim 
et al. 2008a). Additionally, enzastaurin, an inhibitor of EGFR-dependent PKCβ signalling, 
showed anti-proliferative effects in androgen-insensitive PC3 cells (Gelardi et al. 2008) 
1.5.1.3 PKCγ 
PKCγ is solely expressed in the brain and spinal cord; and its localization is restricted to 
neurons. Several neuronal functions, such as long term potentiation and long term 
depression, have been shown to specifically require PKCγ activity (Saito & Shirai 2002). 
PKCγ-/- mice are viable and have normal appearance. They show modest impairments in 
learning and memory tests, slight ataxia and failure of developing pain after partial sciatic 
nerve section (Abeliovich et al. 1993; Tonegawa et al. 1995; Malmberg et al. 1997). 
Overexpression of PKCγ in mammary epithelial cells caused cell transformation, but 
whether this contributes to breast cancer formation is not known (Mazzoni et al. 2003). 
Interestingly, PKCγ expression is a prognostic marker for some forms of B-cell lymphomas 
(Kamimura et al. 2004). However, there is no indication that PKCγ does play a significant 
role in tumour formation, which is likely due to to its restricted expression pattern.  
1.5.2 Novel PKCs 
Despite the presence of a C2 domain and in contrast to classical isoforms, novel PKCs are 
regulated by DAG only. The novel C2 domain lacks the ability to bind Ca
2+
, which is 
compensated by a C1b domain with a two orders or magnitude higher affinity for DAG 
containing membranes than the C1b domain of classical isoforms (Giorgione et al. 2006). 
Furthermore, the increased DAG affinity of novel isozymes results in preferential 
subcellular membrane localization (Carrasco & Merida 2004).  
1.5.2.1 PKCδ 
PKCδ is widely characterized with pro-apoptotic and anti-proliferative functions, which is 
utilized in radiotherapy and by chemotherapeutic agents (Gonelli et al. 2009; Yonezawa et 
al. 2009; Irie et al. 2012). Unlike other novel isoforms, PKCδ is not only regulated by DAG, 
but also through phosphorylation of several tyrosine residues which can be induced by 
various stimuli, such as DNA damaging agents or oxidative stress (Brodie et al. 1998; 
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Kiyotsugu 2007). Depending on phosphorylation site and stimulus, tyrosine phosphorylation 
is either activating or inhibiting PKCδ and can affect its apoptotic functions as well as its 
localization (Steinberg 2004). PKCδ plays a critical role in the intrinsic or mitochondrial 
apoptotic pathway, which is activated in response to cellular stress, i.e. DNA damage (Basu 
2003). Furthermore, PKCδ seems to be involved in the extrinsic apoptotic pathway through 
regulation of receptor induced cell death (Griner & Kazanietz 2007). It has been shown that 
PKCδ is a substrate for caspase-3 generating a constitutively active catalytic fragment, 
which translocates from the cytoplasm into the nucleus inducing apoptosis characteristics 
(Ghayur et al. 1996). An alternative mechanism of PKCδ-mediated apoptosis could be the 
allosteric activation of the isoform. In androgen-dependent LNCaPs, activation of PKCδ 
triggered an apoptotic response without being cleaved by caspase-3 (Fujii et al. 2000). PKCδ 
mediated apoptosis of LNCaPs occurs through autocrine release of apoptosis inducing TNFα 
and TNF-related ligands, which induce JNK and p38 MAPK cascades resulting in caspase-8 
cleavage and activation (Gonzalez-Guerrico & Kazanietz 2005; Xiao et al. 2009). Co-
activation of neutral endopeptidase (NEP) and PKCδ correlates with PMA-induced 
apoptosis in androgen-independent prostate cancer cells, with NEP acting as an inhibitor of 
c-Src mediated PKCδ degradation (Sumitomo et al. 2000). Furthermore, drug-induced 
apoptosis of prostate cancer cells requires PKCδ and ceramides, leading to caspase-9 
activation and cytochrome C release in mitochondria  (Sumitomo et al. 2002). 
In contrast, PKCδ can also act as a tumour promoter through upregulation of migration and 
invasiveness (Razorenova et al. 2011; Li et al. 2013). PKCδ is overexpressed in invasive 
DU145 prostate cancer cells and abrogation of the isoform leads to decreased migration and 
invasiveness of the cells (Kharait et al. 2006). Bradykinin, an inflammatory mediator, 
induced migration of human prostate cancer cells by upregulation of MMP-9 and activation 
of B2 receptor, PKCδ, c-Src and NF-κB pathways (Yu et al. 2013). Furthermore, in mice 
xenografted with androgen-independent PC3 prostate cancer cells, activation of PKCδ 
induced angiogenesis through elevated levels of hypoxia-inducible factor 1 and enhanced 
NADPH oxidase activity (Kim et al. 2011). 
1.5.2.2 PKCε 
While PKCδ appears to be the “good” due to its pro-apoptotic properties in cancer, PKCε 
seems to play the role of the “bad”, since it has been originally described as an oncogenic 
kinase (Mischak et al. 1993; Perletti et al. 1996). PKCε is known to drive oncogenic 
behavior through modulation of the Ras/Raf-1 signaling pathway (Cacace et al. 1996;  
Ueffing et al. 1997), resulting in downstream effects such as an accelerated cell cycle 
through cyclin D1 upregulation (Albanese et al. 1995; Lavoie et al. 1996). In addition to its 
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impact on Ras signaling, PKCε has also been shown to modulate Bcl-2 family members and 
caspases, linking the isoform to anti-apoptotic signaling pathways (Ding et al. 2002; 
McJilton et al. 2003; Lu et al. 2007). Furthermore, PKCε has been described to activate 
Akt/PKB in order to exert pro-survival effects in cells (Wu et al. 2004; Lu et al. 2006b).  
In prostate cancer PKCε plays a key role in growth, survival and anti-apoptosis of tumour 
cells. Genetic ablation of the isoform in a transgenic mouse model of prostate 
adenocarcinoma lead to significant reduction of proliferation, metastasis and the anti-
apoptosis response of prostate cancer cells (Hafeez et al. 2011). PKCε increases survival of 
recurrent CWR-R1 prostate cancer cells through activation of the Akt survival pathway (Wu 
et al. 2004); and promotes growth and enhances cell survival of androgen-independent PC3 
and DU145 prostate cancer cells, through Raf1/ERK1/2 signaling and induction of 
proliferation-related protein synthesis (Wu & Terrian 2002; Wu et al. 2002). Furthermore, 
the constitutive activation of Stat-3 by PKCε through phosphorylation of serine 727, is 
essential for prostate cancer cell invasion (Aziz et al. 2007; Hafeez et al. 2011). PKCε 
provides apoptosis resistance to prostate cancer cells through several pathways, such as IκB 
phosphorylation and degradation (Garg et al. 2012), phosphorylation and inactivation of pro-
apoptotic Bad, inhibition of TNFα induced JNK activation (Meshki et al. 2010) and binding 
to pro-apoptotic Bax (McJilton et al. 2003). Downregulation of PKCε by anticancer agents 
resulted in efficient apoptosis induction in prostate cancer cells and a significant reduction of 
tumour growth in vivo and in vitro (Gundimeda et al. 2008; Sarveswaran et al. 2011; Hafeez 
et al. 2012; Sarveswaran et al. 2012;) 
1.5.2.3 PKCη 
While most studies about novel PKCs have been focused on PKCδ and –ε, little is known 
about the function and regulation of PKCη. This isoform is primarily expressed in epithelial 
cells  and shares highest homology with PKCε (Bacher et al. 1991; Hashimoto et al. 1992). 
PKCη is the only phorbol ester-sensitive PKC that resists downregulation upon prolonged 
phorbol ester treatment (Chen et al. 1997; Resnick et al. 1997; Basu 1998). Until recently, 
little was known about this unique regulation of the isozyme. Pal et al. described that several 
PKC activators, including phorbol esters induced upregulation rather than downregulation of 
PKCη. Responsible for this activator mediated upregulation appears to be the 
phosphorylation of PKCη by PKCε (Pal et al. 2012). So far PKCη has been implicated in 
both tumour suppression and promotion. It has been associated with the progression of 
glioblastoma (Hussaini et al. 2002), renal cell carcinoma (Brenner et al. 2003), breast 
(Masso-Welch et al. 2001) and lung cancer (Krasnitsky et al. 2012). On the other hand, 
PKCη expression is significantly reduced in hepatocellular carcinoma (Lu et al. 2009) and it 
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was shown that overexpression of the isoform caused growth arrest and differentiation in 
keratinocytes (Ohba et al. 1998; Cabodi et al. 2000). Additionally, disruption of PKCη 
enhanced tumour formation in a two-stage skin carcinogenesis model (Chida et al. 2003). In 
regards of prostate cancer PKCη seems to act as a tumour promoter. In androgen-
independent PC3 prostate cancer cells PKCη knockdown caused substantial apoptosis-
induction through TNF-related apoptosis-inducing ligand (TRAIL) (Sonnemann et al. 2004). 
1.5.2.4 PKCθ 
PKCθ is most abundant in hematopoietic cells, especially T cells, resulting in overall high 
expression levels of the enzyme in thymus and lymph nodes (Baier et al. 1993). PKCθ is 
most prominent in the activation and survival of T-cells, reflecting its unique ability to 
activate transcriptions factors, NF-κB, AP-1 and NFAT (Baier-Bitterlich et al. 1996; Sun et 
al. 2000; Pfeifhofer et al. 2003). The isozyme plays a critical role in mediating T cell 
activation which has been demonstrated in vivo by two strains of independently generated 
knockout mice. Both studies observed defects in T cell activation in PKCθ-/- naïve 
lymphocytes, due to the lack of NF-κB, AP-1 and NFAT activation (Altman et al. 2000; 
Bauer et al. 2000). PKCθ has been frequently reported in association with auto-immune 
diseases (Hayashi & Amnon Altman 2007), but its role in cancer remains elusive. The 
isoform is overexpressed in all forms of gastrointestinal stromal tumours, but not in other 
mesenchymal or epithelial cancers. Hence, PKCθ could serve as a sensitive and specific 
marker for gastrointestinal stromal tumours (Blay et al. 2004; Duensing et al. 2004; Lee et 
al. 2008). Recently PKCθ has been implicated in breast cancer, where it promotes c-Rel 
driven mammary tumourigenesis in mice by repressing estrogen receptor α synthesis 
(Belguise & Sonenshein 2007). Furthermore, the active isozyme was shown to enhance 
motility and proliferation of ER-negative breast cancer cells (Wang et al. 2005). 
1.5.3 Atypical PKCs 
The subgroup of atypical PKCs (aPKC) is composed of two members, PKCζ and PKCι 
(PKCλ is the mouse homolog of human PKCι). The two isoforms are highly related and 
share an overall amino acid identity of 72% (Nishizuka 1995). Unlike aPKCs or nPKCs, 
they cannot be activated by DAG, calcium or phorbol esters (Ono et al. 1989; Akimoto et al. 
1994). PKCζ and PKCι activation occurs through either various acidic phospholipids such as 
phosphatidylinositol 3,4,5–trisphosphate (PIP3), or through specific protein-protein 
interactions mediated by a unique PB1 domain in their N-terminus (Nakanishi et al. 1993; 
Palmer et al. 1995). The PB1 motif is a structurally conserved dimerization/oligomerization 
domain found in adaptor and scaffold proteins, as well as kinases. It serves as mediator of 
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homo- and heterotypic interactions between binding partners (Moscat et al. 2006). The 
formation of aPKC complexes with different interaction partners, such as partitioning 
defective (Par)-6, Par4 and p62, has been shown to define kinase specificity and to be 
critical to establish signaling pathways in control of various cellular functions (Moscat et al. 
2009).   
1.5.3.1 PKCι 
Despite the fact that various PKC isoforms have shown a strong association to 
carcinogenesis, to date only PKCι has been identified as a true bona fide oncogene (Parker et 
al. 2014). PKCι overexpression on mRNA and protein level correlates with poor patient 
survival and was shown in multiple cancers types, such as colon (Murray et al. 2004a), 
stomach (Takagawa et al. 2010), liver (Du et al. 2009), brain (Patel et al. 2008), pancreas 
(Scotti et al. 2010); and prostate cancer (Ishiguro et al. 2009). One of the functions of PKCι 
in carcinogenesis is the maintenance of the transformed tumour cell phenotype. 
Pharmacologic or genetic inhibition of PKCι suppresses the proliferative and invasive 
properties of prostate cancer and glioma cells in vitro (Patel et al. 2008; Ishiguro et al. 2009). 
In vivo experiments, using pancreatic ductal adenocarcinoma cells injected into the mouse 
pancreas, revealed that PKCι-deficient tumour cells grew significantly smaller tumours with 
fewer metastases (Scotti et al. 2010).  
PKCι is involved in various signaling pathways that promote cellular transformation. The 
isoform is a downstream effector of oncogenic Ras; and experiments using Ras-transformed 
intestinal epithelial cells demonstrated that PKCι is required for invasion and anchorage- 
independent growth of these cells in vitro and in vivo (Murray et al. 2004b). Other studies 
have linked PKCι to Src-mediated transformation. Non-small-cell lung carcinoma (NSCLC) 
cells treated with nicotine-derived nitrosamine ketone, the most potent carcinogen in 
cigarette smoke, showed an increase of c-Src activated PKCι and the subsequent 
phosphorylation of pro-apoptotic Bad. Consequently, Bad-mediated binding and inhibition 
of anti-apoptotic Bcl-XL is abrogated, resulting in enhanced cell survival and decreased 
sensitivity to anti-cancer drugs, such as cisplatin (Jin et al. 2005). PKCι has also been shown 
to promote tumour cell survival through NF-κB activation. In androgen-independent DU145 
prostate carcinoma cells treated with pro-inflammatory TNFα, PKCι associates with NF-κB 
upstream effectors IKKαβ and IκBα. The phosphorylation of IKKαβ by PKCι subsequently 
results in translocation of NFκB/p65 into the nucleus and activation of transcription (Win & 
Acevedo-Duncan 2008). 
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Another mechanism of oncogenic PKCι signaling is the interaction via its PB1 domain. One 
important binding partner is Par6, a protein with a well-established role in cell polarity that 
can bind aPKCs via PB1:PB1 domain interactions (Etienne-Manneville & Hall 2003; Suzuki 
& Ohno 2006). Par6 links atypical PKC to cell polarity by forming a complex with PKCι 
and the Rho family GTPase Rac1 (Noda et al. 2001; Etienne-Manneville & Hall 2003). Rac1 
represents a critical downstream intermediate of oncogenic PKCι in various cancers such as 
lung (Frederick et al. 2008), pancreas (Scotti et al. 2012) and colon (Murray et al. 2004b). In 
NSCLC, the PB1:PB1 interaction between PKCι and Par6 is necessary for Rac1 activation 
and the transformed phenotype (Regala et al. 2005; Justilien & Fields 2009). In addition, 
RNAi mediated knockdown of Par6, Rac1 or PKCι significantly blocks the growth of 
NSCLC cells (Frederick et al. 2008) 
1.5.3.2 PKCζ 
In contrast to PKCι, the role of atypical PKCζ in tumourigenesis is controversial. Different 
tumour specimens have been shown to express different levels of PKCζ, indicating tissue-
specific functions for this isoform. PKCζ is downregulated in glioblastoma (Rickman et al. 
2001), lung cancer (Bhattacharjee et al. 2001), kidney renal clear cell carcinoma (Lenburg et 
al. 2003), melanoma (Talantov et al. 2005) and pancreatic cancer (Buchholz et al. 2005). On 
the other hand, PKCζ is upregulated in prostate cancer (Rhodes et al. 2007), bladder cancer 
(Sanchez-Carbayo et al. 2006) and lymphomas (Dave et al. 2006). Genome-wide cataloging 
of genetic changes in breast and colorectal tumours identified a particularly common S514F 
mutation in PKCζ (Wood et al. 2007). The S514F mutation causes reduced enzymatic 
activity and significantly inhibits the ability of PKCζ to restrain Ras-induced tumourigenesis 
in vivo (Galvez et al. 2009). These findings suggest that loss of expression or inactivation of 
PKCζ promotes tumourigenesis, a conclusion that is supported using a lung cancer model in 
a PKCζ null background. In this model, lung carcinogenesis is significantly enhanced when 
compared to wildtype mice (Galvez et al. 2009). 
PKCζ has been implicated in the intracellular transduction of mitogenic and anti-apoptotic 
signals, through different signaling pathways (Berra et al. 1993; Kampfer et al. 2001; Leroy 
et al. 2005). An early study identified PKCζ as downstream target of PI3K; and that the 
regulatory domain of PKCζ interacts directly with Ras during mitogenic signaling in vitro 
and in vivo (Diaz-Meco et al. 1994). Hence, PKCζ has been described to be anti-apoptotic 
(Berra et al. 1993) and to enhance chemoresistance in cancer cells (Bezombes et al. 2002; 
Filomenko et al. 2002). PKCζ-induced resistance against chemotherapeutic doxorubicin is 
the result of nuclear translocation through oxidative stress. Under normal conditions, PKCζ 
is excluded from the nucleus and localizes in the cytosol. Upon stress conditions, such as 
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cigarette smoke or bacterial infection which promotes the increase of intracellular reactive 
oxygen species (ROS), PKCζ is redistributed into the nucleus where it inhibits apoptosis 
(Rimessi et al. 2012). In cigarette smoke or lipopolysaccharide (LPS) induced lung 
inflammation, phosphorylated PKCζ accumulates in the nucleus and forms a complex with 
NF-κB, causing histone phosphorylation and promoter acetylation of pro-inflammatory 
genes (Yao et al. 2010). 
In prostate carcinoma, the role of PKCζ remains ambiguous. Early studies have described 
PKCζ expression as a characteristic of human prostate cancer (Cornford et al. 1999b); and 
PKCζ activation has shown to be required for the transition of androgen-dependent to 
androgen-independent prostate cancer cells (Inoue et al. 2006). Furthermore, PKCζ 
downregulation via siRNA in androgen-independent PC3 prostate cancer cells significantly 
reduced their malignant potential (Yao et al. 2010). However, a recent publication of Yao et 
al., reported the transcription and translation of a novel PKCζ splice variant in prostate 
cancer cells only. The catalytic domain of this new PKCζ variant shows characteristics of 
classical PKCβ and atypical PKCι and thereby could provide yet unknown mechanisms to 
modulate the malignant prostatic phenotype (Yao et al. 2012). Interestingly, another PKCζ- 
isoform, containing a novel catalytic domain, has been described to be constitutively active 
and specific to the brain where it is involved in memory formation (Hernandez et al. 2003). 
Genetic inactivation of PKCζ resulted in invasive prostate carcinomas in vivo and led to the 
identification of PKCζ as a tumoursuppressor through phosphorylation and repression of 
proto-oncogene c-myc (Y. J. Kim et al. 2013). Experiments with Spisulosine, a marine 
compound with anti-cancer activity, showed the induction of apoptosis in prostate cancer 
cells through PKCζ activation and the accumulation of ceramides (Sánchez et al. 2008). 
Another study showed that PKCζ overexpression represses invasiveness and metastasis in 
Dunning R-3327 rat prostate cancer cells (Powell, Gschwend, et al. 1996). 
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1.6 Microvesicles 
Intercellular communication is a key mechanism of multicellular organisms that allows 
individual cells to coordinate their functions and behavior, in order to adapt to 
environmental changes. For a long time, it was presumed that communication between cells 
is confined to soluble factors, such as chemokines, cytokines or growth factors; and the 
interaction with their corresponding cell surface receptors. However, another mode of cell-
to-cell communication, via small vesicles released by many if not all cell types, was 
proposed a few decades ago (Bastida et al. 1984) and later proven, when specific processes 
were identified that resulted in the discharge of small vesicles (Beaudoin & Grondin 1991). 
This revealed two major vesicle-release mechanisms, both generating distinct types of 
signaling microvesicles. Exosomes, which are released from the lumen of intracellular 
multivesicular compartments; and ectosomes which are shed directly from the cell surface. 
1.6.1 Exosomes 
Exosomes were first described in a study that investigated reticulocyte maturation. 
Electronic microscopy showed large sacs filled with small membrane-enclosed vesicles of 
nearly uniform size in sheep reticulocytes (Pan et al. 1985). These vesicles were eventually 
secreted by fusion of the larger sacs with the plasma membrane and termed “exosomes” 
(Johnstone et al. 1987). Exosome biogenesis occurs in the endosomal network, an 
interconnected structure of membrane-bounded compartments, functioning as a major 
sorting and distribution platform of cargo that originates from the plasma membrane. The 
sorting of cell surface factors into either degradation, recycling or export compartments, is 
mediated by endosome formation. Initially, targeted components of the plasma membrane 
are internalized into early endosomes, which then either fuse with recycling endosomes or 
undergo transformation into late endosomes. In the latter case, cargo molecules are budding 
into the lumen of late endosomes. This process of inward vesiculation results in the 
accumulation of intraluminal vesicles (ILVs) in late endosomes, also known as multi-
vesicular bodies (MVBs). MVBs are subsequently primed to either fuse with lysosomes in 
order to degrade their content, or with the plasma membrane, leading to the secretion of their 
ILVs as exosomes into the extracellular space (Figure 1.9) (Février & Raposo 2004; 
Mathivanan et al. 2010). So far, the most prominent MVB sorting pathway is regulated by 
endosomal sorting complexes required for transport (ESCRTs). The ESCRT complex 
specifically binds mono-ubiquitinated cargo proteins in early endosomes and mediates their 
internalization into MVBs (Wollert & Hurley 2010). However, growing evidence supports 
the existence of alternative sorting pathways independent of both ubiquitin and the ESCRT 
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machinery (Theos et al. 2006, Trajkovic et al. 2008). A recent study for example described a 
ceramide-dependent mechanism via neutral sphingomyelinase 2, to be involved in the 
regulation of exosome secretion (Kosaka et al. 2010). 
 
Figure 1.9: Exocytosis 
Schematic representation of exosome generation and release into the extracellular space. In 
early endosomes, proteins are either recycled back to the plasma membrane, or sequested in 
intraluminal vesicles (ILVs) of the larger multivascular bodies (MVBs). Hereby, early 
endosomes mature into late endosomes and ILVs are formed by a process of inward budding 
from the limiting membrane into the lumen of MVBs. Via this mechanism, cytoplasmic 
cargo is encapsulated and moreover transmembrane proteins maintain the same orientation 
relative to the cytoplasm and plasma membrane. MVBs can either be degradative by 
devolving into lysosomes, or exocytic by fusing with the plasma membrane and releasing 
their content as exosomes. 
Proteomic analyses of exosomes from various cells showed that they share common 
characteristics in their protein composition and identified several heat-shock proteins, 
tetraspanins and MHC class 1 molecules, as exosomal markers (Keller et al. 2006). One of 
the most interesting groups of proteins found in exosomes were metalloproteinases, with 
expression levels increased under pathological conditions. Cancer cells and stromal cells 
were shown to be the major source of exosome-associated metalloproteinases, belonging to 
the MMP, ADAM and ADAMTS family. ADAM10, 15 and 17 were detected in exosomes 
from malignant tumour cell lines, whereas stromal cells, such as mesenchymal stem cells or 
immune cells, were described to release exosome-associated ADAM9, 10 and 15 (Shimoda 
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& Khokha 2013). As described previously, the main function of metalloproteinases is the 
ectodomain shedding of proteins on the cell surface. However, it has been shown that 
proteolytic cleavage can also occur on the surface of released exosomes, as well as in 
exosomal compartments of the MVBs. ADAM10 has been reported to cleave L1 adhesion 
molecule (CD171) and CD44 on the surface of ILVs in MVBs, which is followed by the 
direct release of the soluble ectodomain fragments via exocytosis (Stoeck et al. 2006). In 
addition, exosomal EpCAM and CD46 from ovarian cancer cells (Hakulinen et al. 2004), as 
well as exosomal TNFR1 from vascular endothelial cells (Hawari et al. 2004), undergo 
proteolytic processing by unknown metalloproteinases. Furthermore, EpCAM was reported 
to be cleaved by serum metalloproteinases on the surface of ascites-derived exosomes of 
ovarian and breast cancer patients (Rupp et al. 2011). It is known that metalloproteinases are 
assembled by tetraspanin-enriched microdomains acting as functional regulatory platforms 
for regulated intramembrane proteolysis and matrix degradation (Arduise et al. 2008; Xu et 
al. 2009; Gutiérrez-López et al. 2011). A similar mechanism could be involved in the 
regulation of exosomal proteolysis as tetraspanins are known to be enriched in exosomes. 
After secretion into the extracellular environment, exosomes can interact with other cells in 
order to induce physiological changes (Théry et al. 2001). Although the underlying 
mechanism of this interaction remains to be clarified, various studies have shown that fusion 
of exosomes with the cell membrane of target cells leads to cargo delivery into neighbouring 
cells (Barry et al. 1998; Skog et al. 2008; Parolini et al. 2009). This process might be pH 
dependent as one of these studies described enhanced exosome-membrane fusion under 
acidic conditions, similar to situations within tumours where hypoxia is common (Parolini et 
al. 2009). Alternative ways of interaction were shown to occur through binding of specific 
surface receptors (Segura et al. 2007), or internalization by endocytosis followed by fusion 
with internal compartments of the target cell (Morelli et al. 2004). Exosomes play most 
likely a role in numerous physiological processes, such as RNA transfer (Valadi et al. 2007), 
antigen presentation (Théry 2011) or tissue repair (Lai et al. 2010). However, it remains 
unclear whether vesicle count and corresponding effects in vitro correlate with physiological 
exosome quantities in vivo. Xiang et al. reported differences between exosomes from tumour 
cells in vitro and tumour cells grown in vivo (Xiang et al. 2010). However, the presence of 
exosomes in biological fluids highlights their in vivo secretion, but their physiological 
relevance remains to be clarified.  
Exosomes have been associated early with carcinogenesis, as the secretion of tumour-
derived vesicles was first described in patients suffering from ovarian cancer (Taylor et al. 
1983). Cancer cell exosomes have been described to be immuno suppressive through 
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apoptosis-induction of activated T cells, or the promotion of differentiation in regulatory T 
lymphocytes (Clayton et al. 2007). Increased amounts of exosomes were reported to 
correlate with advanced head and neck cancer (Bergmann et al. 2009); and plasma analysis 
of ovarian and lung cancer patients revealed significantly elevated exosome levels compared 
to healthy patients (Simpson et al. 2008; Simpson et al. 2009). The fact that exosome content 
is cell type specific and that they are present in different body fluids, made them an 
interesting, non-invasive source for disease-specific biomarkers, such as proteins or 
miRNAs (Mathivanan & Simpson 2009; Rabinowits et al. 2009). It was reported that urinary 
exosomes can be used to evaluate disease progression in prostate cancer patients, as their 
urine showed higher exosome levels than the healthy donors (Mitchell et al. 2009). In 
addition, urinary exosomes from prostate cancer patients contained two distinct mRNA 
biomarkers, PCA-3 and TMPRSS2 (Nilsson et al. 2009). 
Another role of exosomes in tumour tissue is the transport and exchange of oncogenic 
factors. Colon cancer cells with mutated KRAS alleles, were shown to transfer mutant 
KRAS proteins via exosomes to colon cancer cells expressing wild-type KRAS, resulting in 
increased proliferation and tumourigenicity (Demory Beckler et al. 2013). Serum exosomes 
from glioblastoma patients frequently contain tumour-specific EGFRvIII, which has been 
associated with enhanced tumour progression (Skog et al. 2008). Yang et al. observed the 
transport of miRNAs from tumour-associated macrophages to breast cancer cells through 
exosomes and a resulting increase in their invasive properties (Yang et al. 2011).  
1.6.2 Ectosomes 
The term “ectocytosis” was first coined by Stein and Luzio and describes the specific sorting 
of membrane proteins and lipids into vesicles which are shed directly from the cell surface 
as shedding vesicles or ectosomes (Stein, Luzio 1991). Ectosomes represent an exclusive 
class of structure with specific characteristics, such as the exposure of phosphatidylserine on 
their surface (Zwaal & Schroit 1997). The release of ectosomes from the cell surface is 
preceded by the budding of a small cytoplasmic protrusion and the subsequent fission of 
their stalk (Dolo et al. 2000; Cocucci et al. 2007). The membrane, as well as the content of 
the lumen of ectosomes exhibit an accumulation of specific proteins, with exclusion of other 
common proteins of the cytosol and the plasma membrane (Cocucci et al. 2007; Moskovich 
& Fishelson 2007). Ectosomes from tumour cells and neutrophils showed an increased 
concentration of metalloproteinases and other proteolytic enzymes, in order to digest the 
extracellular matrix in the process of inflammation or cancer growth (Gasser et al. 2003; 
Millimaggi et al. 2006; Giusti et al. 2008). Additionally, thrombocytes release shedding 
vesicles that contain various important coagulation factors, such as integrins, glycoproteins 
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and P selectin (Del Conde et al. 2005; Pluskota et al. 2008). Hence, despite being generated 
by the same budding and release mechanism, ectosomes from distinct cells show different 
molecular composition. 
With the essential process of ectocytosis being the same in all cell types, inducing factors 
can vary from one cell to another. In circulating hematocytes and endothelial cells the 
exposure to complement attack induces ectosome release (Pilzer et al. 2005). The 
ectocytosis of monocytes is stimulated upon exposure to bacterial wall components, 
including lipopolysaccharides (LPS); and thrombocytes discharge shedding vesicles through 
thrombin activation (Freyssinet 2003). Another inducer of ectocytosis are Ca
2+
 ionophores, 
as confocal time lapse recording showed the emission of small structures popping out from 
the cell surface as a result of Ca
2+
 stimulation in various cell types (Bianco et al. 2005; 
Pizzirani et al. 2007). In addition, other studies observed increased shedding of vesicles 
upon phorbol ester treatment and the resulting activation of PKC (Sidhu et al. 2004; Baj- 
Pilzer & Fishelson 2005; Krzyworzeka et al. 2006). Despite enhanced ectocytosis upon 
activation, the release of shed vesicles is an ongoing process in many unstimulated cells in 
vivo.  Background levels of osteoblast-specific ectosomes were detected in bone and 
cartilage (Anderson 2003), as well as shed vesicles originating from circulating and 
endothelial cells that were found in blood (Freyssinet 2003). Furthermore, ectosomes 
released from glomerular epithelial cells were detected in urine (Pascual et al. 1994; 
Lescuyer et al. 2008). 
In the process of a vesicle being shed from the cell surface, a small section of the plasma 
membrane is removed from the cell. In resting cells with low discharge rate, this loss is 
compensated through constitutive trafficking of membranes from the cytosol to the cell 
surface. However, in stimulated cells, ectosome release is strongly increased and exceeds 
constitutive membrane traffic. In order to maintain membrane integrity and replenish plasma 
membrane loss, the cell uses the mechanism of non-secretory exocytosis (Morris & Homann 
2001). Hereby, non-secretory vesicles from the membranes of cytoplasmic organelles fuse 
with the plasma membrane in response to stimulation (Chieregatti & Meldolesi 2005). So 
far, it is not fully understood if membrane replenishment by non-secretory exocytosis takes 
place before or after ectosome release. In PC12 cells stimulated with PMA, ectosome 
shedding was necessary to remove the replenished membrane. Interestingly, when non-
secretory exocytosis was stimulated in the same cells by Ca
2+
 ionophores, replenished 
membrane sections were primarily removed by endocytosis (Cocucci et al. 2007). This 
indicates that non-secretory exocytosis happens before ectosome shedding and could further 
explain the delay in ectosome release upon stimulation observed by various groups (Pilzer et 
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al. 2005; Baj-Krzyworzeka et al. 2006; Pilzer & Fishelson 2005; Pizzirani et al. 2007). 
Neurotransmitter release studies showed that it takes some time to complete the intermixing 
of vesicle and plasma membrane components (Valtorta et al. 2001). It was hypothesised that 
plasma membrane domains from non-secretory vesicles, enriched with specific lipids and 
proteins, preferentially accumulate in ectosomes (Figure 1.10). This was confirmed in PC12 
cells, where upon stimulation ectosomes were devoid of common membrane proteins, such 
as Na
+
/K
+
 ATPase, and rich in desmoyokin and annexin 2, representing two markers of the 
non-secretory exocytic organelle (Borgonovo et al. 2002; Cocucci et al. 2007). 
 
Figure 1.10: Ectocytosis 
Ectosomes of variable size (80-200 nm in diameter) bud off the plasma membrane in 
response to cell stimulation. The process of ectosome generation takes place in conjunction 
with the discharge of non-secretory exocytic vesicles stored in the cytoplasm. During their 
generation, ectosomes are delimited by a membrane distinct from the plasma membrane and 
similar, at least in some respects, to that of the non-secretory exocytic vesicles.  
So far, the mechanism of ectosome biogenesis, as well as protein sorting into them, remains 
elusive. Ca
2+
-induced activation of the
 
phospholipid translocators scramblase and floppase 
has shown to alter the asymmetric phospholipid distribution in the plasma membrane, 
leading to the exposure of phosphatidylserine in the outer layer of the membrane. 
Furthermore, cytoskeletal degradation by Ca
2+
-dependent proteases, calpain and gelsolin, 
was observed prior to ectosome release (Pap et al. 2009). Experiments with cancer cells 
described the induction of ectosome generation as a result of small GTPase RhoA signalling 
and the corresponding downstream activation of a Rho-associated coiled-coil containing 
protein kinase (Li et al. 2012). Another study reported that protease-loaded ectosomes were 
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generated upon modulation of the GTP-binding protein ARF6 (Muralidharan-Chari, Clancy, 
et al. 2009). Muralidharan-Chani et al. showed that ARF6 acts through phospholipase D and 
ERK, in order to activate myosin light chain kinase and that the following myosin light 
chain phosphorylation stimulates release of ectosomes from invasive cells (Muralidharan-
Chari, Hoover, et al. 2009).  
Once discharged into the extracellular space, most ectosomes do not remain intact for long 
and break down, which results in the release of their cargo and part of their membrane. A 
prominent example is the release of metalloproteinases and their subsequent digestion of the 
extracellular matrix, in order to increase tumour cell mobility and invasiveness (Mochizuki 
& Okada 2007). Another important purpose of vesicle breakdown seems to be the release of 
signalling molecules that are excluded from the secretory pathways, due to their lack of 
signal sequences. The release of accumulated pro-inflammatory cytokine, IL-1β, from the 
lumen of their ectosomes was observed in macrophages, microglia and dendritic cells 
(MacKenzie et al. 2001; Wilson et al. 2004; Pizzirani et al. 2007). Additionally, ectosomes 
from distinct cell types such as neurons, astrocytes and endothelial cells, were shown to 
release FGF-2 into the extracellular space (Schiera et al. 2007; Proia et al. 2008; Taverna et 
al. 2008). Despite the fact that ectosomes have a short half-life, they can also interact with 
specific target cells. Vesicles shed from thrombocytes were described to interact with 
macrophages and endothelial cells, but not with neutrophils (Lösche et al. 2004), whereas 
shed vesicles from neutrophils interact with thrombocytes, macrophages and dendritic cells 
(Scholz et al. 2002; Gasser et al. 2003; Pluskota et al. 2008). The interaction between vesicle 
and target cell is mediated by receptor binding on the surface, where it can induce signalling 
or serve as reaction scaffold in order to assemble extracellular protein complexes (Gasser & 
Schifferli 2004). Alternatively, binding of the ectosome can lead to endocytic uptake of the 
vesicle or direct fusion with the plasma membrane of the target cell (Köppler et al. 2006). 
This represents another important function of ectosomes, the horizontal transfer of cargo 
proteins from cell to cell.  
Ectosomes in the context of carcinogenesis were first documented in 1978, when they were 
identified in spleen and lymph node cultures of a Hodgkin lymphoma patient (Friend et al. 
1978). It was shown that invasiveness of tumour cells correlates with the amount of released 
ectosomes in vitro (Ginestra et al. 1998) and in vivo (Ginestra et al. 1999). The ectosome-
mediated cargo transfer has been reported to affect many stages of cancer development, 
including ECM degradation, metastasis, angiogenesis and survival (Van Doormaal et al. 
2009). Various studies in the last decade have shown that shedding vesicles released from 
tumour cells promote transfer of nucleic acids (Skog et al. 2008), functional transmembrane 
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proteins (Del Conde et al. 2005), chemokine receptors (Mack et al. 2000), soluble proteins 
(Iero et al. 2008) and receptor tyrosine kinases (RTK) such as HER2 and EGFR (Al-Nedawi 
et al. 2008; Sanderson et al. 2008). Another function of ectosomes in tumourigenesis is the 
direct activation of cells in the surrounding microenvironment, in order to favour cancer cell 
progression. This is highlighted in a study from Castellana et al. describing a reciprocal 
communication of fibroblasts and tumour cells through ectosomes within the tumour 
microenvironment. Hereby, androgen-independent PC3 prostate cancer cells discharged 
vesicles that triggered MMP9 upregulation, ERK phosphorylation, and apoptosis resistance 
in surrounding fibroblasts. In reverse, the activated fibroblasts released ectosomes that were 
able to increase migration and invasiveness of the tumour cells (Castellana et al. 2009). 
1.7 Clathrin-dependent endocytosis 
Opposite to exocytosis, endocytosis is a process in which cells absorb molecules from the 
extracellular space by engulfing them. Endocytotic pathways can be subdivided into four 
distinct categories: clathrin-mediated endocytosis, caveolae, macropinocytosis and 
phagocytosis. However, for most cells, the major route for endocytosis is mediated by 
clathrin molecules (Doherty & McMahon 2009). Uptake of material into cells was shown for 
the first time by electron microscopy of vesicles with proteinaceous coats in various distinct 
tissues, also described as “vesicles in a basket” (Rosenbluth & Wissig 1964; Roth & Porter 
1964). Clathrin was identified as major protein building block of this lattice-like coat around 
the vesicles (Pearse 1976).  Clathrin consists of three heavy chain subunits that interact with 
three light chain molecules, in order to self-assemble into a three-legged trimer or triskelion 
(Ungewickell & Branton 1981). Clathrin triskelions have the ability to spontaneously 
assemble into cages, resembling the lattice that forms around a coated vesicle (Vigers et al. 
1986; Lafer 2002). The process of clathrin-coating undergoes five distinct stages: initiation, 
cargo selection, coat assembly, scission and uncoating.   
The first stage of initiation or nucleation begins with the formation of a pit, representing a 
membrane invagination. Recent endocytosis studies in yeast and mammalian cells suggest 
that the initiation phase requires the formation of a nucleation module, in order to determine 
the membrane location where vesicle budding will take place (Stimpson et al. 2009; Henne 
et al. 2010). The nucleation module contains FER/CIP4-homology-domain only proteins, 
EGFR pathway substrate 15, as well as intersectins and its assembly at the plasma 
membrane is thought to be based on a preference for membrane-specific 
phosphatidylinositol-4,5-bisphosphate (PtdIns(4,5)P2) lipids (Henne et al. 2010; Stimpson et 
al. 2009; Reider et al. 2009). Once localized at the membrane and prior to cargo selection, 
the nucleation module recruits adaptor protein 2 (AP2) together with other cargo-specific 
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adaptor proteins. AP2 represents the second most abundant protein of clathrin-coated 
vesicles and forms an AP2 adaptor complex with several other supporting proteins which 
acts as major interaction hub in the maturing clathrin-coated pit. The stable complex consists 
of a core domain that can bind both PtdIns(4,5)P2 and cargo domains destined for 
internalisation; and two appendage domains that bind to accessory proteins and clathrin 
(Collins et al. 2002). Following cargo selection and binding, the clathrin coat assembles. 
Therefore, AP2 or other cargo-specific adaptors mediate the recruitment of clathrin triskelia 
from the cytosol to the membrane, to support formation of coated vesicles. Subsequently, 
clathrin molecules polymerize around the vesicle, in order to stabilize its curvature and 
organize the arrangement of cargo accessory adaptor proteins and curvature effectors (Tebar 
et al. 1996; Saffarian et al. 2009). Fission of vesicles is performed by dynamin, (Kosaka & 
Ikeda 1983), a GTPase which is recruited to the vesicle neck curvature by specific Bin-
Amphiphysin-Rvs domain-containing proteins (Ferguson et al. 2009; Sundborger et al. 
2011). Although the precise mechanism is not clear, dynamin is thought to undergo a GTP 
hydrolysis-dependent conformational change that facilitates its polymerisation around the 
neck; and results in vesicle scission from the membrane (Sweitzer & Hinshaw 1998; Roux et 
al. 2006; Bashkirov et al. 2008). The importance of dynamin was highlighted by studies 
showing that inhibition of its recruitment or activation resulted in the arrest of vesicle 
formation at the phase of clathrin-coat assembly, prior to vesicle fission (van der Bliek et al. 
1993; Macia et al. 2006). Following endocytosis the clathrin coat is disassembled by the 
plasma membrane ATPase heat shock cognate 70 (HSC70) and its cofactor auxilin 
(Schlossman et al. 1984; Ungewickell et al. 1995). Hereby, auxilin binds to terminal 
domains of clathrin triskelia and subsequently recruits HSC70 to a specific motif at the foot 
of the clathrin tripod to initiate the uncoating reaction (Massol et al. 2006; Xing et al. 2010). 
In vitro studies described that for a maximum disassembly rate, one auxilin and three or 
fewer HSC70 molecules are necessary (Rothnie et al. 2011). Once the vesicle is uncoated, it 
can travel to and fuse with the early endosome, where the cargo components are either 
recycled or transferred into MVBs for further processing.  
The most established role of clathrin-mediated endocytosis is the constitutive or stimulated 
internalisation of plasma membrane receptors, which is involved in various biological 
processes, such as cellular homeostasis, growth control, cell differentiation or synaptic 
transmission. Independent of ligand binding, eukaryotic cells constitutively internalise 
various types of receptors and recycle most of them back to the plasma membrane in a short 
time span. The human transferrin receptor, represents the classic textbook example of a 
receptor being trafficked mainly through the recycling pathway (Jing et al. 1990). However, 
internalisation of many other receptors such as RTKs, (e.g. EGFR) or GPCRs (e.g. β-
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adrenergic receptor), is initiated by stimulation through ligand binding. Ligand-induced 
phosphorylation and the resulting dimerization of RTKs or conformational change of 
GPCRs, is necessary for the binding of adaptor proteins in the process of clathrin-dependent 
endocytosis (Sigismund et al. 2012). After their cellular uptake, receptors are then either 
relieved of their ligand and recycled back to the cell surface or degraded by endosomal 
sorting into lysosomes. In classic signal transduction, this mechanism acts as a termination 
signal through physical removal of activated receptors from the cell surface (Scita & Di 
Fiore 2010). Serving as a prominent example is the clathrin-mediated endocytosis of 
Frizzled as part of the Wnt signalling pathway during embryonic development. Hereby, 
activation by Wnt ligands leads to the AP2-dependent internalisation of the receptor and its 
subsequent lysosomal degradation (Yu et al. 2007). In addition, clathrin-dependent 
endocytosis is also able to activate or amplify signalling, due to the fact that ligand-bound 
receptors within the endosome can also act as internal signalling platforms. Several RTKs, 
including EGFR, have been reported to remain phosphorylated, ligand bound and active 
until late stages of endosomal trafficking (Sorkin 2002). 
Clathrin-mediated endocytosis is an essential tool to organise intracellular trafficking and 
signalling. Loss of function of any of the involved central components has been shown to 
cause embryonic lethality (Mitsunari et al. 2005; Chen et al. 2009). Despite these severe 
effect in early development, first evidence for an involvement in cancer was the observation 
of gene fusions and translocations of clathrin components with transcriptions factors or 
kinases in human leukemias and lymphomas (Bernard et al. 1994; Dreyling et al. 1996). In 
addition, cancer genome sequencing revealed somatic mutations of clathrin and several 
associated factors primarily in breast, renal and lung cancers (Kan et al. 2010; Dalgliesh et 
al. 2010). However, it remains unclear if these mutations play a role in the tumourigenic 
phenotype. Interestingly, alterations of gene expression levels and somatic mutations were 
mostly found in solid tumours, whereas fusion genes were exclusively observed in blood 
cancers. It is speculated that dividing cells of solid tumours can only tolerate mild 
disturbances in clathrin-mediated endocytosis, while differentiated immune and blood cells 
can survive more severe perturbations (McMahon & Boucrot 2011). This goes in line with 
observations that showed that inhibition of clathrin-dependent endocytosis had no effect on 
B lymphocytes (Wettey et al. 2002). Altered expression levels in cancer cells were only 
reported for few proteins associated with clathrin-mediated endocytosis. Dab2, an adaptor 
protein similar to AP2, is downregulated in ovarian (Mok et al. 1998), prostate (Tseng et al. 
1998), bladder (Karam et al. 2007) and breast cancer (Fazili et al. 1999), whereas Hip1R, a 
component of clathrin-coated vesicles involved in actin organization, is overexpressed in 
colon cancer (Scanlan et al. 2002) and chronic lymphocytic leukemia (Porpaczy et al. 2009).  
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1.8 Aim of the thesis 
The main aim of this project was to characterize the proteolytic cleavage of Trop2 and to 
investigate how Trop2 processing is regulated. In order to achieve this aim, I was trying to 
answer the following questions: 
-Which ADAM proteases are capable to promote Trop2 cleavage? 
-What is the effect of ADAM overexpression on AP-Trop2 stalk sequence deletion mutants? 
-How does activation of classical and novel PKC isoforms through PKC activators affect 
Trop2 shedding? 
-What is the role of atypical PKCζ in regulating Trop2 cleavage? 
-Is Trop2 released in microvesicles?  
-Are there other, yet unknown, cleavage sites within the Trop2 ectodomain? 
-Does endocytosis influence Trop2 processing? 
-Is Trop2 cleaved in prostate cancer cell lines? 
-Does Serine 303 regulate Trop2 shedding? 
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2. Material & Methods 
2.1 Cell culture 
DMEM, Ham’s F12 and RPMI 1640 culture medium were obtained from Lonza, fetal 
bovine serum (FBS), Opti-MEM culture medium, trypsin/EDTA solution and Hygromycin 
B from Life Technology and poly-L-lysine solution from Sigma-Aldrich. All plastic ware 
used in tissue culture was purchased from Sarstedt Ltd. unless otherwise stated. 
2.1.1 Cultivating and counting of human cell lines 
Culture conditions for the cell lines used are displayed in Table 2.1. In general, cell lines 
were cultured at 37 °C in humidified air, containing 5 % CO2. The cells were passaged every 
3-4 days upon confluency. Cells were washed once with phosphate buffered saline (PBS) 
(without Ca
2+
 and Mg
2+
) and then incubated with 1ml trypsin/EDTA solution per 75 cm
2
 
tissue culture flask for 5 min at 37 °C. Trypsination of cells was stopped by adding 7 ml of 
DMEM/10% FBS and followed by centrifugation for 5 min at 1.500 rpm. The medium was 
then removed and the cells were diluted in a ratio of 1:5 to 1:10 respectively in growth 
medium. Depending on the experiment different defined cell numbers were needed. 
Therefore, the cells were counted using a Neubauer cell counting chamber. HEK293 cells 
were seeded on poly-L-lysine (Sigma-Aldrich) coated plates, whereas stably expressing 
HEK293s and prostate cancer cell lines did not require additional coating. 
Cell line Origin Culture medium 
HEK293 Flp-In Human embryonic kidney 90% DMEM, 10% FBS 
HEK293 AP-Trop2-V5 Human embryonic kidney 90% DMEM, 10% FBS 
100µg/ml hygromycin 
HEK293 Trop2-V5 Human embryonic kidney 90% DMEM, 10% FBS 
100µg/ml hygromycin 
HEK293  
Δ254-271AP-Trop2-V5 
Human embryonic kidney 90% DMEM, 10% FBS 
100µg/ml hygromycin 
HEK293  
Δ247-273AP-Trop2-V5 
Human embryonic kidney 90% DMEM, 10% FBS 
100µg/ml hygromycin 
LNCaP Human prostate adenocarcinoma 90% RPMI 1640, 10% FBS 
PC3 Human prostate adenocarcinoma 90% Ham’s F12, 10% FBS 
Table 2.1: Culture conditions for cell lines 
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2.1.2 HEK293 model system 
The HEK293 Flp-In cell line was obtained from Life Technologies. HEK293 cell lines 
stably expressing AP-Trop2-V5 or Trop2-V5 were established by Dr. Vera Knäuper, 
whereas Δ254-271AP-Trop2-V5 and Δ247-273AP-Trop2-V5 expressing cells were generated, as 
described below (Chapter 2.1.6). 
2.1.3 LNCaP and PC3 cell model 
PC3 and LNCaP cells were a kind gift from Dr. Anne Collins and Prof. Norman Maitland 
from the University of York. Both cell lines originate from human prostate adenocarcinoma 
tissue. LNCaP cells are androgen-sensitive and were derived from lymph node metastases, 
whereas PC3 cells are androgen-independent and were derived from bone metastases. They 
are two of the most commonly used prostate cancer cell lines in research, as they represent 
an indolent (LNCaP) and aggressive (PC3) form of the disease. 
2.1.4 Thawing and freezing of human cell lines 
Cells stored in liquid nitrogen were rapidly thawed in a 37 °C water bath, washed with 
medium and then cultured in their according medium with 10% FBS under normal 
conditions. The medium was changed the next day. 
For long time storage, cells were cultured in a T-175 flask until they reached a confluency of 
80-90%. The cells were then washed with PBS, trypsinized and resuspended in 7ml of 
freezing medium (DMEM/10% FBS + 10% DMSO). The cell suspension was evenly 
distributed into seven cryo vials, which were placed in a freezing container for 24h at -80 °C 
prior to long time storage in a liquid nitrogen dewar.  
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2.1.5 Creation of stably-transfected HEK293 cells 
In order to establish stably expressing cell lines, HEK293 Flp-In cells were used. These cells 
contain a single Flp-In recombination site, allowing targeted integration of cDNA at this site 
through co-transfection of appropriate expression vectors with pOG44 recombinase. 
In preparation for transfection 2.0 x 10
5
 cells were seeded in a 6-well plate; and cultured in 
DMEM with 10% FCS for 24 h at 37 °C and 5 % CO2. The cells were then co-transfected 
with 1.8 µg pOG44 plasmid, encoding the Flp recombinase and 0.2 µg of a pcDNA5/FRT 
expression vector, encoding Trop2 variants using FuGENE 6. After transfection, the cells 
were cultured for another 24 h. Stable transfectants were selected with 100µg/ml 
hygromycin in DMEM medium containing 10% FCS. The cells were cultured for approx. 20 
days, with a medium change on each day to remove dead cells and to ensure selection 
pressure. Growing colonies of stably transfected cells were then transferred into a T-75 flask 
and cultured in hygromycin selection medium. 
2.1.6 Transient transfection of HEK293 cells 
Transfection of HEK293 cells was performed with the transfection agent FuGENE 6 
(Promega) using a FuGENE to plasmid ratio of 3:1. First, the transfection agent was diluted 
in serum-free Opti-MEM and incubated for 5 min. Then, the plasmid solution was added and 
incubated for 15 min at room temperature (RT) before the complex was pipetted onto the 
cells.  
2.1.6.1 Transfection of overexpression plasmids 
HEK293 cells were plated onto a 24-well plate at a density of 1.0 x 10
5
 cells/well and grown 
for 24h. Next day, each well was transfected with 0.5μg of plasmid DNA, using FuGENE 6 
transfection agent. For co-transfection of two different vectors, plasmids were mixed in a 
ratio of 1:1. Cells were then cultured for 48h, before they were further analysed.  
2.1.6.1 Transfection of shRNA encoding plasmids 
HEK293 cells were plated onto a 24-well plate at a density of 0.2 x 10
5
 cells/well and grown 
for 24h. Next day, each well was co-transfected with 0.5μg of shRNA plasmid and 0.25μg of 
AP-Trop2 plasmid using, FuGENE 6 transfection agent. Cells were then grown for 48h, 
before they were again transfected with 0.5μg of shRNA plasmid per well. They were then 
cultured for another 24h, before being further analysed. 
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2.2 Alkaline phosphatase (AP) – shedding assay 
2.2.1 Measurement of AP-activity in the medium 
Transiently transfected or stably expressing HEK293 cells were cultured and treated under 
various conditions, before their conditioned medium was analysed. Therefore, the medium 
was taken off the cells and centrifuged for 10 min at 13.000 rpm, in order to remove cells 
and cell debris. The cleared medium was mixed in a 1:1 ratio with a 2mg/ml solution of 4-
nitrophenyl phosphate (4-NPP) in AP assay buffer and then placed in duplicates in a 96-well 
plate. The hydrolysis of 4-NPP into 4-nitrophenolat anion by AP was measured at 405 nm 
every 30 to 60 minutes over a period of several hours using a microplate reader (Omega 
Plate Reader, BM Labtech). OD values >1 were dismissed, in order to ensure linearity of 
substrate hydrolysis. 
2.2.2 Statistical analysis 
The data was analysed by One-way Anova with Tukey post-test, using GraphPad Prism
®
. 
All p values below 0.05 (95% confidence interval) were considered significant. The final 
presentation of every experiment contains the data of 3 independent AP shedding assays, 
performed with 4 repeats per condition in each assay (n=12).  
2.3 Protein analysis by Western blotting 
2.3.1 Cell lysis 
After removal of the medium, cells were lysed by adding 35 µl of lysis buffer in every well 
of a 24-well plate. The lysates were incubated for 30 min on ice and then centrifuged at 
13.000 rpm for 10 min, to remove cellular debris. The supernatant was removed and stored 
at -80 °C for further analysis. 
2.3.2 Protein concentration assay (DC assay) 
To determine protein concentrations, the colorimetric DC-assay from Bio-Rad was used. 
BSA concentrations ranging from 0.2 – 1.5 mg/ml in lysis buffer were used to create a 
protein standard curve. 5µl of the BSA standard and each sample were pipetted in duplicates 
into a 96-well plate. Subsequently, 25µl of reagent A’ (20µl reagent S in 1ml reagent A) and 
200µl of reagent B, were added per well. The plate was then incubated for 20 min at room 
temperature followed by measurement of the absorbance at 570nm using a microplate reader 
(Omega Plate Reader, BMG Labtech). Protein concentrations were derived from the gradient 
of the BSA standard curve. 
 53 
 
2.3.3 Deglycosylation of lysates with PNGase F 
Since Trop2 is highly glycosylated, it needed to be deglycosylated in order to determine the 
molecular weight of its fragments. This was performed using PNGase F from New England 
Biolabs. Therefore, 20µg of lysate was combined with 1µl of 10x glycoprotein denaturing 
buffer and H2O to a total reaction volume of 10µl. The sample was then incubated for 10 
min at 100 °C, to denature the glycoproteins. Next, the total reaction volume was increased 
to 20µl by adding 2µl of 10x G7 reaction buffer, 2µl of 10% NP-40, 1µl of PNGase F and 
5µl H2O. The reaction was allowed to proceed for 1h at 37 °C, before the samples were 
analysed by Western blotting.  
2.3.4 Tricine SDS-PAGE 
The regular Glycine-SDS-PAGE (also known as Lämmli-SDS-PAGE) is the commonly 
used SDS electrophoretic technique for separating proteins in the molecular range of 20 – 
100 kDa. However, for proteins or fragments whose molecular mass is less than 20 kDa, a 
Tris-Glycine buffer system does not provide the optimal band resolution. As a consequence I 
used a Tricine-SDS-PAGE system that is more suitable for the resolution of proteins < 20 
kDa. Tricine, used as the trailing ion in the running buffer, migrates faster than glycine and 
small proteins, thereby allowing a better separation of low molecular weight bands 
(Schägger & Von Jagow 1987).  
Analytical Tricine SDS-PAGE was performed with 16% and 10% polyacrylamid gels, 
which were cast from an acrylamide-bisacrylamide (AB-3) stock solution (49.5%), 
according to Schägger (Schägger 2006) and outline in Table 2.2. Prior to loading, 25μg of 
cell lysate were diluted in 2 x SDS loading buffer and heated at 95 °C for 2 min, to denature 
the proteins. The samples were loaded onto the gel together with 7μl of protein marker 
(BLUeye prestained protein ladder, Geneflow). The gel then run with cathode buffer in the 
cathode chamber and anode buffer in the anode chamber until the marker dye reached the 
bottom. Low percentage gels (10%) were run at 130V at room temperature, whereas high 
percentage gels were run at 160V at 4 °C, using a BioRad Gel Run System. 
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 4 % sample gel 10% gel 16 % gel 
AB-3 solution 1 ml 3 ml 5 ml 
Gel buffer (3x) 3 ml 5 ml 5 ml 
Glycerol - 1.5 g 1.5 g 
H2O to final volume 12 ml 15 ml 15 ml 
Polymerize by adding : 
APS (10%) 150 µl 150 µl 150 µl 
TEMED 15 µl 15 µl 15 µl 
Table 2.2: Composition of Tricine SDS gels 
2.3.5 Western blotting 
Polyvinylidene difluoride (PVDF) membranes (Thermo Fisher Scientific) were activated for 
30s in methanol, followed by equilibration in transfer buffer, in conjunction with the SDS 
polyacrylamide gels. Proteins were transferred onto the PVDF membrane at 75V for 1.5h, or 
at 20V overnight, in a Bio-Rad transfer cell containing transfer buffer and a cooling block. 
To block unspecific binding sites, the membrane was incubated for 1 h in 5 % milk 
dissolved in Tris buffered saline with tween (TBS-T). The membrane was incubated 
overnight at 4°C with primary antibody in 2.5 % milk in TBS-T.  This was followed by 
several washing steps with PBS-T for at least 30 min. The secondary antibody conjugated to 
horseradish peroxidase and specific against the Fc domain of the primary antibody was 
incubated for 1 h in 1.25 % milk in TBS-T, at room temperature. Several washing steps with 
TBS-T for at least 30 min were performed. The secondary antibody was detected via 
chemiluminescence. Therefore, the membrane was incubated with a self-made ECL solution 
mix for 3 min and the membrane exposed to ECL films (GE Healthcare). The compositions 
of the self-made ECL solution, as well as all primary and secondary antibodies used for 
Western blotting, are outlined in the appendix (Appendix I).  
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2.3.6 Densitometry  
Band intensities were quantified using ImageJ software. Briefly, gel pictures were opened 
with ImageJ and bands were marked using the Rectangular selection tool. The Plot lanes 
option was used to draw profile blots of all bands, which represented the relative density of 
the contents of the rectangle for each lane. The peaks were enclosed using the Straight line 
tool by drawing a line across the base of the peak. The size of each peak was then quantified 
by the Wand tool; and the obtained values were used to compare intensities of protein bands 
with the GAPDH loading control. For analysis, blots from three independent experiments 
were used (n=3).  
2.4 Medium concentration 
Stably expressing HEK293 cells were plated onto a 6-well plate at a density of 3.0 x 10
5
 
cells/well and grown for 48h, or until they reached a confluency of 80-90%. Culture medium 
was removed and each well was washed with 1 ml of serum-free Opti-MEM. The cells were 
then incubated for 3h in 1 ml of serum-free Opti-MEM, under various conditions. Next, the 
conditioned medium was taken off and centrifuged for 10 min at 13.000 rpm, in order to 
remove dead cells and cell debris. Now, the medium was concentrated to ~100μl using 
centrifugal concentration tubes (Amicon Ultra-4, Millipore), with a 3kDa molecular mass 
cut-off. Therefore, the tubes were centrifuged for ~90 min at 4.000 rpm. 20μl of the final 
concentrate was diluted with 2x SDS sample buffer (reducing or non-reducing), denatured at 
95°C for 3 min and analysed by Western Blotting.  
2.4.1 Ultracentrifugation 
In order to separate cellular vesicles from soluble proteins, the cleared conditioned medium 
was subjected to ultracentrifugation at 100.000g for 1h, at 4°C. This was done with a Sorvall 
Discovery 100SE centrifuge (Thermo Scientific), using a SW 32 Ti 32.000RPM rotor 
(Beckmann Coulter). The resulting pellet was dissolved in 2x SDS sample buffer (reducing 
and non-reducing); and the supernatant was further concentrated and analysed, as described 
above. 
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2.5 Immunofluorescence 
All primary and secondary antibodies used for immunofluorescence are outlined in Table 
2.3. Cells were analysed using a Leica SP5 Confocal Microscope (Leica, Microsystems). 
Images were acquired with a 63x oil immersion objective, using the 488 and 543 laser line. 
Primary antibodies 
Antibody Working dilution Manufacturer 
Mouse anti-V5 1:500 Invitrogen 
Goat anti-Trop2 1:500 R&D Systems 
Secondary antibodies 
Antibody Working dilution Manufacturer 
Anti-mouse AlexaFluor
®
594 1:500 Invitrogen 
Anti-goat AlexaFluor
®
488 1:500 Invitrogen 
Table 2.3: Antibodies used for immunofluorescence 
2.5.1 Immunodetection of AP-Trop2 in HEK293 cells 
HEK293 cells stably expressing AP-Trop2 were seeded onto glass cover slips in 24-well 
plates, at a density of 0.2 x 10
5
 cells/well. These were cultured for 48 h in DMEM/10% FBS 
and then stimulated using various conditions, prior to immunodetection of AP-Trop2. Cells 
were washed with PBS, fixed with 4% paraformaldehyde in PBS for 7 min; and then washed 
again 3x with PBS. They were then permeabilised with 0.5% saponin/PBS for 10 min, 
washed 3x with PBS and blocked for 30 min in 1% BSA/PBS blocking buffer. 
Subsequently, the cells were incubated with of both anti-V5 and anti-Trop2 primary 
antibodies in blocking buffer at 4°C for 2h in a humidified chamber. Cells were then washed 
3x with PBS, incubated with both anti-mouse AlexaFluor
®
594 and anti-goat 
AlexaFluor
®
488 secondary antibodies in blocking buffer, for 1h at room temperature; and 
washed again 3x with PBS. Nuclei were counter stained with DAPI-containing vectashield 
mounting medium (Vector Laboratories). 
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2.6 Co-Immunoprecipitation 
Co-immunoprecipitation (Co-IP) was used to investigate the potential interaction between 
Trop2 and PKC isoforms. Therefore, HEK293 cells stably expressing Trop2-V5 were seeded 
in 6-well plates and cultured until they were confluent. Prior to the Co-IP, cells were 
stimulated and lysed, as described previously (Chapter 2.3.1).  
An input control was taken before 600μl of cell lysate was rotated for 1h at 4°C with 20μl of 
Protein G Sepharose beads (Sigma-Aldrich).  This preclearing was done to remove proteins 
from the lysate that would bind unspecifically to the beads. The beads were centrifuged and 
the supernatant transferred into a new Eppendorf vessel. Then, 5μg of anti-Trop2 antibody 
or goat IgG negative control was added to 300μl of pre-cleared lysate. The tubes were placed 
on a rotating wheel for mixing (2h at 4°C), before addition of 20μl of Protein G Sepharose 
beads. Next, samples were rotated for another hour at 4°C. The beads were then washed 5x 
with lysis buffer and resuspended in 2x SDS loading buffer. Proteins were released from the 
beads by incubation at 95°C for 5 min and the samples were stored at -80°C, prior to further 
Western blot analysis.  
2.7 Nanoparticle tracking analysis (NTA) 
Measurement of extracellular vesicles in medium was performed using a Nanosight LM10 
instrument (NanoSight Company), consisting of a conventional Optical Microscope, charge-
coupled device camera and a LM10 unit (sample unit), with a laser light source. Conditioned 
media was taken off the cells and centrifuged for 10 min at 13.000 rpm, in order to remove 
intact cells and cell debris. Approximately 300μl of the samples were injected into the LM10 
unit with a 1ml sterile syringe. Capturing settings (shutter: 9ms; gain: 250) were manually 
set according to the manufacturer’s instructions. The LM10 was used to record 60s sample 
videos, which were than analysed with the Nanoparticle Tracking Analysis (NTA) 2.0 
Analytical Software. The calculated concentration values, as well as the size distribution 
tables, were then exported and further analysed using GraphPad Prism
®
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2.8 Stimulation with PKC activators and ionomycin 
Stably expressing HEK293 cells were plated onto a 24-well plate at a density of 1.0 x 10
5
 
cells/well and grown for 72h, or until they reached a confluency of 80-90%. Culture medium 
was removed and each well was washed with 200µl of serum-free Opti-MEM. PKC 
activator or ionomycin solutions were prepared in serum-free Opti-MEM in defined 
concentrations (Table 2.4). 250 µl of the solutions or a DMSO solvent control were then 
added onto the cells of each well, followed by incubation for 3 h at 37 °C. 
Chemical agent Concentration 
PMA 100 ng/ml 
IngM 100 ng/ml 
EBC46 500 ng/ml 
Ionomycin 1 µM 
Table 2.4: Phorbol ester and ionomycin concentrations 
2.9 Inhibition of ADAM metalloproteinases 
ADAM inhibitors GW280264x, (GW64) targeting ADAM17 and GI254023x (GI23) 
targeting ADAM10, were obtained from Dr. Amour at GlaxoSmithKline. The broad-
spectrum matrix metalloproteinase inhibitor, GM6001, was purchased from Millipore. The 
inhibitors were used at defined concentrations of 1µM (GW64 and GI23) and 25µM 
(GM6001) respectively. 
Stably expressing HEK293 cells were plated onto a 24-well plate at a density of 1.0 x 10
5
 
cells/well; and grown for 72h or until they reached a confluency of 80-90%. Prior to 
stimulation cells were pre-incubated for at least 16 h with fresh serum-containing growth 
medium containing the inhibitors or DMSO as solvent control. The medium was then 
removed and cells washed with 200µl of serum-free Opti-MEM, before they were stimulated 
in the presence of the inhibitors or DMSO solvent control, in serum-free Opti-MEM for 3h 
at 37 °C. 
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2.10 Inhibition of classical and novel PKCs 
Gö6976, an inhibitor against classical PKC isoforms was obtained from Merck, whereas 
bisindolylmaleimide I (BIM-1), an inhibitor against classic and novel PKC isoforms, was 
purchased from Millipore. Both inhibitors were used at a defined concentration of 1µM. 
Stably expressing HEK293 cells were plated onto a 24-well plate at a density of 1.0 x 10
5
 
cells/well; and grown for 72h or until they reached a confluency of 80-90%. Prior to 
stimulation, cells were pre-incubated for 1h with serum-free Opti-MEM containing the 
inhibitors or DMSO as solvent control. The medium was then removed and cells washed 
with 200µl of serum-free Opti-MEM, before they were stimulated in the presence or absence 
of the inhibitors in serum-free Opti-MEM for 3h at 37 °C. 
2.11 Inhibition of atypical PKCζ 
PKCζ was inhibited by using shRNA directed against the isoform or synthetic peptides 
mimicking the pseudosubstrate domain of atypical PKCζ.  
2.11.1 shRNA transfection 
Expression vectors of shRNA targeting PKCζ and a scrambled shRNA negative control, 
were obtained from Sigma-Aldrich (Mission
®
 shRNA). Both shRNA targeting sequences are 
outlined in Table 2.5. Overexpression plasmids for AP-Trop2 and shRNA were co-
transfected using FuGENE 6 transfection agent, as previously described (Chapter 2.1.7). 
Oligonucleotide Sequence 
shPKCζ 
CCGGCGCGTGATTGACCCTTTAACTCTCGAGAGTTAAAGGG
TCAATCACGCGTTTTT 
shScrambled 
CCGGGCGCGATAGCGCTAATAATTTCTCGAGAAATTATTAG
CGCTATCGCGCTTTTT 
Table 2.5: shPKCζ and shscrambled oligonucleotide sequences. 
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2.11.2 Pseudosubstrate inhibitors to PKCζ 
The PKC-ζ PS and mPS (pseudosubstrate and myristoylated pseudosubstrate) peptides with 
the sequences SIYRRGARRWRKL and Myr-SIYRRGARRWRKL were purchased from 
R&D Systems. The control peptide with a scrambled sequence, Myr-SRIYRGRARWRLK, 
was custom synthesized by GeneScript. All peptides were used at 10µM doses. 
Stably expressing HEK293 cells were plated onto a 24-well plate at a density of 1.0 x 10
5
 
cells/well; and grown for 72h or until they reached a confluency of 80-90%. Culture medium 
was removed and each well was washed with 200µl of serum-free Opti-MEM. Then, 250µl 
of serum-free Opti-MEM, containing the inhibitory peptide or a distilled H2O solvent control 
were added  onto the cells of each well; followed by incubation for  3 h at 37 °C. 
2.12 Inhibition of clathrin-mediated endocytosis 
Dynasore, a dynamin inhibitor of clathrin-mediated endocytosis was purchased from Sigma-
Aldrich and used at 80µM. Stably expressing HEK293 cells were plated onto a 24-well plate 
at a density of 1.0 x 10
5
 cells/well; and grown for 72h or until they reached a confluency of 
80-90%. Prior to stimulation, cells were pre-incubated for 30 min with serum-free Opti-
MEM containing Dynasore or DMSO as a solvent control. The medium was then removed 
and cells washed with 200µl of serum-free Opti-MEM, before they were stimulated with 
mPS or PMA in the presence of Dynasore or DMSO solvent control, in serum-free Opti-
MEM for 3h at 37 °C. 
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3. Trop2 shedding by ADAM metalloproteinases 
3.1 Introduction 
Large numbers of transmembrane proteins are proteolytically cleaved within their 
ectodomain, which is then released into the extracellular space. This shedding process 
regulates the physical location and fate of membrane-anchored growth factors (Massagué & 
Pandiella 1993), growth factor receptors (Rose-John & Heinrich 1994); and cell adhesion 
molecules (Ehlers & Riordan 1991). Many of these cell-surface proteins are of practical 
importance. For example, both TNF-α and homing receptor L-selectin play a role in 
inflammatory responses (Vassalli 1992; Gearing & Newman 1993). Membrane protein 
ectodomain shedding is recognized as an important aspect of cell-cell interaction and cell 
regulation. In this process, it converts membrane receptors into soluble decoy receptors for 
their own ligand, membrane-anchored growth factors into soluble signalling molecules  
(Gearing & Newman 1993); and cell adhesion molecules into products no longer capable of 
mediating physical interactions with neighbour cells or the extracellular matrix (Fernandez-
Botran 1991).  
Major mediators of ectodomain shedding are metalloproteinases of the ADAM family but 
many transmembrane proteins are also cleaved by membrane-anchored serine proteases 
(Hayashida et al. 2010). Cleavage of the ectodomain occurs constitutively by activated 
ADAMs on the cell surface, or is induced in response to different stimuli. One of the most 
effective activators of ADAM-dependent shedding is the phorbol ester, PMA, which will be 
discussed in detail in Chapter 4. Another ADAM activation mechanism works through the 
generation of reactive oxygen species (ROS). The so called “cysteine switch” that keeps 
ADAM proforms inactive, can be disrupted by ROS-mediated oxidation of the electrophilic 
thiol groups which results in the activation of the ADAM catalytic domain (Maeda et al. 
1998). Cleavage of membrane proteins by ADAMs is facilitated by UV radiation and 
hypertonic osmotic pressure, as it was shown for HB-EGF, TGFα and neuregulins (Montero 
et al. 2002, Takenobu et al. 2003). ADAM-mediated shedding was also shown to be 
stimulated by cytokines, like IL-1β and TNFα, which induce cleavage of tomoregulin-2 (Lin 
et al. 2003). Ectodomain shedding by members of the ADAM family can also be regulated 
by their cell surface localization. ADAM12 activation occurs within the trans-Golgi 
network, prior to translocation to the cell surface as constitutively active protease (Kveiborg 
et al. 2008). On the contrary, ADAM17 was shown to be removed from the cell surface by 
endocytosis shortly after its activation, which represents another potential ADAM control 
mechanism (Doedens & Black 2000). Membrane proteins are usually processed by ADAMs 
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present on the surface of the same cell (cis orientation). However, it was reported that 
ADAM10 is able to cleave substrates that a are localized on adjacent cells (trans orientation) 
(Janes et al. 2005). 
A recent study described that Trop2 undergoes ectodomain shedding mediated by ADAM17 
(Stoyanova et al. 2012), in the process of regulated intramembrane proteolysis. However, it 
is possible that Trop2 might not be cleaved by ADAM17 alone. Various studies have shown 
that inhibition of ADAM mediated shedding events can be compensated for by other ADAM 
family members. Gall et al. demonstrated that many ADAM17 substrates, such as TGF-α, 
TNF-α, HB-EGF or L-selectin, are cleaved by ADAM10 in ADAM17-/- fibroblasts and 
primary B cells (Le Gall et al. 2009). Another example for an overlapping substrate 
repertoire was the finding that the Notch receptor can be cleaved by either ADAM10 or 
ADAM17, depending on ligand interactions (Bozkulak & Weinmaster 2009). Due to this 
fact, we hypothesized that Trop2 can be shed by other ADAMs than ADAM17. Trop2 
shedding by distinct ADAMs could occur at the same cleavage site, in order to compensate 
loss of ADAM17 activity, or at alternative sites to regulate other functions of Trop2. This 
hypothesis is further supported by the recent discovery of 9 novel cleavage sites in the 
extracellular and transmembrane domain of Trop2 homologue EpCAM, indicating the 
presence of yet unknown regulatory mechanisms (Hachmeister et al. 2013; Schnell et al. 
2013). 
This chapter introduces an alkaline phosphatase (AP) reporter system that enables the 
investigation of ectodomain shedding. It was developed by Carl Blobel to monitor the 
cleavage of EGFR ligands by ADAM proteases (Zheng et al. 2002). In this project, the 
spectrophotometric AP-shedding assay was used with fusion proteins containing an AP 
domain attached to the N-terminus of Trop2. When AP-Trop2 is expressed in HEK293 cells, 
shedding of its ectodomain by ADAMs can be detected by quantification of AP levels in the 
culture supernatant. For this purpose, AP activity is measured by the rate of increase in 
absorbance at 405nm, which is based on the catalytic processing of a colourless substrate 
into a yellow product. HEK293 cells were chosen as a model cell line, as they are easy to 
culture and transfect. More important, HEK293 cells were shown to have only low 
endogenous AP activity, in comparison to other cell lines (Inoue et al. 2012). In addition to 
the AP-tag, the expression construct contains an N-terminal HA-tag and a C-terminal V5-
tag, to allow the detection of AP-Trop2 by Western blot analysis (Figure 3.1). 
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Figure 3.1: Schematic representation of Trop2 shedding  
N-terminal alkaline phosphatase (AP) and C-terminal V5 tagged Trop2 were expressed in 
HEK293 cells, which allowed monitoring of proteolytic Trop2-release through measurement 
of AP-activity in the medium. Full length AP-Trop2 and C-terminal fragments were detected 
by Western blotting using anti-HA, anti-Trop2 and anti-V5 antibodies.  
So far, ADAM17 is the only reported metalloproteinase capable of cleaving Trop2. 
However, it is not known how the proteolytic processing of Trop2 is regulated. It was shown 
that ADAM17-dependent substrate cleavage is not only determined by the actual cleavage 
site, but also by the so called “stalk” region between the transmembrane domain and the first 
globular part of the substrate (Schlöndorff & Blobel 1999; Wang et al. 2002; Hinkle et al. 
2004). Therefore, Dr. Vera Knauper created two AP-Trop2 stalk sequence deletion mutants, 
in order to investigate whether Trop2 shedding is regulated or cleaved within the stalk 
region (Figure 3.2). As it is known that most ADAM substrates are cleaved 8-10 amino acids 
close to the plasma membrane (Edwards et al. 2008), the deleted sequences were chosen 
accordingly.  
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I wanted to investigate if ADAM17-mediated Trop2 shedding is also regulated by the stalk 
region (Figure 3.2). Therefore, Dr. Vera Knauper created two AP-Trop2 stalk sequence 
deletion mutants, 
 
Figure 3.2: Stalk sequence motif deletion mutants of AP-Trop2  
Schematic representation of AP-Trop2 domain structure. The deleted sequences for both 
AP-Trop2 stalk mutants are indicated. TM = transmembrane domain, ICD = intracellular 
domain. 
3.1.1 Aims of the chapter 
The main aim of the experiments summarized in this chapter was to investigate if other 
ADAM proteases than ADAM17 are capable to promote Trop2 cleavage. Therefore, 
HEK293 cells overexpressing AP-Trop2 and distinct ADAMs were analysed using the AP 
shedding assay and Western blotting. The nature of the detected cellular Trop2 fragments 
was further examined by treatment with the γ-secretase inhibitor, DAPT. Time course 
experiments were performed to confirm that the timeframe is within the linear range of 
Trop2 cleavage. Furthermore, the effect of ADAM overexpression on AP-Trop2 stalk 
sequence deletion mutants was investigated. Stably expressing HEK293 cell lines were 
generated, in order to determine cell surface localization of AP-Trop2 and the stalk mutants, 
using Confocal Microscopy. 
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3.2 Results 
3.2.1 Trop2 is cleaved by ADAM12 and ADAM17 
In order to identify ADAM proteases which can cleave Trop2, their impact on Trop2-ECD 
release was investigated. HEK293 cells were co-transfected with cDNA overexpression 
plasmids encoding AP-Trop2-V5 and the most prominent proteolytic active members of the 
ADAM family (ADAM9, ADAM10, ADAM12 and ADAM17). An inactive ADAM15b 
E/A mutant was used as a negative control. Data from three independent experiments 
showed increased AP-Trop2 release in cells overexpressing ADAM12 and ADAM17. 
Transfection of ADAM9 and ADAM10 overexpression vectors had no significant effect on 
Trop2 shedding, when compared to the inactive ADAM15b control transfection 
(Figure 3.2.1A). Cellular Trop2 fragments were detected by Western blot analysis, using the 
anti-V5 antibody. Overexpression of ADAM17 resulted in slightly increased intensity of a 
Trop2 fragment running at ~11 kDa, whereas for ADAM12 overexpression this signal nearly 
disappeared. An additional Trop2 fragment was observed in all lanes at ~45 kDa with signal 
intensities increasing upon ADAM17 overexpression. Full length AP-Trop2 levels were 
reduced in cells overexpressing ADAM12 (Figure 3.2.1B). Both fragments likely represent 
the products of two distinct Trop2 cleavage events and were termed metalloproteinase 
fragment (MP) = 11kDa and alternative metalloproteinase fragment (aMP) = 45kDa. 
Overexpression of ADAMs was confirmed by Western blot analysis of lysates. The 
ADAM12 cDNA encodes a C-terminal V5-tag and thus, ADAM12 was detected accordingly 
running at ~130 kDa. Staining with anti-ADAM9 antibody showed the active form of the 
protease running at ~70 kDa in cells transfected with ADAM9 overexpression vector. 
ADAM15b and ADAM17 overexpression resulted in increased signal intensities for the 
particular ADAM proteases, at ~100 kDa for ADAM15b and ~130 kDa for ADAM17. All 
ADAMs with the exception of ADAM9 were detected as double bands with the upper band 
representing the inactive zymogen and the lower band the active protease lacking its pro-
domain (Figure 3.2.1C). ADAM10 overexpression could not be detected with various 
commercial antibodies.  
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Figure 3.2.1: ADAM overexpression reveals AP-Trop2 cleavage by ADAM12 and 
ADAM17  
HEK293 cells were co-transfected with overexpression plasmids for AP-Trop2-V5 and 
proteolytic or inactive ADAMs. (A) AP-shedding assay showed a significant increase of 
cleavage following overexpression of ADAM12 and ADAM17, whereas ADAM9 and 
ADAM10 overexpression had no effect and showed similar molecular levels of shedding as 
the negative inactive A15 E/A mutant control. Histograms show fold of increase compared 
to the negative control based on mean values of three independent experiments ± SD; * p < 
0.05; *** p < 0.001; n = 12. (B) Trop2 was detected by Western blotting using anti-V5 
antibody. Both ADAM12 and ADAM17 overexpression lead to an accumulation of a 45kDa 
Trop2 fragment. ADAM17 overexpression led to the accumulation of a second ~11kDa 
band, which was missing upon ADAM12 overexpression. GAPDH served as loading 
control. (C) Detection of ADAM expression levels with antibodies targeting each ADAM9, 
ADAM15 and ADAM17. The ADAM12 overexpression construct contains a V5-tag and 
was detected with anti-V5 antibody. ADAM10 overexpression could not be detected with 
various commercial antibodies.  
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3.2.2 The Trop2 metalloproteinase fragment generated by ADAM12 
cleavage undergoes rapid processing in the cell 
Following the detection of the Trop2 11kDa MP-fragment, we investigated whether this 
band represents the product of the metalloproteinase-induced cleavage event in the process 
of RIP. Therefore, subsequent γ-secretase cleavage was inhibited with DAPT (Dovey et al. 
2001; Micchelli et al. 2003). The experiment was performed in ADAM12-overexpressing 
HEK293 cells, as previous results showed that the Trop2 MP-fragment was below the 
detection limit. DAPT treatment was thereby used to clarify whether the reason for the 
missing band is either that ADAM12 is unable to generate the MP-fragment or that 
subsequent to its cleavage, the MP-fragment undergoes rapid processing in the cell. Data 
from three independent experiments showed a slight, but insignificant decrease of AP-Trop2 
release in the AP-shedding assay in response to DAPT treatment (Figure 3.2.2A). Trop2 in 
the cell lysates was detected by immunoblot analysis using anti-V5 antibody. ADAM12 
overexpression in untreated cells confirmed very low amounts of the MP-fragment, when 
compared to the ADAM15b E/A negative control. However, DAPT treatment caused 
accumulation of the Trop2 11 kDa MP-fragment in both samples. Full length, AP-Trop2 
levels were strongly reduced in ADAM12 expressing cells, indicating that substrate 
depletion may have occurred (Figure 3.2.2B). 
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Figure 3.2.2: Identification of the Trop2 MP-fragment with γ-secretase inhibitor, 
DAPT, in ADAM12 overexpressing cells 
HEK293 cells were co-transfected with AP-Trop2 and ADAM12 overexpression vector in 
the presence or absence of γ-secretase inhibitor, DAPT (5µM). (A) DAPT inhibition did not 
significantly alter shedding levels in the AP-shedding assay. Histograms show fold of 
increase compared to the negative ADAM15b E/A control, based on mean values of three 
independent experiments ± SD; n = 12. (B) Western blot analysis was used to detect cellular 
Trop2 with anti-V5 antibody. DAPT caused an increase of the MP-fragment for both 
ADAM12 and ADAM15 E/A. In addition, substrate depletion of AP-Trop2 was observed 
for ADAM12 overexpressing cells after 3h of incubation in serum-free conditions.  GAPDH 
was used as loading control. 
 
 
 
 
 
 
 
 69 
 
3.2.3 Trop2 is cleaved by ADAM12 over a time period of 6 h, 
whereas ADAM17 cleavage decreased after 6 h 
Measurement of shedding efficiency was performed by quantification of AP-Trop2 release 
in serum free-medium. To confirm that the chosen incubation timeframe of 3 h is in the 
linear range of Trop2 cleavage, shedding was investigated at 2, 4 and 6 h. Data from three 
independent experiments showed a significant increase of AP-Trop2 release in cells 
overexpressing ADAM12, rising in a linear fashion over a time period of 6 h, when 
compared to the negative control. Comparison between ADAM12 cleavage and the negative 
control after 2 h was insignificant. A significant increase was seen after 4 h and 6 h of 
incubation. The basal cleavage activity represented by cells overexpressing inactive 
ADAM15b E/A showed a small increase of shedding over time (Figure 3.2.3.1A). V5 
immunoblot staining showed an increase of the MP-fragment over time for the ADAM15b 
E/A negative control. In cells transfected with ADAM12, only small amounts of the MP- 
fragment were visible after 4 h and 6 h of transfection, despite the high signals in the AP 
shedding assay. Bands for the aMP-fragment were detected with very low signal intensities 
in all lanes. Full-length, AP-Trop2 was observed in higher amounts for the negative control, 
compared to ADAM12 expressing cells (Figure 3.2.3.1B). 
Trop2 cleavage in cells overexpressing ADAM17 was significantly increased after 2 h and 4 
h of incubation. The signal then decreased at the 6 h time point to nearly the level of 
background shedding. The basal cleavage activity of cells expressing inactive ADAM15b 
E/A slowly increased over time (Figure 3.2.3.2A). Western blot analysis using anti-V5 
antibody confirmed the results of the AP shedding assay. ADAM17 overexpression resulted 
in high amounts of the MP-fragment after 2 h, which continuously decreased after 4 h and 6 
h of incubation. The aMP fragment was detected in nearly equal amounts after 2 h and 4 h, 
but decreased in intensity after 6 h. The negative control showed a constant increase of the 
MP fragment over 6 h. Full-length AP-Trop2 levels decreased over time for ADAM17 and 
increased in cells co-expressing ADAM15b E/A (Figure 3.2.3.2B). 
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Figure 3.2.3.1: Linear increase of Trop2 shedding by ADAM12 overexpression 
HEK293 cells were co-transfected with overexpression plasmids for AP-Trop2 and 
ADAM12 or ADAM15b E/A. Shedding was monitored over a 6 h time course with distinct 
time points at 2, 4 and 6 h. Inactive ADAM15b E/A mutant was used as a negative control. 
(A) ADAM12 cleavage was slightly elevated after 2 h, compared to the negative control. A 
significant increase of AP-Trop2 release was observed after 4 h and 6 h. Histogram shows 
fold increases compared to the negative control, based on mean values of three independent 
experiments ± SD; * p < 0.05; *** p < 0.001; n = 12. (B) Immunoblotting was used to detect 
Trop2 with anti-V5 antibody. In contrast to ADAM12, the co-transfection of inactive 
ADAM15b E/A led to an accumulation over time of AP-Trop2 and the MP fragment. 
GAPDH was used as loading control.  
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Figure 3.2.3.2: Substrate depletion in response to ADAM17 overexpression at a 6 h 
time point 
HEK293 cells were co-transfected with overexpression vectors for AP-Trop2-V5 and 
ADAM17; and incubated over a 6 h time course. Inactive ADAM15b E/A mutant was used 
as negative control. (A) Comparison between ADAM17 shedding and the negative control 
revealed significant increases in AP-Trop2 release at the 2 h and 4 h time-points,  whereas 
after 6 h substrate depletion occurred in the ADAM17 co-expressing cells. Histograms show 
fold increases compared to the negative control, based on mean values of three independent 
experiments ± SD; * p < 0.05; n = 12. (B) Western blot analysis with anti-V5 antibody was 
used to detect cellular Trop2. ADAM17 overexpression for 2 h and 4 h led to an 
accumulation of the two Trop2 MP fragments (11 + 45kDa). At the 6 h time point, substrate 
depletion resulted in reduction of both fragment bands. GAPDH was used as loading control. 
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3.2.4 Cleavage of Trop2 by ADAM12 and ADAM17 is regulated by 
the stalk sequence of Trop2  
Both Trop2 stalk mutants, Δ254-271AP-Trop2 and Δ247-273AP-Trop2, are encoded by cDNA 
expression vectors with an N-terminal AP-tag and a C-terminal V5-tag similar to wt AP-
Trop2-V5. HEK293 cells were co-transfected with overexpression plasmids of wt AP-
Trop2, Δ254-271AP-Trop2 or Δ247-273AP-Trop2; and either ADAM12 or ADAM17. Inactive 
ADAM15b E/A mutant was used as a negative control. Measurement of the increase of 
absorbance at 405 nm over time showed distinctive differences between the three Trop2 
substrates. Trop2 and Δ254-271Trop2 showed nearly the same amount of basal background 
shedding, represented by similar signal intensities of the negative controls. Overexpression 
of ADAM12 and ADAM17 resulted in elevated shedding of wt AP-Trop2, whereas 
Δ254-271Trop2 was not cleaved. With regards of the shorter Δ247-273Trop2 stalk mutant, a 
strong overall decrease of AP activity was observed (Figure 3.2.4A). Calculating the fold 
increases in shedding showed that ADAM12 and ADAM17 overexpression led to 
significantly elevated wt AP-Trop2 release as observed in previous experiments. In contrast, 
both stalk mutants were not cleaved by ADAM12 or ADAM17 and signals were equivalent 
to the negative ADAM15b E/A control (Figure 3.2.4B). Western blot detection with anti-V5 
antibody further confirmed the results of previous experiments with regards to AP-Trop2 
shedding. The Trop2 45 kDa aMP-fragment showed higher signal intensities for ADAM17 
overexpression, compared to the inactive ADAM15b E/A mutant. In contrast, I was unable 
to detect Trop2 MP or aMP fragments in cells expressing Δ254-271Trop2 and Δ247-273Trop2 
mutants. The expression levels of full-length AP-Δ254-271Trop2 and AP-Δ247-273Trop2 were 
reduced, compared to wild type AP-Trop2 (Figure 3.2.4C). 
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Figure 3.2.4: ADAM12 and ADAM17 do not cleave Trop2 stalk mutants  
HEK293 cells were co-transfected with plasmids encoding wt AP-Trop2, Δ254-271AP-Trop2 
and Δ247-273AP-Trop2 with overexpression vectors for ADAM12 or ADAM17. Inactive 
ADAM15b E/A mutant was used as negative control. (A) In comparison to wt AP-Trop2 
and Δ254-271AP-Trop2, overexpression of Δ247-273AP-Trop2 resulted in a significant overall 
reduction of shedding and a loss of AP activity in the medium. Histogram shows increase of 
absorbance at 405 nm over time compared to the ADAM15b E/A negative control based on 
mean values of three independent experiments. (B) Cleavage by ADAM12 and ADAM17 
led to a significant increase in AP-Trop2 release as observed in previous experiments. This 
effect was abolished when Δ254-271Trop2 and Δ247-273Trop2 were used as substrates showing 
no significant difference compared to the negative control. Histogram shows fold of increase 
compared to the negative controls based on mean values of three independent experiments ± 
SD; * p < 0.05; *** p < 0.001; n = 12. (C) Western blot analysis was used to detect Trop2 
and the stalk mutants with anti-V5 antibody. Detection of wt AP-Trop2 corresponded with 
the banding pattern observed in previous experiments. In contrast, full length APΔ254-271 and 
Δ247-273AP-Trop2 were expressed at significantly lower levels than full length wt AP-Trop2. 
Additionally, both MP-fragments were absent in cells expressing the stalk mutants. GAPDH 
was used as loading control. 
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3.2.5 Establishment of HEK293 cells stably expressing AP-Trop2-V5 
constructs 
Transient transfection of AP-Trop2 overexpression plasmids can result in varying protein 
expression levels, which potentially affect the experimental outcome. Therefore, I used the 
Flp-In recombination system to create HEK293 cell lines stably expressing AP-Trop2-V5, 
Δ254-271AP-Trop2-V5 and Δ247-273AP-Trop2-V5. Immunoblot staining with anti-V5 and anti-
Trop2 antibodies were used to verify stable expression levels of the constructs. Both 
antibodies detected full-length AP-Trop2-V5 at 130 kDa, full-length Δ254-271AP-Trop2-V5 at 
approximately 120 kDa and full-length Δ247-273AP-Trop2-V5 at approximately 100 kDa 
(Figure 3.2.5A and B). For both AP-Trop2 and the longer Δ254-271AP-Trop2 stalk mutant 
weak signals of the Trop2 aMP fragment were observed at 45 and 40 kDa respectively. This 
fragment was not seen for the shorter Δ247-273AP-Trop2 stalk mutant (Figure 3.2.5A).  
 
Figure 3.2.5: HEK293 cell lines stably expressing AP/V5 tagged Trop2, Δ254-271Trop2 
and Δ247-273 Trop2 
Stably transfected HEK293 cells were created using the Flp-In recombination system. 
Expression levels of wt AP-Trop2-V5, Δ254-271AP-Trop2-V5 and Δ247-273AP-Trop2-V5, were 
confirmed by Western blotting using, (A) anti-V5 and (B) anti-Trop2 antibody.  
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3.2.6 Cell surface expression of stalk sequence deletion mutants of 
Trop2 
To validate that the Trop2 stalk mutants were expressed at the cell surface, stably expressing 
HEK293 cells were cultivated on cover slips, fixed, permeabilised; and labelled with mouse 
anti-V5 and goat anti-Trop2 antibodies. To visualise intra- and extracellular Trop2 domains, 
anti-mouse AlexaFluor
®
594 (red pseudocolour) and anti-goat AlexaFluor
®
488 (green 
pseudocolour) antibodies were used. The coverslips were mounted with DAPI-containing 
solution, in order to detect cell nuclei (blue pseudocolour). Finally, the labelled cells were 
analysed by Confocal Microscopy, as presented in figure 3.2.6.  
Extracellular (green) and intracellular (red) wt AP-Trop2 was pre-dominantly co-localized 
(yellow, white arrows) in the membrane and membrane extensions of the cells. In contrast, 
Δ254-271 AP-Trop2 signal intensity was strongly reduced, as co-localization at the plasma 
membrane was only partially detected (yellow, white arrows) and the majority of Trop2-
ECD and –ICD fragments were seen inside the cells. Signals of the second stalk mutant, 
however, were nearly undetectable and restricted to the cytoplasm, which contradicts the 
Δ247-273 AP-Trop2 positive immunoblot data. The impaired cell surface localization of both 
Δ254-271 AP-Trop2 and Δ247-273 AP-Trop2 explain the strong signal reduction that was 
observed in previous experiments (Chapter 3.2.4). 
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Figure 3.2.6: Cell-surface localization of wt, Δ254-271 and Δ247-273 AP-Trop2  
HEK293 cells stably expressing wt, Δ254-271 and Δ247-273 AP-Trop2 were fixed, permeabilised; 
and labelled using mouse anti-V5 and goat anti-hTrop2 primary antibodies, to detect the 
intracellular and extracellular domains of Trop2 respectively. Anti-mouse AlexaFluor
®
594 
(red pseudocolour) and anti-goat AlexaFluor
®
488 (green pseudocolour) were used as 
secondary antibodies and cell nuclei were visualised with DAPI (blue pseudocolour). The 
majority of wt AP-Trop2-V5 was localized at the cell surface, where extracellular (green) 
and intracellular (red) domains co-localised (yellow, white arrows). Δ254-271 AP-Trop2 also 
partially co-localised at the plasma membrane (yellow, white arrows), but showed dramatic 
reduction in signal intensity. In contrast, Δ247-273 AP-Trop2 was not detected in the cell 
membrane and only very weak signals were only seen in the cytoplasm. 
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3.3 Discussion 
The main experimental focus at the beginning of this PhD project was the investigation of 
metalloproteinase-mediated Trop2 shedding. Preliminary results by Dr. Vera Knäuper 
indicated that Trop2 is cleaved by members of the ADAM family, resulting in the release of 
its ectodomain from the cell surface. Analogous to EpCAM shedding, this ADAM-
dependent extracellular processing was followed by γ-secretase mediated transmembrane 
cleavage, releasing a short-lived intracellular fragment into the cytoplasm (Knäuper, 
unpublished). In the course of this study, Stoyanova et al. published and confirmed the 
processing of Trop2 by ADAM17 and the following intramembranous cleavage by a 
γ-secretase complex (Stoyanova et al. 2012). In the process of refocussing the study I 
investigated among other things whether other ADAMs are capable of Trop2 cleavage. 
Therefore, HEK293 cells were transiently co-transfected with overexpression plasmids of 
AP-tagged Trop2 and different proteolytic active ADAM proteases (ADAM9, 10, 12, and 
17). To verify ADAM expression levels, HEK293 cells were first transfected with ADAM 
expression constructs only and lysates analyzed by Western blotting. This confirmed 
overexpression of ADAM9, ADAM17 and the inactive ADAM15b E/A mutant, which was 
used as a transfection control in shedding assays, as it lacked enzymatic activity (Figure 
3.2.1C). However, expression above baseline levels could not be shown for ADAM10 and 
ADAM12, although cDNA sequencing of both expression constructs confirmed that these 
were error free. Immunoblot detection with different commercially available ADAM10 and 
ADAM12 antibodies showed no change in expression level and a high amount of unspecific 
antibody binding (data not shown). One reason for this could be that HEK293 cells already 
express high levels of endogenous ADAM10 and ADAM12; and that the additional amount 
of overexpressed protein was too small to detect. However, we cannot rule out that the 
negative outcome was due to insufficient antibody quality. In order to detect ADAM12, Dr. 
Vera Knäuper cloned an ADAM12 expression construct containing a V5-tag, which was 
subsequently used to show ADAM12 overexpression in transfected cells (Figure 3.2.1C). In 
contrast, overexpression of tagged ADAM10 could not be shown due to the lack of an 
according expression vector. However, ionomycin experiments leading to ADAM10 
activation showed no impact on Trop2 cleavage (Chapter 4.1). Thus, Trop2 is not an 
ADAM10 substrate, confirming the overexpression study performed here.  
To investigate Trop2 cleavage, the amount of released AP-Trop2 from the cell surface was 
quantified by measurement of the catalytic AP activity in the medium. The strongest 
increase of AP- activity, compared to the negative control, was detected in the medium of 
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HEK293 cells transfected with ADAM12 (2-fold) and ADAM17 (1.5-fold) (Figure 3.2.1A). 
Due to the fact that overexpression of these two particular ADAMs induced the release of 
significantly high amounts of AP-Trop2, it is highly likely that Trop2 is not only cleaved by 
ADAM17 but also by ADAM12. Overexpression of ADAM9 and ADAM10 had no 
significant effect on shedding, implying that these two ADAMs do not process Trop2. The 
cytoplasmic tail of Trop2 is tagged with a C-terminal V5-tag which can be detected by 
Western blotting (Figure 3.2.1B). Two intracellular Trop2 fragments were detected running 
at ~11kDa and ~45kDa. An increase of these bands was detected as a result of ADAM17 
overexpression but not for ADAM9 and ADAM10. As it is known that Trop2 undergoes 
RIP, the 11kDa band would match a membrane-tethered Trop2 fragment that was processed 
only once by ADAM17 or another metalloproteinase (Figure 3.3). To determine whether 
inhibition of intramembrane proteolysis has an effect on the 11kDa band, γ-secretase 
dependent cleavage was inhibited specifically with the  chemical compound, DAPT (Dovey 
et al. 2001; Micchelli et al. 2003). As DAPT treatment resulted in the accumulation of the 11 
kDa band (Figure 3.2.2B), it was termed the metalloproteinase fragment (MP-fragment). 
However, the γ-secretase mediated release of Trop2-ICD into the cell and its potential 
nuclear localization, described by Stoyanova (Stoyanova et al. 2012), could not be 
confirmed. The reason for this discrepancy could be the fast proteolytic degradation of 
Trop2-ICD in HEK293 cells and the use of eGFP-fusion proteins by others. Hachtmeister et 
al. demonstrated for EpCAM that γ-secretase cleavage generates EpCAM-ICDs, which are 
prone to proteasomal degradation (Hachmeister et al. 2013).  
The identification of a second Trop2 fragment running at ~45 kDa was unexpected and I 
hypothesized that it represents the product of a novel N-terminal Trop2 cleavage event. 
Based on its size, we placed an alternative cleavage site somewhere in the region of the 
EGF-TY domain boundary (Figure 3.3). For EpCAM, an N-terminal cleavage site in the 
TY-domain was reported, although its function remains unclear (Thampoe et al. 1988; Szala 
et al. 1990).  Four N-linked glycosylation sites in the Trop2 ectodomain are predicted, with 
only one of them located in the EGF-like repeats. Therefore, we can assume that the Trop2 
45 kDa fragment is glycosylated at one or more positions of its polypeptide chain. We 
showed that ADAM17 overexpression caused an accumulation of the Trop2 11 kDa MP 
fragment, as well as the 45kDa band, and I will therefore refer to the latter fragment as the 
alternative metalloproteinase fragment (aMP).  
Interestingly, ADAM12 overexpression showed the highest AP-Trop2 release in AP 
shedding assays, but caused only slightly elevated levels of the 45 kDa aMP-fragment and 
more surprisingly, the disappearance of the 11kDa MP-fragment (Figure 3.2.1B). The reason 
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for this remains unclear, but one could speculate that the 11kDa MP fragment undergoes 
faster processing due to a somehow increased turnover rate, which would be supported by 
the observed substrate depletion of full-length AP-Trop2 in cells overexpressing ADAM12. 
This again could also be explained by differences in transfection efficiencies, but the high 
AP activity in the shedding assay following ADAM12 overexpression contradicts this 
argument. Another possibility could be that ADAM12 cleaves a different peptide bond in the 
stalk region than ADAM17, with the resulting Trop2 fragment being a better γ-secretase 
substrate. One could also argue that the 11kDa MP-fragment is not generated by ADAM12, 
however, this was ruled out as γ-secretase inhibition led to accumulation of the 11kDa MP-
fragment in ADAM12 expressing cells (Figure 3.2.2B). This indicates that Trop2 is most 
likely processed by ADAM12. Nonetheless, it cannot be excluded that ADAM12 induces 
Trop2 shedding indirectly, by activating the responsible protease or cleavage promoting 
factors, which could not be investigated due to the lack of ADAM12 specific inhibitors. 
 
Figure 3.3: Schematic representation of Trop2 domains with potential cleavage sites 
indicated 
Schematic representation of the AP-Trop2 expression construct. The molecular sizes of each 
tag and domain are indicated. Western blot analysis with anti-V5 antibody recognizes AP-
Trop2 as a 130 kDa band, comprised of Trop2-V5 (35kDa), AP-tag (70kDa) and N-linked 
glycosylations. Two C-terminal membrane-bound metalloproteinase (MP) fragments of ~45 
and ~11kDa were detected in cell lysates and their domain compositions are indicated to the 
right. They represent products of Trop2 processing at two different cleavage sites located in 
the N-terminus and close to the plasma membrane.  
 80 
 
To rule out that substrate depletion is affecting the experimental outcome, time course 
experiments were set up to ensure that an incubation time of 3 h is in the linear range of 
Trop2 cleavage. Interestingly, ADAM12 overexpression showed a linear increase in AP-
activity over the entire 6 h time course (Figure 3.2.3.1A). This would further support the 
hypothesis that ADAM12 expression is associated with an elevated Trop2 turnover rate and 
therefore preventing substrate depletion. In contrast, for ADAM17 overexpression, the 
signal went down to base line shedding levels after 6 h (Figure 3.2.3.2A). This indicates that 
ADAM17-induced shedding leads to substrate depletion, which was confirmed by Western 
blot analysis showing a strong decrease of the Trop2 11kDa MP-fragment after 6h (Figure 
3.2.3.2B). Another explanation could be that released Trop2-ECD molecules are re-
internalized over time, via binding to a Trop2-ECD receptor. Comparison of shedding assay 
data between cleavage (3.2.1) and time course (3.2.3) experiments showed variances in 
overall AP-activity and thus, AP-Trop2 release. This is highly likely a result of varying 
transfection efficiencies based on the fact that the cells were transiently transfected. 
Next, I analysed the processing of two Trop2 stalk sequence deletion mutants (Δ254-271AP-
Trop2 and Δ247-273AP-Trop2), in response to ADAM12 and ADAM17 overexpression. The 
comparison of shedding assay data showed similar basal background shedding for Trop2 and 
Δ254-271AP-Trop2, whereas for the shorter Δ247-273Trop2 stalk mutant, an overall decrease of 
AP-activity was observed (Figure 3.2.4A). A significant increase of the signal in response to 
ADAM12 and ADAM17 expression was only observed for wt AP-Trop2, while both stalk 
mutants were cleavage resistant (Figure 3.2.4B). Staining with V5-antibody showed that the 
Trop2 11 kDa MP and 45 kDa aMP fragments were only detectable in wt AP-Trop2 
expressing cells, whereas the bands disappeared for both AP-Trop2 stalk mutants 
(Figure 3.2.4C). The reason for this could be that due to missing amino acids in the stalk 
proper folding of the actual cleavage site is impossible or that transport to the cell surface is 
impaired. Our results suggest that the stalk region might be playing a crucial role in Trop2 
processing. This is further supported by various studies that have shown that ADAM17 
mediated substrate cleavage does not solely depend on the actual cleavage site, but also on 
the so called “stalk” region between the transmembrane domain and the first globular part of 
the substrate (Schlöndorff & Blobel 1999; Wang et al. 2002; Hinkle et al. 2004). 
In order to reduce experimental error caused by variation in transfection efficiencies, stably 
transfected HEK239 cell lines were created expressing AP/V5-tagged Trop2, Δ254-271Trop2 
and Δ247-273Trop2. To confirm expression of these proteins, cell lysates were analysed by 
Western blotting, showing full-length AP-Trop2 at 130 kDa and both stalk mutants 
according to their shorter length, at 120 kDa and 100 kDa (Figure 3.10). Interestingly, V5-
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staining revealed the existence of a smaller Trop2 aMP fragment running at ~40kDa in 
Δ254-271Trop2 cells, which was not visible in HEK293 cells expressing Δ247-273Trop2. This 
implicates that alternative Trop2 cleavage might depend on the stalk region. 
In order to rule out that reduced shedding of Δ254-271AP-Trop2 and Δ247-273AP-Trop2 results 
from lack of cell surface localization, plasma membrane expression levels of both Trop2 
stalk mutants were analysed by Confocal Microscopy, using stably expressing HEK293 
cells. Analysis of wt AP-Trop2 revealed high expression levels and confirmed the 
localization of Trop2 primarily in the cell membrane (Figure 3.2.6). In contrast, Δ254-271AP-
Trop2 expression levels were dramatically reduced and only partially localized at the plasma 
membrane. Most of the signals were observed as red (V5-tag) and green (Trop2-ECD) dots 
in the cytoplasm (Figure 3.2.6), indicating a trafficking defect. Another explanation could be 
that Δ254-271AP-Trop2 has only a short half-life at the plasma membrane and is quickly 
endocytosed. Δ247-273AP-Trop2 was only seen in very low amounts in the cytosplasm (Figure 
3.2.6), indicating that the translated mutant is highly unstable and undergoes immediate 
proteasomal degradation. The observed overall decrease of AP activity for Δ247-273AP-Trop2 
in the AP-shedding assay would further confirm this assumption. In contrast, we detected 
large amounts of Δ247-273AP-Trop2 in cell lysates, via immunoblotting. However, due to the 
high specificity of the anti-V5 antibody, it is possible that this is misleading as blots were 
not quantified versus a loading control. 
In summary, the data presented in this chapter shows that Trop2 is not only cleaved by 
ADAM17, but also by ADAM12. Moreover, we identified a novel Trop2 metalloproteinase 
cleavage product, which points to the existence of an alternative N-terminal Trop2 cleavage 
site. In addition, the influence of the “stalk” region between the transmembrane domain and 
the TY-domain of Trop2 was investigated, showing impaired cleavage for two AP-Trop2 
stalk mutants and I demonstrated that this was due to reduced or abolished cell surface 
expression. 
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4. Induction of Trop2 shedding by PMA 
4.1 Introduction 
ADAM metalloproteinases are known to cleave a large number of substrates and nearly all 
shedding reactions in most cells are performed by three family members: ADAM9, 
ADAM10 and ADAM17 (reviewed by Edwards et al. 2008). As a consequence, hundreds of 
substrates are processed by only a few ADAMs and it is absolutely necessary that cleavage 
events are specific and tightly regulated, as the shedding of membrane proteins is crucial for 
a wide variety of cellular and physiological processes. This requirement is further 
emphasized by the fact that the same ADAM protease can release substrates of opposite 
functions. For example, ADAM17 has been described as the main protease responsible for 
the cleavage of TNF-α, but was also shown to process both TNF-α receptors in macrophages 
(Bell et al. 2007). Their constitutive simultaneous release would result in neutralization of 
TNF-α activity, as it would bind to its decoy receptor. Therefore, to prevent the cell from 
producing molecules that counteract each other, tight regulation of substrate cleavage is 
essential.  
A multitude of stimuli including calcium influx, activation of GPCRs or the release of DAG 
can induce specific shedding of a substrate ectodomain. Several signaling pathways 
downstream these stimuli were shown to be involved in the selection of the according 
protease targets. Nonetheless, in almost all cases it is not clear which step of regulation these 
pathways address: protease, substrate or a third protein (Hartmann et al. 2013). Various 
mechanisms of cleavage modulation at the protease level have been reported for ADAM17. 
These include the regulation of maturation, trafficking and expression (Murphy 2009), as 
well as the posttranslational modification of the ADAM17 C-terminus (Xu & Derynck 
2010), or its ectodomain (Xu et al. 2012). However, with only a few proteolytically active 
ADAMs available, it is unlikely that cleavage regulation is solely based on modulation of 
the protease activity and therefore, it remains unclear how cleavage specificity is achieved. 
Furthermore, the vast majority of publications on ADAM-induced shedding only monitored 
substrate cleavage and used it as a surrogate measure of protease activity. So there is in fact 
only limited data that unequivocally describe changes in ADAM activities. Two interesting 
studies using ADAM17 inhibitors report that conformational changes might be responsible 
for induction of ADAM17 activity. Le Gall et al. described that tight binding of an inhibitor 
to the catalytic site of ADAM17 was only seen after stimulation with phorbol 12-myristate 
13-acetate (PMA). Furthermore, after treatment and washing out the reversible ADAM17 
inhibitor, application of a PKC inhibitor prevented the re-induction of ADAM17 cleavage by 
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PMA (Le Gall et al. 2010). This introduces the novel concept that ADAM17 is regulated 
through controlled access of its catalytic domain by conformational changes; and that PKCs 
play a role in this mechanism. Most interestingly, the C-terminal tail of ADAM17 was 
unnecessary for the structural change of the extracellular catalytic site (Le Gall et al. 2010), 
ruling out PKC-dependent modification of the metalloprotease tail. This stands in contrast 
with other studies reporting that phosphorylation of the ADAM17 C-terminus is essential for 
its response to p38/MAPK and induces amphiregulin (AR) release and EGFR activation (Xu 
& Derynck 2010; Lemjabbar-Alaoui et al. 2011). 
Another factor in ADAM regulation is the redox status of the cell. ADAM17 contains 
several putative disulphide bonds in its ectodomain, so that oxidized or reduced forms of the 
protease not only differ in conformation, but potentially enzymatic activity. Hydrogen 
peroxide induced ADAM17-mediated cleavage of L-selectin, but as protease and substrate 
both contain oxidizable CxxC motifs, the data did not strictly show which one was affected 
(Wang et al. 2009). More insight brought the finding that ADAM17 interacts on the cell 
surface with the redox regulator, protein disulfide isomerase (PDI). Downregulation of 
endogenous PDI enhanced PMA-induced processing of the ADAM17 substrate, HB-EGF, 
whereas the opposite effect was seen after addition of exogenous PDI (Willems et al. 2010). 
Furthermore, PDI altered ADAM17 topology which made epitopes in the cysteine-rich 
domain inaccessible to specific monoclonal antibodies (Willems et al. 2010). Regulatory 
functions of ADAM subdomains, such as the cysteine-rich region, are well established in the 
literature (Edwards et al. 2008), so that structural changes outside the active site could still 
affect substrate interactions. It is hypothesized that PMA treatment causes the production of 
hydrogen peroxide and other oxidants that can cross the plasma membrane and then trigger 
redox-dependent structural changes in ADAMs, their substrates or other involved factors at 
the cell surface. However, as neither study unequivocally determined ADAM17 activity 
independent from substrate shedding, it remained unclear if cleavage induction requires 
enhanced enzymatic activity.  
As a consequence, proteolytic activity matrix analysis (PrAMA) was developed, to allow 
measurement of protease activity independently from monitoring endogenous substrate 
cleavage. With this technique panels of synthetic, moderately specific and FRET-based 
peptide substrates are incubated directly with live cells to emit fluorescence upon cleavage 
(Miller et al. 2011). Utilisation of PrAMA revealed for the first time that PMA-induced 
shedding of EGF family members does not require enhanced ADAM17 activity. Instead, 
cleavage was promoted by activation of two distinct signaling pathways without affecting 
proteolytic activity. One pathway used PKCα and the PKC-regulated protein phosphatase 1 
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(PPP1) inhibitor 14D (PPP1R14D), to induce cleavage of TGF-α, HB-EGF and AR, 
although the exact nature of their involvement remains unclear. In a second pathway, PKC-δ 
dependent phosphorylation of neuregulin (NRG) leads to its proteolytic processing (Figure 
4.1) (Dang et al. 2013). The activation of two different PKCs through separate signaling 
pathways explains how specific cleavage, in response to the same stimulus, can be 
performed by only one ADAM protease. 
 
Figure 4.1: Schematic of ADAM17 mediated ligand cleavage through distinct pathways 
PMA induced processing of EGF family ligands by ADAM17 occurs through different 
signalling pathways. PKCα and PPP1R14D are necessary for shedding of TGFα, AR and 
HB-EGF, whereas PKCδ mediated phosphorylation of NRG is required for cleavage. 
It was already known that members of the PKC family were involved in shedding and 
individual PKCs were described to enhance cleavage of ADAM substrates: PKCδ and PKCα 
were previously reported to regulate HB-EGF release (Izumi et al. 1998; Herrlich et al. 
2008; Kveiborg et al. 2011); PKCδ and PKCη were shown to be involved in IL-6 receptor 
cleavage (Thabard et al. 2001); PKCε was associated with TNFα shedding (Wheeler et al. 
2003), whereas PKCδ (Esper & Loeb 2009) and PKCζ (Dang et al. 2011) appear to regulate 
NRG processing. It is possible that regulation of shedding by PKC isoforms does not occur 
through modulation of ADAM activity, but through modification of substrates or substrate-
selecting factors. Indeed, it was shown for the NRG precursor that phosphorylation of its 
cytoplasmic tail triggers ADAM17 mediated ectodomain shedding (Liu et al. 1998; Dang et 
al. 2011). In addition, dephosphorylation of a phosphoserine in the ICD of angiotensin-
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converting enzyme was reported to induce the release from its transmembrane proform 
(Kohlstedt et al. 2002). However, other substrates are known to be processed even in the 
absence of their cytoplasmic tail, such as TNF receptor (Crowe et al. 1993) or Kit ligand 
(Cheng & Flanagan 1994). Substrate phosphorylation by PKCs could also alter 
conformation directly or affect the interactions with other proteins. Increased L-selectin 
shedding was observed after the introduction of a phosphomimetic residue close to the 
ezrin/radixin/moesin (ERM) binding motif, suggesting that PKC phosphorylation of L-
selectin is required for ERM interaction (Killock & Ivetić 2010).  
However, shedding regulation can also occur through modulation of “third party” regulatory 
proteins. Recently, the inactive intramembrane rhomboid protease, iRhom2, was identified 
as essential component of the mechanism that controls substrate specificity in some 
ADAM17 dependent shedding events. The study showed that PMA induced cleavage of 
some ADAM17 substrates, such as HB-EGF and Kit ligand 2, was severely impaired in the 
absence of iRhom2 (Maretzky et al. 2013). Another possible mechanism of substrate 
regulation by interaction partners is the modulation of internalization through endocytosis. 
For instance, binding of the APP homolog amyloid precursor-like protein 1 to APP blocks 
endocytosis of APP and as a result, enhances its proteolytic cleavage rate (Neumann et al. 
2006). Furthermore, mono-ubiquitylation of amphiregulin has been described to induce its 
immediate endocytosis and thereby prevents ADAM17-mediated ectodomain shedding 
(Fukuda et al. 2012). 
4.1.1 Aims of the chapter 
The experiments described in this chapter were performed to investigate Trop2 shedding 
induced by PMA, and in addition, by other PKC activators such as ingenol mebutate (IngM) 
or EBC46. In order to shed light on cleavage regulation, intra- and extracellular Trop2 
fragments as well as released Trop2-containing vesicles were analysed in response to 
inhibition of ADAMs and PKCs. It was further examined if Trop2 interacts with different 
PKC isoforms. Other experiments explored how endocytosis affects Trop2 processing and 
how Trop2 S303 cytoplasmic tail mutants behaved, in response to PMA treatment.   
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4.2 Results 
4.2.1 Trop2 shedding is stimulated by phorbol ester PMA, whereas 
calcium inducer ionomycin had no effect 
To further investigate the mechanism of Trop2 cleavage by ADAMs, I tested the effect of 
phorbol ester PMA; and ionophore ionomycin on HEK293 cells stably expressing AP-
Trop2. PMA has been shown to induce ADAM17 cleavage whereas ionomycin activates 
ADAM10 (Hundhausen et al. 2003; Maretzky, Schulte, et al. 2005; Eichenauer et al. 2007). 
As outlined in Chapter 3, a significant effect on Trop2-ECD release was observed after 
ADAM17 overexpression, which could not be seen for ADAM10. In order to evaluate an 
incubation time frame that is in linear range, Trop2 shedding following PMA stimulation 
was measured in a time course experiment, at 1, 2 and 3h respectively. Quantification of AP-
Trop2 release using the AP-shedding assay showed a slight, but insignificant elevation after 
1 and 2h; and a significant signal increase after 3h. The basal shedding activity of DMSO 
control cells was slightly increasing over time (Figure 4.2.1A). When cells were incubated 
for 3h with ionomycin, no effect on Trop2 shedding was seen (Figure 4.2.1B). Western blot 
analysis using the anti-V5 antibody showed an accumulation of the Trop2 11kDa MP 
fragment in cells stimulated with PMA, but not for ionomycin (Figure 4.2.1C). Due to these 
results, an incubation time of 3h for PMA treatment was used in the following experiments, 
as I could not detect significant loss of full length AP-Trop2 in cell lysate in the analysed 
time frame. 
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Figure 4.2.1: Stimulation of Trop2 cleavage after 3h of PMA-induced, ADAM17 
activation  
AP-Trop2 expressing cells were incubated with PMA, in order to activate ADAM17; and 
ionomycin to activate ADAM10. DMSO was used as solvent control. (A) Analysis of PMA-
induced Trop2 cleavage in a time course experiment at 1, 2 and 3h. AP-Trop2 release 
showed slight elevation after 1h and 2h; and was significantly increased after 3h of PMA 
stimulation. (B) Ionomycin treatment had no effect on Trop2 shedding. Histogram shows 
fold of increase compared to the solvent control based on mean values of three independent 
experiments ± SD; ** p < 0.01; n = 12. (B) Western blot analysis was used to detect AP-
Trop2 with anti-V5 antibody. Accumulation of the 11kDa MP fragment was seen for PMA 
but not for ionomycin. GAPDH was used as loading control. 
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4.2.2 PMA-induced Trop2 shedding results in the release of vesicles 
containing full-length Trop2 and cleaved, dimerized Trop2 
ectodomain from the cell surface 
So far, extracellular Trop2 was only quantified using the AP-shedding assay. While being a 
functional tool for the quantification of AP-Trop2 in the medium, the assay does not permit 
us to characterize the nature of soluble Trop2 fragments. For all we know, detected signals 
could originate from full length AP-Trop2 on discharged vesicles, as well as from AP-Trop2 
cleavage fragments, that were shed and released from the cell surface. Hence, the medium of 
PMA-treated cells was ultracentrifugated at 100.000g, to separate extracellular vesicles in a 
pellet fraction from soluble proteins. As Trop2 is rich in disulphide bond forming cysteine 
residues with the ability to facilitate dimerization or polymerization, Western blot analysis 
was performed under reducing, as well as non-reducing, conditions. Figure 4.2.2A shows 
V5-positive full-length AP-Trop2 and a 45kDa aMP fragment in starting medium and the 
pellet with increased intensities in response to PMA stimulation. The V5 signals were not 
seen in the soluble fraction. In non-reduced starting medium only full-length AP-Trop2 was 
detected, indicating that the cleaved Trop2 45 kDa aMP fragment might be still connected to 
its N-terminal AP-part via an internal disulphide bond (Figure 4.2.2B and D). Staining with 
anti-Trop2 antibody under non-reducing conditions revealed the presence of large amounts 
of dimerized Trop2-ECD in the starting medium and the soluble fraction (Figure 4.2.2C). 
The weak signals of Trop2-ECD dimers in the pellet fraction and full-length AP-Trop2 in 
the soluble fraction, are most likely attributed to insufficient washing of the pellet. In 
addition, full length AP-Trop2 and Trop2-ECD were detected as double bands in the starting 
medium, as well as in lower amounts in the soluble fraction (Figure 4.2.2C). Due to the fact, 
that the protein band running between 180 and 245 kDa was only detected with anti-Trop2 
antibody, it can be concluded that it represents cleaved Trop2-ECD in form of a disulphide 
bonded dimer (Figure 4.2.2D). Sample lanes that were not relevant to this experiment were 
cut out of Figure 4.2.2. The complete blots are displayed in the supplemental section 
(Supplement II Figure S2). 
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Figure 4.2.2: Identification of extracellular AP-Trop2, Trop2-ECD and Trop2-ECD 
dimers in the medium following PMA stimulation 
Detection of extracellular Trop2 fragments in the medium of PMA and DMSO control 
treated cells. The conditioned medium was collected and concentrated by using centrifugal 
filter units, with a 3kDa cutoff. Samples were then analysed by ultracentrifugation, to 
separate the released vesicles in the pellet fraction from soluble proteins. The samples were 
then analysed for AP-Trop2 and Trop2 fragments by immunoblotting. Western blot analysis 
of the medium in reducing (A) and non-reducing (B) conditions showed an increase of AP-
Trop2 and the 45kDa aMP fragment, when stained with anti-V5 antibody. This increase was 
also seen in the pellet, but not in the soluble fraction. (C) In contrast, Trop2-ECD monomers 
and dimers were enriched under non-reducing conditions in the soluble fraction, when 
probed with anti-Trop2 antibody. (D) Schematic representation of AP-Trop2 and its Trop2-
ECD cleavage fragments as a monomer or disulphide bond mediated dimer. 
 90 
 
4.2.3 PMA induced increased vesicle release 
In order to determine the nature and concentration of the released AP-Trop2 containing 
vesicles, nanoparticle tracking analysis (NTA) was used. NTA allows determination of 
vesicle concentration in solution, as well sizing of vesicles from about 30 to 1000nm. A 
combination of laser light scattering microscopy, with a charge-coupled device (CCD) 
camera, operating at 30 frames per second enabled the visualization and recording of 
vesicles in solution. The NTA software identifies and tracks individual vesicles moving 
under Brownian motion and calculates vesicle size as well as concentration. NTA is a 
relatively new technique which allows characterization of particles and vesicles at the 
nanoscale in liquids. NTA was already used to evaluate cell-derived vesicles in the plasma 
of atherosclerosis patients (Kapustin et al. 2014); and conditioned media of breast cancer 
cells (Riches et al. 2014). Vesicles in medium of PMA-treated and control cells were shown 
to have a similar size distribution peaking at ~130nm. However, the total concentration of 
vesicles in medium was significantly upregulated after PMA treatment (Figure 4.2.3).  This 
confirms the result from the previous experiment (Chapter 4.2.2), where PMA caused 
accumulation of full length AP-Trop2 containing vesicles in the medium. 
 
Figure 4.2.3: PMA stimulation induces vesicle release  
PMA stimulated medium from AP-Trop2 shedding assays was analysed for the presence of 
vesicles, using a NanoSight LM10 instrument. Vesicle size distribution for PMA treated and 
DMSO control cells shows a peak at ~130nm. The bar graph presents the fold of increase of 
the vesicle concentration, compared to the DMSO control. PMA treatment caused a 
significant increase of vesicle release. The data is based on mean values of three independent 
experiments ± SD; * p < 0.05; n = 9. 
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4.2.4 Trop2 shedding is partially inhibited by metalloproteinase 
inhibitors 
As described in the introductory part of this chapter, PMA stimulation has been associated 
with ADAM17-mediated substrate cleavage by various studies. In previous experiments, I 
demonstrated that Trop2 shedding can be activated by ADAM17 overexpression as well as 
by phorbol ester, PMA, treatment. In order to validate, that PMA-induced Trop2 cleavage is 
indeed performed by ADAM17, I investigated the effect of two ADAM inhibitors from 
GlaxoSmithKline. GW280264x (GW64) inhibits both ADAM10 and ADAM17 when used 
at a 10µM dose, but was shown to inhibit ADAM17 specifically at a molecular dose of 1µM 
(Hundhausen et al. 2003). The other compound, GI254023x (GI23), inhibits ADAM10 with 
a ~100-fold increased potency, when compared to ADAM17 and was used as a negative 
control. HEK293 cells stably expressing AP-Trop2 were pre-incubated with the inhibitors 
overnight, before being serum-starved and stimulated with PMA, in the presence or absence 
of GW64 or GI23. The AP shedding assay showed a significant reduction of PMA-induced 
AP-Trop2 release for the ADAM17 inhibitor, GW64, but not for GI23. Both compounds had 
no effect on the basal shedding of the DMSO solvent control (Figure 4.2.4A). Staining of 
lysates with anti-V5 antibody revealed that both GW64 and GI23 partially blocked the PMA 
mediated production of the Trop2 11 kDa MP and 45 kDa aMP-fragment (Figure 4.2.4B). 
In order to examine the effect of GW64 and GI23 on extracellular Trop2 fragments, 
conditioned medium was concentrated using centrifugal filter units and analysed for V5 
positive Trop2 species, by Western blotting. PMA stimulation caused an increase of full 
length AP-Trop2, which was further enhanced when cells were incubated simultaneously 
with GW64 or GI23. Furthermore, both inhibitory compounds negated the PMA mediated 
accumulation of the Trop2 45 kDa aMP fragment (Figure 4.2.4C). Staining with anti-Trop2 
antibody showed strong reduction of PMA-induced Trop2-ECD levels, in response to 
ADAM17 inhibition (Figure 4.2.4D). This confirms that ADAM17 takes part in PMA-
induced Trop2 shedding. However, the Western blot results also indicate a possible 
involvement of ADAM10 in contrast to the shedding assay data and previous experiments, 
where ADAM10 overexpression and ionomycin treatment had no effect.  
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Figure 4.2.4: ADAM17 inhibitor, GW64, partially inhibits Trop2 shedding 
In order to investigate whether PMA-induced Trop2 cleavage is metalloproteinase 
dependent, cells were inhibited with either ADAM17-specific GW64 (1µM) or ADAM10-
specific GI23 (1µM). DMSO was used as solvent control. (A) The AP shedding assay 
revealed partial inhibition of AP-Trop2 release by GW64, but not GI23. The histogram 
shows fold of increase compared to the solvent control, based on mean values of three 
independent experiments ± SD, *** p < 0.001; n = 12. (B) Western blot analysis was used to 
detect Trop2 with anti-V5 antibody. GW64 also partially blocked the production of both the 
MP and aMP Trop2 fragment in cell lysates. GAPDH was used as loading control. 
Immunoblot analysis of conditioned media with anti-V5 antibody showed full length AP-
Trop2 accumulation and loss of the membrane retained ~45kDa aMP fragment, in response 
to GW64 and GI23 treatment (C). Staining with anti-Trop2 antibody revealed GW64-
induced reduction of cleaved Trop2-ECD in the medium (D). 
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4.2.5 Trop2 shedding is inhibited by classical and novel PKC 
inhibitors 
Phorbol esters are generally known for their tumour promoting ability and have been 
established as potent PKC activators, by mimicking the action of the natural PKC activator 
DAG. PMA as the most commonly used phorbol ester has a wide range of effects in cells 
and tissues; and is a very potent mouse skin tumor promoter (Goel et al. 2007). However, 
over the last decade more and more naturally occurring phorbol esters have been shown to 
display not only carcinogenic but also anti-tumour activity. 
Ingenol mebutate (IngM) is a non-tumour promoting phorbol ester-like compound purified 
from the sap of Euphoria peplus which was recently approved for chemotherapeutic 
treatment of actinic keratosis (Lebwohl et al. 2013); and is currently under review for the 
treatment of non-melanoma skin cancers (Ramsay et al. 2011). Various studies have 
described that the effects of IngM are principally mediated by activation of PKC isoforms, 
most notably PKCδ (Gillespie et al. 2004; Ghoul et al. 2009; Lee et al. 2010; Mason et al. 
2010). Interestingly, IngM was reported to induce a different PKCδ translocation pattern 
compared to PMA; and to inhibit PKCα activation to a lesser extent (Kedei et al. 
2004;Serova et al. 2008). IngM causes rapid translocation of cytosolic PKCδ to intracellular 
and nuclear membranes (Hampson et al. 2005), whereas PMA induces translocation of the 
isoform preferably to the plasma membrane and then, slowly to the nuclear membrane 
(Wang et al. 1999). Another novel PKC activator is 12-tigloyl-13-(2-methylbutanoyl)-6,7-
epoxy-4,5,9,12,13,20-hexahydroxy-1-tiglian-3-one (EBC46), one of several related 
anticancer compounds which naturally occur within the seeds of the Common Blushwood 
Tree (Fontaina picrosperma) (Dong et al. 2008; 2009). EBC46 treatment of melanoma, 
sarcoma and carcinoma in animal models has been shown to stimulate exceptional dermal 
healing in vivo and is therefore being further developed by the pharmaceutical company 
QBiotics as an anti-cancer drug (www.qbiotics.com). Similar to IngM, it was reported that 
the effects induced by EBC46 and its analogues are mediated through activation of PKC 
isoforms (Krauter et al. 1996; Durán-Peña et al. 2014). It was shown that EBC46 specifically 
activates classical PKC isoforms (Boyle et al. 2014), whereas the structurally related PMA 
stimulates both classical and novel PKC activity.  
A collaboration with Dr. Ryan Moseley from Cardiff University provided us with both IngM 
and EBC46 compounds to use in our experiments. As PKC activation by IngM differs from 
traditional phorbol esters, we were highly interested to know if it had the same effect on 
Trop2 shedding as PMA. Additionally, EBC46 was tested and compared to PMA and IngM 
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in its ability to induce Trop2 cleavage. In order to further distinguish the three PKC 
activators we co-treated the cells with inhibitors against classical and novel PKCs. 
Indolocarbazole Gö6976 is a very potent inhibitor with high selectivity for the Ca
2+
-
dependent PKC isoforms α and β, which has no effect on Ca2+-independent PKCs even at 
high concentrations (Martiny-Baron et al. 1993). On the other hand, bisindolylmaleimide I 
(BIM-1) is commonly used as potent inhibitor of all novel and classical PKC isoforms 
(Toullec et al. 1991). Prior to the experiment, IngM and EBC46 concentrations in the range 
of 50-1000 ng/ml were tested and the highest increase in signal strength was observed at 100 
ng/ml for IngM and 500ng/ml for EBC46, respectively (Supplement I, Figure S1). 
Treatment with equal concentrations of IngM or PMA caused 2.5-fold enhancement of AP-
Trop2 release. A significant increase was also observed for classical PKC activator EBC46, 
although the observed signal was 50 % lower when compared to IngMA and PMA (Figure 
4.2.5A). Inhibition of classical PKCs by Gö6976 had no effect on basal shedding levels, but 
caused an overall signal reduction of 50 % for PMA, IngM and EBC46. A more drastic 
effect was observed with BIM-1 which completely negated PKC activator induced AP-
Trop2 release. Furthermore, BIM-1 treatment led to a slight reduction of basal shedding 
although the effect was insignificant (Figure 4.2.5A). Western blot analysis using anti-V5 
antibody revealed that both IngM and EBC46 induced the production of the Trop2 11kDa 
MP fragment, similar to PMA (Figure 4.2.5B). Interestingly, immunoblotting band pattern 
of V5 positive Trop2 species was similar for all three PKC activators in response to PKC 
inhibition. Gö6976 treatment caused an overall reduction of band intensity, but when 
compared to DMSO control cells the 11kDa MP fragment levels were still increasing under 
stimulating conditions. BIM-1 inhibition on the other hand blocked the production of the 
Trop2 11kDa MP fragment in PKC activator stimulated cells only; and a general loss of 
signal intensity was not observed (Figure 4.2.5B).  
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Figure 4.2.5: Trop2 cleavage induced by PKC activators PMA, IngM and EBC46- is 
regulated by classical and novel PKCs  
AP-Trop2 expressing cells were stimulated with phorbol esters PMA, IngM (100 ng/ml) and 
EBC46 (500 ng/ml). In order to investigate the role of PKCs in PKC activator induced 
shedding, cells were co-incubated with cPKC inhibitor Gö6976 (1µM) or BIM-1 (1µM), an 
inhibitor against both cPKCs and nPKCs. DMSO was used as solvent control. (A) PMA, 
IngM and EBC46 caused a significant enhancement of AP-Trop2 release. The IngM-
mediated increase was in the same range as with PMA whereas the EBC46 signal was about 
50% lower. The effect of all PKC activators was similarly reduced by 50% with Gö6976 and 
was brought down to a baseline level with BIM-1. Histogram shows fold of increase 
compared to the negative control based on mean values of three independent experiments ± 
SD, ** p < 0.01, *** p < 0.001; n = 12. (B) Trop2 was detected by immunoblotting with 
anti-V5 antibody. Gö6976 treatment resulted in a strong reduction of the Trop2 ~11kDa MP 
fragment which was observed only under PMA stimulated conditions for BIM-1. This 
banding pattern was similar for all three PKC activators. GAPDH was used as loading 
control. 
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4.2.6 Differential regulation of vesicle release and Trop2 cleavage by 
PKCs 
I showed in the previous section that classical and novel PKC isoforms play a role in PMA-
induced Trop2 shedding. Next, we wanted to know how extracellular Trop2 fragments are 
affected by PKC inhibitors, Gö6976 and BIM-1. Therefore, I analysed soluble Trop2 
fragments in concentrated medium by Western blotting, using anti-Trop2 antibodies. In 
control cells, PMA stimulation caused a strong accumulation of both full length AP-Trop2 
and Trop2-ECD in the medium. However, when treated with Gö6976 under stimulating 
conditions, only Trop2-ECD remained detectable, whereas full length AP-Trop2 was 
strongly reduced. BIM-1 treatment resulted in a nearly complete loss of both bands in the 
medium of PMA stimulated, as well as DMSO control cells (Figure 4.2.6A).   
The observed loss of full length AP-Trop2 in the medium raised the question whether 
vesicle release is also affected by PKC inhibition. In order to determine changes in 
extracellular vesicle concentrations, I analysed conditioned media using a NanoSight LM10 
instrument. As observed previously (Figure 4.2.3), vesicle release into the medium was 
significantly enhanced when cells were stimulated with PMA, but completely negated by 
both PKC inhibitors. Under stimulating conditions, vesicle concentration was brought down 
to basal levels by BIM-1. Gö6976 strongly suppressed vesicle formation in the medium in 
both stimulated and unstimulated cells, below basal levels of the DMSO control cells 
(Figure 4.2.6B). 
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Figure 4.2.6: Classical PKCs regulate full length AP-Trop2 release in vesicles, but 
novel PKCs regulate Trop2-ECD cleavage 
HEK293 cells stably expressing AP-Trop2 were stimulated with PMA, in the presence or 
absence of cPKC inhibitor Gö6976 (1µM) or BIM-1 (1µM), an inhibitor against both cPKCs 
and nPKCs. DMSO was used as solvent control. The conditioned medium was collected and 
concentrated using centrifugal filter units, with a 3kDa cutoff. (A) Trop2 fragments in the 
medium were detected by immunoblotting with anti-hTrop2 antibody: cPKC inhibition by 
Gö6976 led to a reduction of full length AP-Trop2 only, whereas BIM-1 caused a strong 
decrease of both AP-Trop2 and Trop2-ECD in the medium. (B) Vesicle release into the 
medium was analysed using a NanoSight LM10 instrument. Inhibition with both Gö6976 
and BIM-1 of PMA stimulated cells, blocked vesicle release completely. The histogram 
presents the fold of increase of the vesicle concentrations compared to the DMSO control. 
The data is based on mean values of three independent experiments ± SD; *** p < 0.001; n = 
9. 
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4.2.7 Stable Trop2-PKC complexes cannot be detected by 
immunoprecipitation 
The growing evidence that PKC isoforms are involved in Trop2 processing led to the 
question about how PKCs and Trop2 interact. One possibility was provided by a recent 
publication about the role of EpCAM in regulation of PKCs. Maghzal et al. described that a 
short motif in the cytoplasmic tail of EpCAM resembles the PKC pseudosubstrate sequence; 
and therefore acts a potent binding partner and inhibitor of novel PKCs, notably PKCδ and 
PKCη (Maghzal et al. 2013). The identification of similar motifs in other cell adhesion 
molecules, including Trop2, proposes that binding of PKCs might also occur in HEK293 
cells stably expressing Trop2.  
Hence, I used co-immunoprecipitation as an experimental approach of choice to isolate 
stable Trop2-PKC complexes. To exclude potential interference, as well as 
dephosphorylation by the AP-tag, the experiments were performed using HEK293 cells 
stably expressing Trop2-V5 (Figure 4.2.7A). In order to establish a working protocol, cell 
lysates were immunoprecipitated with anti-Trop2 antibody conjugated to protein G 
Sepharose beads, followed by Western blotting. Detection with both anti-Trop2 and anti-V5 
antibody revealed Trop2 enrichment in the immuno-precipitate with lack of signals in the 
IgG control precipitation, confirming the efficiency and specificity of the IP. Furthermore, it 
was shown that PMA stimulation did not influence the amount of immuno-precipitated 
Trop2 (Figure 4.2.7B). Sample lanes that were not relevant to this experiment were cut out 
of Figure 4.2.7. The complete blots are displayed in the supplemental section (Supplement II 
Figure S3). 
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Figure 4.2.7.1: Immunoprecipitation of Trop2  
Schematic representation of the Trop2-V5 expression constructs (A). HEK293 cells stably 
expressing Trop2-V5 treated, with PMA and DMSO as solvent control, were lysed and 
subjected to immunoprecipitation (IP) with an anti-Trop2 antibody, followed by Western 
blotting using anti-hTrop2 and anti-V5 antibodies (B). Anti-IgG antibody was used as 
negative control. Immunoblots show the efficiency of the Trop2 immunoprecipitation. 
Western blot analysis with anti-V5 and anti-Trop2 antibody recognizes Trop2 as a 63 kDa 
band, comprised of Trop2-V5 (35kDa) and N-linked glycosylations. 
Once we established that Trop2 was precipitated, lysates were analysed for co-precipitated 
PKCs by Western blotting, using antibodies against classical, novel and atypical PKCs. 
Figure 4.2.7.2 shows all blots with the IgG control removed. The complete blots are 
displayed in the supplemental section (Supplement II, Figure S4, S5, and S6). Several of the 
antibodies caused unspecific background staining, so that the expected molecular weight of 
PKC bands was marked with an arrow. Detection of classical PKCs in the input controls 
revealed relatively high expression levels for PKCα only. It is of note that both PKCβ and 
PKCγ antibodies preferentially stained non-specific bands. Therefore, both isoforms were 
either not expressed or below the detection limit. In the precipitate, none of the three 
classical PKCs was detected (Figure 4.2.7.2A). The novel PKCε, PKCδ, PKCη and PKCθ 
were observed in all input controls, however, the PKCθ antibody caused staining of multiple 
unspecific protein bands. Nonetheless, immunoprecipitates were negative throughout 
(Figure 4.2.7.2B). This was the same for atypical PKCι and PKCζ, which were detected in 
the input control but not in the precipitate (Figure 4.2.7.2C). In conclusion, stable Trop2-
PKC complexes were not identified in the lysates of either PMA stimulated or DMSO 
control cells. PMA had no effect on the expression level of any PKC isoform except for a 
potential slight reduction of PKCα, which would require further repeats to confirm.  
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Figure 4.2.7.2: PMA stimulation does not induce PKC binding to Trop2 
HEK293 cells stably expressing Trop2-V5 were treated with PMA or DMSO solvent 
control, subjected to immunoprecipitation (IP) with an anti-Trop2 antibody followed by 
Western blotting to detect co-precipitated PKC isoforms with antibodies specific for 
classical, novel and atypical PKCs. Anti-IgG antibody was used as negative control and the 
complete blots are shown in the supplemental section. Co-immunoprecipitation of PKC 
isoforms with Trop2 was not observed in either stimulated or unstimulated cell lysates. 
Respective blots show the input lysate and IP-lanes for Trop2 immunoprecipitation. (A) 
Blots were stained for classical PKC isoforms: PKCα, PKCβ and PKCγ. (B) Novel isoforms: 
PKCε, PKCδ, PKCη and PKCθ. (C) Atypical isoforms: PKCι and PKCζ. 
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4.2.8 Inhibition of endocytosis with Dynasore leads to an 
accumulation of AP-Trop2 containing vesicles in medium, but 
does not affect the formation of the 11kDa MP fragment in 
response to PMA stimulation 
Endocytosis of shedding substrates, such as amyloid precursor protein or pro-amphiregulin, 
has been shown to regulate their proteolytic processing (Neumann et al. 2006, Fukuda et al. 
2012). In order to investigate whether Trop2 processing is affected by internalization, I 
tested the effect of endocytosis inhibitor, Dynasore. Dynasore has been shown to be a potent 
inhibitor of the endocytic pathway by interfering with the GTPase activity of dynamin which 
is essential for clathrin-dependent coated vesicle formation (Macia et al. 2006). Treatment 
with Dynasore caused the largest increase of AP-Trop2 release in the AP shedding assay in 
both PMA stimulated and DMSO control cells (Figure 4.2.8.1A). Interestingly, analysis of 
the cell lysates by Western blotting showed no changes in the levels of V5 positive Trop2 
species. Dynasore treatment had no effect on PMA-induced production of the Trop2 11 kDa 
MP fragment, or the amount of full length AP-Trop2 in the cell lysate (Figure 4.2.8.1B). 
Next, I looked into changes of Trop2 fragment composition in the conditioned media of 
Dynasore treated cells. Firstly, the medium was analysed by immunoblotting, using anti-V5 
antibody in reducing conditions, which revealed that inhibition of endocytosis resulted in 
strong accumulation of full length AP-Trop2. PMA-induced increases in the Trop2 45 kDa 
aMP fragment was reduced, in the presence of Dynasore (Figure 4.2.8.2A). Western blotting 
using anti-Trop2 antibody, under non-reducing conditions, confirmed the Dynasore induced 
increase of full length AP-Trop2 levels in the medium (Figure 4.2.8.2B). 
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Figure 4.2.8.1: Inhibition of clathrin-dependent endocytosis by Dynasore increases 
cleavage-independent AP-Trop2 release 
Dynasore (80µM), a dynamin inhibitor, was used to block clathrin-mediated endocytosis in 
PMA stimulated cells. DMSO was used as solvent control. (A) Dynasore treatment caused a 
4-fold increase of AP-Trop2 release, in both PMA treated and control cells. Histogram 
shows fold of increase compared to the solvent control, based on mean values of three 
independent experiments ± SD; *** p < 0.001; n = 12. (B) Trop2 in lysates was detected by 
immunoblotting using anti-V5 antibody. Cellular levels of AP-Trop2 and the MP fragment 
were not affected by Dynasore treatment. GAPDH was used as loading control. 
These results indicate that inhibition of clathrin-mediated endocytosis results in the 
accumulation of AP-Trop2 containing vesicles in the medium. Therefore, I further 
investigated vesicle size and concentration in the medium, using the NanoSight LM10 
instrument. Over the course of the experiment, it became apparent that data between 
Dynasore treated and DMSO control cells could not be compared. Nano-sized Dynasore 
crystals were detected in control medium, which led to increased background readings which 
were higher than medium taken from cells after the 3h time point. As vesicle size and 
concentration in the medium of PMA stimulated cells was already described above (Chapter 
4.2.3), I therefore only analysed medium of cells that were treated with Dynasore. Both 
PMA stimulated and DMSO control cells showed the same size distribution with a peak at 
~130nm. This indicates that the endocytosis inhibition does not influence vesicle size, as 
previous experiments have shown similar size distribution in the absence of Dynasore. Total 
vesicle concentration in the presence of Dynasore was slightly (1.5-fold) but insignificantly 
elevated in the medium of PMA treated cells, when compared to the DMSO control (Figure 
4.2.8.2C). 
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Figure 4.2.8.2: Clathrin-mediated endocytosis inhibition led to an accumulation of 
vesicles containing AP-Trop2 
HEK293 cells stably expressing AP-Trop2 were treated with both PMA and Dynasore 
(80µM), a dynamin inhibitor, to block clathrin-mediated endocytosis. DMSO was used as 
solvent control. The conditioned medium was collected, concentrated by centrifugal filter 
units and analysed by immunoblotting to detect Trop2. Both anti-V5 (A) and anti-Trop2 (B) 
antibodies showed that Dynasore inhibition caused a massive accumulation of full length 
AP-Trop2 in the medium of both PMA stimulated and DMSO control cells. (C) Vesicles in 
the medium of Dynasore-treated cells were detected using the NanoSight LM10 instrument. 
With Dynasore being a difficult to solve compound, nano-sized crystals of the inhibitor 
prevented a direct comparison to the DMSO control samples. Particle size distribution shows 
a peak at ~130nm in both samples. Treatment of PMA stimulated cells with Dynasore 
resulted in a slight, but insignificant, increase of vesicles in the medium. The histogram 
represents the fold of increase of the vesicle concentration, compared to the negative DMSO 
control; and the data is based on mean values of three independent experiments ± SD; n = 9.    
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4.2.9 Dynasore inhibition results in loss of AP-Trop2 cells surface 
localization 
The inhibition of clathrin-dependent endocytosis has been shown to cause massive 
accumulation of extracellular vesicles, containing AP-Trop2. The reason for this could be 
that cellular re-uptake of discharged vesicles is blocked and as a consequence, the amount of 
full length Trop2 in the plasma membrane would be reduced. In order to follow up this 
hypothesis, I performed immuno localization experiments in Dynasore treated and DMSO 
control cells using Confocal Microscopy. Therefore, HEK293 cells stably expressing AP-
Trop2 were stimulated with PMA, in the presence or absence of Dynasore, followed by 
fixation, permeabilization and staining of cells with mouse anti-V5 and goat anti-Trop2 
antibodies recognizing intra- and extracellular Trop2 domains. These were visualized with 
anti-mouse AlexaFluor
®
594 (red pseudocolour) and anti-goat AlexaFluor
®
488 (green 
pseudocolour) antibodies, whereas DAPI solution was used to stain cell nuclei (blue 
pseudocolour). Hence, full length AP-Trop2 is represented by co-localization (yellow) of 
extracellular (green) and intracellular (red) signals. 
In unstimulated control cells, AP-Trop2 was detected predominantly in the plasma 
membrane and membrane extensions, where it was evenly distributed. It is of note that co-
localization was only partially complete, which was indicated by the presence of membrane-
bound Trop2-ICD molecules (red). PMA stimulation caused partial loss of cell surface AP-
Trop2, in addition to clustering of C-terminal Trop2 fragments (red) in the cytoplasm 
(Figure 4.2.9A, white arrows). These observations are in accordance with the expected 
outcome of PMA induced Trop2 shedding and the generation of cleavage products. In 
response to Dynasore treatment, PMA stimulated, as well as DMSO control cells showed 
dramatic loss of cell surface AP-Trop2-ECD staining. Additionally, Dynasore caused 
intracellular accumulation of C-terminal Trop2 fragments (red), although this was more 
pronounced in the cytosplasm of cells that were treated with PMA (Figure 4.2.9B, white 
arrows).  
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Figure 4.2.9: Loss of AP-Trop2 cell surface localisation as a result of endocytosis 
inhibition 
Visualisation of AP-Trop2 cell surface localization in cells treated with both PMA and 
Dynasore (80µM), a dynamin inhibitor of clathrin-mediated endocytosis. DMSO was used 
as solvent control. Cells were fixed, permeabilised and labelled using mouse anti-V5 and 
goat anti-Trop2 primary antibodies, to detect the intracellular and extracellular domains of 
Trop2 respectively. Anti-mouse AlexaFluor
®
594 (red pseudocolour) and anti-goat 
AlexaFluor
®
488 (green pseudocolour), were used as secondary detection antibodies and the 
cell nuclei were visualised with DAPI (blue pseudocolour). (A) DMSO control cells showed 
evenly distributed AP-Trop2 at the plasma membrane. PMA stimulation led to partial loss of 
cell surface, AP-Trop2; and some accumulation of C-terminal Trop2 fragment (red, white 
arrows), at the cell membrane and in the perinuclear region. (B) Inhibition of endocytosis by 
Dynasore in both PMA stimulated and DMSO control cells resulted in a massive loss of cell-
surface AP-Trop2-ECD staining along with a strong accumulation of V5-tagged Trop2 
fragments (red, white arrows) in the cytoplasm.  
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4.2.10 S303 in the Trop2 cytoplasmic tail regulates PMA-induced 
shedding 
Substrate phosphorylation has been shown to influence proteolytic cleavage and thereby, 
represents a potential regulatory mechanism of ADAM induced shedding. This is further 
supported by the findings that serine residues in the L-selectin tail are phosphorylated by 
several PKC isoforms (Kilian et al. 2004); and that mutations of these residues affected 
PMA induced ADAM17 dependent cleavage of L-selectin (Killock & Ivetić 2010). The 
cytoplasmic tail of Trop2 contains a serine residue at position 303 (Ser
303
), which can be 
phosphorylated by a yet unknown PKC isoform (Cubas et al. 2009). Furthermore, mutation 
of the serine residue abrogated the stimulatory tumour growth capacity of Trop2 (Basu et al. 
1995). Due to its potential relevance for Trop2 processing, I investigated the shedding of 
Trop2 serine mutants. Therefore, Dr. Vera Knäuper created AP-Trop2 expression vectors for 
either a non-phosphorylatable alanine mutant (AP-Trop2 S303A), or a phosphor-mimicking 
aspartate mutant (AP-Trop2 S303D). The overexpression plasmids were transiently 
transfected individually into HEK293 cells, which were then subjected to further analysis.  
An increase of AP-Trop2 release in response to PMA was only observed for the S303A 
mutant and was insignificant. PMA treatment of cells expressing AP-Trop2 S303D had no 
effect, when compared to the DMSO control (Figure 4.2.10A). This was confirmed by 
Western blotting using anti-V5 antibodies, showing slight accumulation of the Trop2 11 kDa 
MP and 45 kDa aMP fragment for AP-Trop2 S303A only (Figure 4.2.10B). This indicates 
that phosphomimetic mutation of Ser
303 
renders Trop2 resistant to PMA-induced shedding, 
whereas non-phosphorylatable Trop2 might be still sensitive to PMA induced cleavage. 
However, when we immunostained the medium of PMA stimulated and DMSO control cells 
for extracellular Trop2 fragments, both mutants showed equal amounts of V5 positive full 
length AP-Trop2. The same was seen for staining with anti-Trop2 antibody. Independent 
from PMA stimulation, cleavage of both AP-Trop2 S303A and S303D resulted in equal 
amounts of Trop2-ECD and Trop2-ECD dimers in the medium (Figure 4.2.10C). This shows 
that basal shedding of AP-Trop2 is not impaired by the mutants. 
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Figure 4.2.10.: PMA-induced shedding of Trop2 phosphoserine mutants, S303A and 
S303D  
HEK293 cells were transfected with S303A or S303D AP-Trop2 overexpression vectors, 
prior to PMA treatment. DMSO was used as the solvent control. (A) PMA stimulation 
caused a slight, but insignificant, increase in AP-Trop2 release for the Trop2 S303A mutant 
only. Histogram shows fold of increase compared to the negative control, based on mean 
values of three independent experiments ± SD; n = 12. (B) Western blot analysis was used to 
detect Trop2 with anti-V5 antibody. PMA-induced shedding resulted in an accumulation of 
the MP and the aMP fragment for the S303A mutant only. GAPDH was used as loading 
control. (C) Trop2 fragments in conditioned media were detected using immunoblot analysis 
with anti-V5 and anti-Trop2 antibodies, under reducing or non-reducing conditions. The 
medium of PMA stimulated and control cells showed equal amounts of AP-Trop2, Trop2-
ECD and Trop2-ECD Dimers for both mutants. 
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4.3 Discussion 
The experiments described in chapter 4 focused on the mechanism of PMA-induced Trop2 
shedding. As it was already outlined above, the phorbol ester, PMA, is a common tool which 
is used to induce cleavage of transmembrane proteins; and its course of action is associated 
with the activation of ADAM17 and PKC isoforms. Therefore, the first experiment I 
performed was the treatment of HEK293 cells stably expressing AP-Trop2 with PMA. 
Based on previous studies in our laboratory and the majority of publications on PMA 
induced substrate cleavage, I chose a PMA working concentration of 100 ng/ml. When 
Sahin et al. investigated the shedding of six different EGFR ligands, they stimulated their 
cells for 60 min with PMA (Sahin et al. 2004). On the other hand, an incubation time of 120 
min was used for the identification of PMA-induced cleavage of cell adhesion molecule L1 
(Maretzky, Schulte, et al. 2005). In order to identify a time point within the linear range of 
Trop2 cleavage, I performed a time course experiment and stimulated the cells with PMA 
for 60, 120 and 180 min. In contrast to EGFR ligands, AP-Trop2 release into the medium 
did not change after 60 min and was only slightly, but insignificantly, elevated after 120 
min. However, stimulation for 180 min caused a significant signal increase in the AP 
shedding assay (Figure 4.2.1A); and therefore, I chose this timeframe for all further 
experiments on PMA-induced Trop2 shedding. Another commonly used stimuli for 
ectodomain shedding is ionomycin-induced calcium influx, which has been shown to 
specifically activate ADAM10 dependent, cleavage of EGFR ligands (Horiuchi et al. 2007). 
Calcium influx, however, did not result in increased AP-Trop2 release in the AP-shedding 
assay (Figure 4.2.1B); and when I analysed the lysates I did not see alterations of V5-
positive Trop2 species, in response to the ionophore. In contrast, PMA stimulation caused an 
accumulation of the Trop2 11 kDa MP fragment, similar to previous ADAM17 
overexpression experiments (Figure 4.2.1C). Our data supports the findings from Stoyanova 
et al., that ADAM17 is the major sheddase of Trop2 (Stoyanova et al. 2012); and shows that 
its cleavage can be induced with the phorbol ester, PMA, as well as the other PKC activators 
tested. 
Once I established a working protocol for PMA stimulation, I wanted to investigate the 
nature of extracellular Trop2 fragments in the medium. When I analysed ultracentrifuged 
samples for V5 positive, Trop2 species, I detected full length AP-Trop2 only in the pellet, 
along with accumulation of the molecule in response to PMA treatment (Figure 4.2.2A). It is 
known that PMA treatment and the resulting PKC activation can trigger the release of either 
ectosomes (Pilzer & Fishelson 2005; Sidhu et al. 2004; Baj-Krzyworzeka et al. 2006) or 
exosomes (Gillis et al. 1996; Shoji-Kasai et al. 2002; Shu et al. 2008). Therefore, the V5 
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signals in the pellet fraction originate most likely from extracellular vesicles, containing full 
length AP-Trop2. This data suggest that stably expressing HEK293 cells constitutively 
release AP-Trop2 containing vesicles; and that it is likely that PMA specifically promotes 
their discharge, as I have not seen a reduction of cellular AP-Trop2 earlier. Interestingly, 
PMA treatment also caused an increase of Trop2 45 kDa aMP fragments, which was only 
seen in the pellet (Figure 4.2.2A). The accumulation of Trop2 aMP fragment containing 
vesicles could either be phorbol ester specific, or a side effect of the general PMA-induced 
stimulation of vesicle release. Nonetheless, the data confirms that ADAM17 activity is 
required for Trop2 aMP fragment accumulation, as seen in the overexpression study in 
chapter 3 (Figure 3.2.1B). 
Next, I analysed samples under non-reducing conditions, before staining with anti-V5 
antibody. With AP-Trop2 running unaltered at a molecular height of 130 kDa (Figure 
4.2.2A), I can assume that full length Trop2 monomers occur on the surface of extracellular 
vesicles. This is insofar interesting, as it was reported that Trop2 homologue EpCAM 
dimerizes on the cell surface via disulphide bonds in their TY-domain (Balzar et al. 2001). 
To my surprise, I was unable to detect the Trop2 45 kDa aMP fragment, when samples were 
not reduced (Figure 4.2.2A). As I did not see other bands with higher molecular weight, I 
can rule out that the aMP fragment forms dimers or oligomers on vesicle surfaces. It is, 
however, possible that following N-terminal cleavage, both fragments are still attached to 
each other via internal disulphide bonds and as a result, the molecule would be 
undistinguishable from uncleaved full length AP-Trop2. This hypothesis is further supported 
by the fact that this was already observed for the products of N-terminal, EpCAM cleavage 
(Schnell et al. 2013). Trop2 cleavage at the cell surface results in the release of Trop2-ECD 
lacking the C-terminal V5-tag. In order to identify these fragments in the medium I stained 
non-reduced samples with anti-Trop2 antibody. Interestingly, this led to the detection of 
high intensity bands, running between 180 and 245 kDa. The molecular weight of these 
fragments would concur with Trop2-ECD dimers, which goes along with a recent study 
demonstrating recombinant Trop2-ECD dimers in solution (Vidmar et al. 2013). I did not 
see any V5-positive species running at a similar molecular weight, so that the signals can 
only represent dimerized Trop2-ECD fragments. However, knowing that Trop2 is cleaved at 
two distinct sites, I cannot exclude that these dimers consist of different sized Trop2-ECD 
molecules. Furthermore, the lack of full length AP-Trop2 containing dimers in lysates 
(Figure 5.2.6.1A), raises the question when dimerization occurs. The metalloproteinase 
mediated shedding of MHC I chain related molecule A (MICA) was shown to depend on 
disulphide isomerase ERp5. In the process of cleavage, ERp5 and membrane-bound MICA 
form transitory mixed disulphide complexes, from which soluble MICA is released after 
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cleavage (Kaiser et al. 2007). However, it is unlikely that AP-Trop2 cleavage and disulphide 
isomerase mediated dimerization occurs at the same time on the cell surface. Such 
mechanism would generate intermediate complexes, containing AP-Trop2-ECD and V5-
tagged full-length AP-Trop2, which I did not detect. So it is more likely that dimerization of 
Trop2-ECD fragments occurs after their release into the extracellular space, most probably 
catalyzed by an extracellular isomerase or spontaneous oxidation, if there are free –SH 
groups in the Trop2 ectodomain.  
In order to further evaluate vesicle release upon PKC activation, I performed nanoparticle 
tracking analysis (NTA) experiments which showed that particles in the medium of both 
PMA stimulated and DMSO control cells had a similar size distribution, peaking at ~130 nm 
(Figure 4.2.3). This confirms their identity as extracellular vesicles, but does not clarify if 
they are exosomes or endosomes. Extracellular vesicles are of spherical shape and normally 
have a diameter of no more than 200 nm. Exosomes, however, are thought to be a bit smaller 
than ectosomes with their size ranging from 40 – 100 nm (Cocucci et al. 2009). There is 
therefore, some overlap in their size making it difficult to distinguish these two vesicle 
populations. PMA treatment resulted in significantly higher vesicle numbers in the medium 
(Figure 4.2.3), which showed that the phorbol ester does indeed enhance vesicle release. 
These results, along with the data from the previous experiment, clearly confirm that PMA 
not only induces Trop2 shedding but also discharge of extracellular vesicles containing full 
length AP-Trop2.  
Due to the fact that Trop2 is cleaved by ADAM17, I wanted to know how ADAM specific 
inhibitors affect PMA stimulated Trop2 shedding. The AP-shedding assay data revealed that 
ADAM17 inhibition caused a significant signal reduction of about ~50%, whereas inhibition 
of ADAM10 had no effect (Figure 4.2.4A). This indicated that ADAM17 inhibition only 
blocked Trop2 cleavage but not vesicle release, which would mean that the PMA-induced 
AP signal increase originates from both soluble AP-Trop2-ECD fragments in the medium 
and full length AP-Trop2 on the surface of discharged vesicles. V5 staining of the lysates 
showed a reduction of PMA-induced accumulation of the Trop2 11 kDa MP fragment, in 
response to ADAM17 inhibition (Figure 4.2.4B). To my surprise, I observed that the slight 
PMA-induced accumulation of the Trop2 45 kDa aMP fragment was blocked by both 
ADAM10 and ADAM17 inhibition (Figure 4.2.4B). This would imply that N-terminal 
Trop2 cleavage is somehow connected with ADAM10 or ADAM17 activity.  
Next, I investigated how ADAM inhibition affected Trop2 fragments in the medium. 
Staining with anti-V5 antibody showed that PMA-induced accumulation of full length AP-
Trop2 in the medium was enhanced when ADAM10 or ADAM17 were inhibited (Figure 
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4.2.4C). This was expected as blocking ADAM17 activity would result in reduced shedding 
and increased amounts of full length AP-Trop2 on extracellular vesicles. Interestingly, I was 
again observing the loss of the 45 kDa aMP fragment in the medium of cells that were 
treated with either ADAM10 or ADAM17 inhibitor (Figure 4.2.4C). The hypothesis that 
ADAM10 is involved in production of the aMP fragment, would explain why I saw the 
accumulation of uncleaved AP-Trop2, in response to ADAM10 inhibition. When we stained 
the samples with anti-Trop2 antibody, I detected two closely running bands at 130 kDa. The 
upper band represents full-length AP-Trop2, whereas the lower band is the reduced Trop2-
ECD cleavage product (Figure 4.2.4D). Stimulation of Trop2 shedding with PMA resulted in 
an expected increased signal for Trop2-ECD, compared to uncleaved AP-Trop2. 
Accordingly, ADAM17 inhibition reversed the PMA-induced accumulation of the Trop2-
ECD cleavage fragment, to the same level as full length AP-Trop2. Blocked ADAM10 
activity did not affect Trop2-ECD which was detected in similar amounts as full length AP-
Trop2 (Figure 4.2.4D). In summary, the data shows that Trop2 shedding in response to PMA 
does indeed occur through ADAM17; and that alternative N-terminal cleavage of Trop2 
most likely involves ADAM17, ADAM10 or both.  
In my next experiment, I inhibited cPKCs and nPKCs in order to determine whether PMA 
induced Trop2 shedding is mediated through PKC activation. The experimental setup 
included two additional naturally occurring PKC activators, IngM and EBC46, which have 
been shown to be tumour suppressive and therefore, might activate a different set of PKCs 
than PMA. I used Gö6976 as a specific inhibitor against cPKCs; and BIM-1 with the ability 
to block both cPKCs and nPKCs. Data from the AP-shedding assay showed that both PMA 
and IngM were able to induce the release of AP-Trop2 at a similar level, whereas five times 
the amount of EBC46 was needed to achieve 50% of the same signal (Figure 4.2.5A). The 
small effect of EBC46 can have many reasons including the possibility that the molecule is 
less effective in activating Trop2 cleavage, or that EBC46 has a different PKC activation 
profile, compared to PMA and IngM. To investigate the latter, I incubated stably expressing 
HEK293 cells simultaneously with the PKC activators and inhibitors. Interestingly, the 
resulting inhibitory patterns in response to both compounds were the same for PMA and 
IngM. AP-Trop2 release of stimulated cells was about 50 % lower with Gö6976, while BIM-
1 completely abolished the effect by bringing the signal down to basal shedding level 
(Figure 4.2.5A). The fact that both inhibitors had the same effect on PMA and IngM treated 
cells, indicates that they activate Trop2 shedding through the same pathway. A similar 
observation was made for EBC46, with the exception that cPKC inhibition alone was able to 
reduce the signal to nearly baseline level.  
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Lysate staining for V5-positive Trop2 species revealed the same inhibitory band pattern for 
PMA, IngM and EBC46. PKC activator induced production of the Trop2 11 kDa MP 
fragment was not affected by Gö6976, although an overall reduction in signal intensity was 
observed. BIM-1 treatment, however, blocked PMA-induced accumulation of the 11 kDa 
band, without affecting band intensities (Figure 4.2.5B). Due to previous experiments, I 
know that AP-Trop2 release in response to PMA, is based on both cleavage and vesicle 
release. The fact that cPKC inhibition caused partial signal reduction in the AP-shedding 
assay, but did not affect production of the 11 kDa cleavage fragment led to the assumption 
that PMA induced vesicle release is potentially cPKC dependent. As it remains unclear if the 
released vesicles are created by ecto- or exocytosis, it is difficult to speculate which 
mechanism regulates vesicle release. So far there is no evidence of cPKC involvement in 
ectosome formation, but it is well established that several PKC isoforms contribute to the 
regulation of various stages of exocytosis (Morgan et al. 2005). But as nearly all studies do 
not distinguish between PKC subclasses and were using bisindolylmaleimide inhibitors 
against both cPKCs and nPKCs (Terbush & Holz 1990; Yawo 1999; Berglund et al. 2002), it 
is unlikely that PKC involvement in exocytosis is restricted to classical isoforms. This, 
however, would lead to the conclusion that the vesicles observed in our experiments are 
ectosomes; and not exosomes. Furthermore, the observation that PMA-induced Trop2 
cleavage is not affected by Gö6976, but BIM-1, implies that proteolytic processing of Trop2 
by ADAM17 solely depends on novel PKC isoforms. This would concur with a majority of 
reports that describe the involvement of nPKCs in ADAM mediated shedding, as outlined in 
the introductory section of this chapter (Chapter 4.1).  
In order to obtain further confirmation that cPKC inhibition does indeed block AP-Trop2 
containing vesicle discharge, I analysed the medium of PMA stimulated cells in the absence 
or presence of Gö6976 or BIM-1. Staining with anti-Trop2 antibody showed that cPKC 
inhibition negated PMA-induced accumulation of full length AP-Trop2, whereas Trop2-
ECD levels were not affected. BIM-1 treatment, on the other hand, blocked entirely the 
release of both AP-Trop2 and Trop2-ECD, in response to phorbol ester stimulation (Figure 
4.2.6A). In addition, we quantified the vesicle numbers in the conditioned media Both PKC 
inhibitors were able to completely shut off PMA-triggered discharge of extracellular vesicles 
(Figure 4.2.6B). Taken together, the results clearly confirm our previous hypothesis that 
PMA triggers the release of full-length AP-Trop2 containing vesicles; and that this process 
is solely cPKC dependent, while cleavage is not affected by cPKC inhibition. It further 
shows that Trop2 shedding in response to PMA is not regulated by cPKCs, but nPKCs. This 
is insofar interesting as Confocal Microscopy data showed Trop2 dependent activation and 
recruitment of classical PKCα to the cell surface, where both molecules co-localized at 
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specific membrane domains (Trerotola & Alberti 2007). Based on these findings, Trop2 
might be able to recruit other PKC isoforms to the cell membrane, in order to promote its 
proteolytic processing.   
To investigate this possibility, I performed co-immunoprecipitation experiments in order to 
identify stable Trop2-PKC complexes.  To my surprise, I did not detect co-precipitated 
PKCα or any of the other 8 PKC isoforms in PMA stimulated or DMSO control cells (Figure 
4.2.7.2). EpCAM was recently reported to act as potent PKC inhibitor, through binding of 
PKCδ and PKCη (Maghzal et al. 2013), so I assumed that a similar mechanism might occur 
in Trop2 cells. An explanation for the negative outcome could be that Trop2 does not bind 
PKC molecules until specific pathways are activated, or that interactions are transient and 
difficult to detect using Co-IP as an experimental approach.  
My next experiment was based on reports that connected substrate endocytosis with 
regulation of their proteolytic processing (Neumann et al. 2006; Fukuda et al. 2012). 
Therefore, endocytosis could negatively regulate Trop2 shedding by removing cleavable 
molecules from the cell surface; and in this case, inhibition of internalization would result in 
enhanced cleavage. We used Dynasore as an inhibitor of clathrin-mediated endocytosis, to 
investigate its effect on PMA-induced Trop2 shedding. Data from the AP-shedding assay 
showed that Dynasore treatment caused a 4-fold increase of AP-Trop2 release for both PMA 
stimulated and DMSO control cells (Figure 4.2.8.1A). In order to examine whether this huge 
signal increase is based on Trop2 vesicle release or cleavage, I stained the lysates for V5 
positive Trop2 species. Production of the Trop2 11 kDa MP fragment in response to PMA 
was not affected by inhibition of endocytosis (Figure 4.2.8.1B), indicating that the elevated 
AP signals in response to Dynasore are primarily caused by the discharge of vesicles 
containing full length AP-Trop2. Due to the fact that cells can communicate through vesicle 
exchange, it is plausible that Dynasore treatment results in blocked internalization of 
extracellular vesicles. Therefore, this data suggests that AP-Trop2 molecules are exchanged 
between cells through vesicle transport and that this process is disrupted by inhibition of 
endocytosis. Furthermore, substrate depletion could be the reason that Dynasore induced 
AP-Trop2 release was equally high for both PMA stimulated and DMSO control cells.  
To verify that extracellular AP-Trop2 carrying vesicles accumulated in response to 
endocytosis inhibition, I analysed conditioned media samples. Anti-V5 antibody staining 
under reducing conditions confirmed a strong increase of full-length AP-Trop2 for Dynasore 
treated cells, in the presence and absence of PMA. Additionally, I observed that Dynasore 
also caused a reduction of PMA-induced release of Trop2 45 kDa aMP fragment containing 
vesicles (Figure 4.2.8.2A). Detection with anti-Trop2 antibody, under non-reducing 
 115 
 
conditions, also revealed strong accumulation of full-length AP-Trop2 in response to 
Dynasore with no visible changes on the amount of cleaved Trop2-ECD dimers (Figure 
4.2.8.2B). NTA quantification of Dynasore treated samples showed a slight but insignificant 
increase in vesicle numbers in response to PMA stimulation (Figure 4.2.8.2C). However, 
this cannot be directly compared to the DMSO controls, as Dynasore was causing high 
background readings. These results confirm that Dynasore treatment does not affect Trop2 
cleavage, but causes the accumulation of AP-Trop2 containing vesicles in the medium. It is 
well established that vesicle uptake generally occurs through endocytosis (Morelli et al. 
2004; Escrevente et al. 2011; Montecalvo et al. 2012); and that clathrin-mediated 
endocytosis is one of most common pathways used (McMahon & Boucrot 2011; Mulcahy et 
al. 2014). Therefore, it can be assumed that the observed effect is caused by blockage of 
vesicle re-uptake, which further points towards constitutive AP-Trop2 exchange between 
cells. 
The experiment above showed that endocytosis inhibition resulted in high levels of 
extracellular full length AP-Trop2 for both PMA stimulated and DMSO control cells. In 
contrast to previous observations (Figure 4.2.3), I also saw vesicle accumulation was not 
significantly elevated in response to PMA, when cells were treated with Dynasore. The 
reason for this could be that constitutive discharge of Trop2 positive vesicles leads to 
depletion of Trop2 cell surface levels. In order to test this scenario, I looked at cell surface 
Trop2 expression levels using Confocal Microscopy. When cells were stimulated with PMA, 
partial loss of cell surface AP-Trop2 was observed, in addition to clustering of some Trop2-
ICD fragments in the cytoplasm (Figure 4.2.9A). This outcome was expected, as PMA 
stimulation and the resulting activation of ADAM17, would eventually lead to γ-secretase 
mediated release of intracellular Trop2-ICD, although I never detected the γ-secretase 
fragment by Western blotting. Trop2 shedding and discharge of AP-Trop2 containing 
vesicles explains the loss of cell surface localization; and it is likely that this reduction is 
counteracted by vesicular AP-Trop2 exchange between cells.  However, when cells were 
treated with Dynasore I observed a dramatic loss of cell surface AP-Trop2 in the presence or 
absence of PMA. This was accompanied with intracellular accumulation of C-terminal 
Trop2 fragments, which was more pronounced for PMA stimulated cells (Figure 4.2.9B). 
The observed massive deprivation of Trop2 from the plasma membrane confirms the 
previously stated hypothesis of substrate depletion, in response to release and accumulation 
of AP-Trop2 containing extracellular vesicles. Trop2 has been shown to undergo RIP 
(Stoyanova et al. 2012) which comprises ectodomain shedding by a metalloproteinase, 
followed by γ-secretase complex mediated cleavage of the transmembrane domain. 
However, γ-secretase mediated intramembranous cleavage must not necessarily occur at the 
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cell surface but can also occur in endocytic compartments, as it was shown for Notch 
(Gupta-Rossi et al. 2004; Kaether et al. 2006). It was reported that Notch signaling intensity 
is regulated by endocytosis; and that Notch-ICD molecules that were cleaved at the cell 
surface were more stable than fragments produced by endosomal γ-secretase activity 
(Tagami et al. 2008). This is insofar interesting, as a recent publication proposed a similar 
mechanism for the Trop2 homologue EpCAM. Hachtmeister et al. described five different 
cleavage sites within the EpCAM transmembrane domain; and showed that 
intramembranous cleavage can happen on either the cell surface or in endosomes, releasing 
EpICDs with different stabilities towards proteasomal degradation (Hachmeister et al. 2013). 
According to high similarities at the amino acid sequence level, it is possible that this feature 
is shared by Trop2. If intramembranous processing of Trop2 can occur either at the cell 
surface or in subcellular compartments, it could lead to the production of Trop2-ICD 
fragments with different stabilities. Therefore, one explanation of the observed intracellular 
Trop2-ICD clustering in response to Dynasore could be, that under normal conditions, the 
Trop2 MP fragment is internalized prior to γ-secretase cleavage; and that the resulting 
fragment is rapidly processed or degraded. Inhibition of endocytosis on the other hand, 
might force transmembrane cleavage of Trop2 ADAM fragment at the cell surface, 
liberating a more stable Trop2-ICD molecule.  
The last experiment in this chapter asked the question whether the phosphorylatable serine 
residue at position 303 (Ser
303
) in the cytoplasmic tail of Trop2, is involved in cleavage 
regulation. Therefore, I used either a non-phosphorylatable alanine mutant (AP-Trop2 
S303A) or a phosphor-mimicking aspartate mutant (AP-Trop2 S303D) in AP-shedding 
assays. To my surprise, PMA stimulation had absolutely no effect on AP-Trop2 S303D, 
whereas for the S303A mutant, AP-Trop2 release was slightly, but insignificantly, elevated 
in response to the phorbol ester treatment (Figure 4.2.10A). This is interesting as it was 
recently shown that phosphorylation of the cytoplasmic tail of NRG by PKCδ induces 
ADAM17 mediated shedding of the substrate (Dang et al. 2013). Immunoblotting with anti-
V5 antibody revealed PMA-induced accumulation of both the 11 kDa MP and 45 kDa aMP 
Trop2 fragment for AP-Trop2 S303A but not S303D (Figure 4.2.10B). To our surprise we 
did not detect different Trop2 fragment levels in the conditioned media of PMA stimulated 
and DMSO control cells (Figure 4.2.10C), which shows that basal shedding is probably not 
affected by the Ser
303
 mutation. Nonetheless, it is possible that due to the transient nature of 
the transfection, the amount of released Trop2 fragments is too low to detect differences by 
Western blotting. Taken under consideration that the insignificance of the AP-shedding 
assay data could be caused by low transfection efficiencies, the results propose that PMA 
might only stimulate AP-Trop2 S303A but not AP-Trop2 S303D shedding. This is 
 117 
 
interesting as one might expect that PMA-induced PKC activation leads to Trop2 cleavage 
through Ser
303
 phosphorylation. The data suggests the opposite, that serine phosphorylation 
protects from PMA stimulated shedding of Trop2. There has been reports describing that 
phosphorylation protects several substrates from caspases cleavage. In these cases, however, 
the phosphorylated residue was very close to the cleavage site, suggesting that the effect 
caused a disruption of enzyme binding (Desagher et al. 2001; Yin et al. 2001; Ruzzene et al. 
2002). Most interestingly, another study on collagen XVII cleavage showed that 
phosphorylation of ectodomain serine residues prevented binding of ADAM17 to its 
substrate (Zimina et al. 2007). One reason for the PMA unresponsiveness of the S303D 
mutant could be that Ser
303 
phosphorylation induces conformational changes that prevents 
ADAM17 binding to Trop2. Although it is possible that this includes the Trop2 ectodomain, 
it is more likely that potential structural alterations affect the cytoplasmic tail. Especially, as 
Ser
303
 is located within the PIP2-binding motif of Trop2. Consequently, serine 
phosphorylation could prevent direct binding of ADAM17, although it was reported that the 
C-terminus of the metalloprotease is not always necessary for PMA-induced ADAM17 
shedding activity (Reddy et al. 2000; John R Doedens et al. 2003). Another possibility 
would be that Ser
303 
phosphorylation blocks the binding of third party proteins that are 
required for cleavage induction. For instance, it was recently described that the cytoplasmic 
domain of iRhom was essential for PMA-induced ADAM17 cleavage of some EGF ligands 
(Maretzky et al. 2013); and a similar mechanism could be applicable for Trop2.   
In summary, the results in this chapter show that PMA is able to activate two distinct Trop2 
release pathways which are both regulated by PKCs. First, the phorbol ester activates 
ADAM17 mediated Trop2 cleavage at the cell surface. This process is regulated by novel 
members of the PKC family and leads to release and subsequent dimerization of Trop2-ECD 
fragments in the extracellular space. Additionally, PMA triggers the budding and release of 
ectosomes directly from the plasma membrane. The release of ectosomes containing full 
length Trop2; and potentially ADAM molecules (Stoeck et al. 2006), is regulated by 
classical members of the PKC family (Figure 4.3.1). 
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Figure 4.3.1: Schematic model of PMA-mediated Trop2 cleavage and release of Trop2 
containing ectosomes 
PMA stimulation activates two different pathways leading to Trop2 shedding and its 
ectosomal release from the cell surface. ADAM17-mediated Trop2 cleavage is regulated by 
novel PKC family members and results in release and dimerization of Trop2-ECD 
fragments. Discharge of full length Trop2 containing ectosomes, on the other hand, is 
regulated by classical PKCs.  
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5. Induction of Trop2 shedding by PKCζ inhibition 
5.1 Introduction 
To achieve a better understanding of the PKC involvement in PMA induced Trop2 shedding, 
I investigated the effect of inhibitors directed against distinct classes of PKC isoforms. The 
majority of effective PKC inhibitors in prevalent laboratory use are derivatives of 
bisindolylmaleimides or indolocarbazoles that target the ATP binding site. So as previously 
described (Chapter 4.2.5), I used small molecule compounds, Gö6976 and BIM-1, in order 
to block classical and novel PKC activity. However, when it comes to inhibition of atypical 
PKCs, ATP-site competitors are of limited use, as they show overlapping selectivity with 
either classical or novel isoforms (Wu-Zhang & Newton 2013). As it was reported that 
inhibition of PKCζ using a pseudosubstrate peptide enhances NRG release upon PMA 
stimulation (Dang et al. 2011), I wanted to know if this isoenzyme is also involved in Trop2 
shedding.  
Auto-inhibition represents a mechanism of protein kinase regulation in which a part of the 
polypeptide chain, termed the pseudosubstrate domain, occupies the substrate binding 
pocket of the active site in its catalytic domain. Pseudosubstrate sequences are characterized 
by their resemblance to sequences derived from target phosphorylation sites. Members of the 
PKC family contain a pseudosubstrate sequence of about 13 amino acids in length, which is 
located in the N-terminal region of each isoform (Eldar-Finkelman & Eisenstein 2009). This 
mechanism was utilized to generate selective PKC inhibitors through creation of synthetic 
peptides, mimicking the pseudosubstrate domain of several PKC isoforms (α, β, η, θ and ζ) 
(Kemp et al. 1991; Eichholtz et al. 1993; Théodore et al. 1995). Due to the fact that the 
plasma membrane is impermeable for most proteins, various methods were developed to 
facilitate passage of these peptides into the cell. For instance, the modification of the 
polypeptide chain with a hydrophobic fatty acid (usually myristate), was successful in 
making the peptide membrane-permeable (Thiam et al. 1999; Harishchandran & Nagaraj 
2005).  
mPS is a myristoylated peptide that mimics the pseudosubstrate sequence of PKCζ. In the 
past decade, it has been employed as a primary pharmacological tool to establish the role of 
PKMζ, an alternative transcript encoding the catalytic domain only, as the responsible kinase 
for the maintenance of long term potentiation of synaptic transmission and for learning and 
memory (Ling et al. 2002; Pastalkova et al. 2006; Shema et al. 2007). While it was 
confirmed that mPS inhibits both PKCζ and PKMζ in vitro (Ling et al. 2002; Wu-Zhang et 
al. 2012), recent observation raised questions on mPS specificity in vivo. The amino acid 
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sequence of mPS (myr-SIYRRGARRWRKL) is identical to the auto-inhibitory 
pseudosubstrate domain of both PKCλ/ι and PKCζ (Price & Ghosh 2013). Hence, various 
studies reported that mPS inhibits not only PKMζ, but also the second atypical isoform, 
PKCλ/ι (Lee et al. 2013; Ren et al. 2013; Volk et al. 2013).  
A recent study reported that PKCζ plays an important role in podosome formation, through 
regulation of metalloproteinase activity. Podosomes are actin-rich structures at the cell 
membrane that stick out into the extracellular matrix, where localized remodeling activities 
associated with enhanced invasiveness has been observed (Linder & Aepfelbacher 2003; 
Buccione et al. 2004). Xiao et al. showed that novel PKCs, especially PKCδ, recruits PKCζ 
to the podosomes, where it regulates the proteolytic activity of matrix metalloproteinase-9 
(MMP9) resulting in release and activation of the proteinase (Xiao et al. 2010). Stable 
overexpression of PKCζ in immortalized mammary epithelial cells induced phenotypic 
alterations, associated with tumor progression and significantly increased expression of 
urokinase-type plasminogen activator and MMP-9 (Urtreger et al. 2005). Furthermore, 
PKCζ regulates transcription of the MMP-9 gene in C6 glioma cells, where MMP-9 
expression is one of the key processes in brain tumor invasion (Estève et al. 2002). 
However, despite the well-established connection between MMP-9 and PKCζ, there have 
been no reports so far that propose are direct interaction between PKCζ and members of the 
ADAM family.  
5.1.1 Aims of the chapter 
The main aim of the experiments in the following chapter was to investigate the effect of 
PKCζ inhibition on N-terminal Trop2 shedding using a myristoylated pseudosubstrate 
peptide inhibitor. I confirmed specific inhibition of the atypical PKC isoform and analysed 
its effect on intra- and extracellular Trop2 fragments, as well as on vesicle release. The 
effect of metalloproteinase inhibitors on mPS-induced cleavage was tested, to identify the 
nature of the responsible proteinase. I determined the actual Trop2 fragment sizes through 
deglycosylation and looked for the Trop2 aMP fragment in prostate cancer cell lines, PC3 
and LNCaP. It was further examined if PKCζ inhibition leads to binding of Trop2 to other 
PKC isoforms. Other experiments were performed to scrutinize if mPS treatment triggers 
Trop2 endocytosis; and how the phosphorylatable Ser
303 
in the Trop2 cytoplasmic tail 
influenced shedding, in response to PKCζ inhibition.  
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5.2 Results 
5.2.1 PKCζ inhibition promotes AP-Trop2 release into medium and 
enrichment of the 45kDa aMP Trop2 fragment in lysates 
In the course of PKC inhibition in previous experiments, preliminary data showed a strong 
increase of AP-Trop2 release, in response to a myristoylated pseudosubstrate (mPS) directed 
against PKCζ. In order to confirm these observations, I treated HEK293 cells stably 
expressing AP-Trop2 for 3h with 10µM mPS or equal amounts of control peptides. A non-
myristoylated form of the pseudosubstrate (PS) was used to rule out potential interactions 
with cell surface receptors, whereas a myristoylated scrambled peptide (mPS Scr.) should 
exclude unspecific interactions within the cell.  
Quantification of AP-Trop2 release using the AP-shedding assay revealed an increase for 
mPS (> 2-fold) and to a lesser extent, for mPS Scr (> 1.5-fold). However, the elevated mPS 
signal was significantly higher in comparison to the scrambled peptide, which points 
towards specificity of the effect (Figure 5.2.1A). This was further confirmed by 
immunoblotting, showing that accumulation of the V5 positive 45 kDa aMP fragment only 
occurs in response to mPS treatment. Interestingly, the 11 kDa MP fragment was not 
affected by mPS, which indicates that inhibition of PKCζ induces specifically the production 
of the 45 kDa Trop2 cleavage product (Figure 5.2.1B).  
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Figure 5.2.1: PKCζ inhibition by a myristoylated pseudosubstrate (mPS) induces 
Trop2 shedding 
HEK293 cells stably expressing AP-Trop2 were treated for 3h with mPS (10µM), a 
myristoylated inhibitory peptide against PKCζ. Control treatment consisted of a non-
myristoylated (PS, 10µM) and scrambled (mPS Scr., 10µM) peptide, to confirm specificity 
of inhibition. Distilled water was used as a solvent control. (A) The AP shedding assay 
revealed a > 2-fold increase of AP-Trop2 release for mPS and also to a lesser extent for 
scrambled mPS. However, the mPS-induced signal was significantly higher, when compared 
to the scrambled mPS peptide. Histogram shows fold of increase compared to the water 
control, based on mean values of three independent experiments ± SD; *** p < 0.001; n = 
12. (B) Western blot analysis was used to detect AP-Trop2 with anti-V5 antibody. An 
accumulation of the 45kDa aMP Trop2 fragment was observed only in the mPS treated 
sample. GAPDH was used as loading control. 
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5.2.2 PKCζ knockdown induces Trop2 shedding and accumulation 
of the 45kDa fragment 
When myristoylated peptides are used as analytic tools, it is generally assumed that the 
modification itself does not interfere with cellular processes. However, it was shown that 
myristoylation of synthetic peptides can confer new properties beyond their original 
function. Krotova et al. reported that mPS, scrambled mPS and other myristoylated peptides, 
are able to activate a variety of enzymes, including endothelial nitric oxide synthase (eNOS), 
in endothelial cells. However, the effect was not observed in HEK293 cells, although an 
overall rise in intracellular Ca
2+
 was common to all cell lines tested (Krotova et al. 2006).  
This was further confirmed by another study that showed that mPS can induce degranulation 
in human mast cells by increase of Ca
2+
 levels via a PKCζ-independent pathway (Lim et al. 
2008). In order to rule out any myristoylation-dependent side effects, I knocked down PKCζ 
gene expression, using shRNA vectors specifically targeting this PKC isoform. 
HEK293 cells were co-transfected with overexpression plasmids for AP-Trop2 and shRNA 
directed against PKCζ. Knockdown of PKCζ resulted in a significant increase of AP-Trop2 
release, when compared to a scrambled shRNA negative control (Figure 5.2.2A). 
Immunoblotting using anti-V5 antibody further revealed increased production of 45 kDa 
aMP Trop2 fragment, in response to diminished PKCζ expression. Quantification of band 
intensities, using ImageJ software, showed that the 45 kDa aMP fragment levels were 
approximately 3-fold higher, when compared to the scrambled shRNA control (Figure 
5.2.2B). The efficiency of the shRNA-mediated knockdown was attested by detection of 
reduced levels of cellular PKCζ (Figure 5.2.2C). These results provide evidence that mPS-
induced, processing of AP-Trop2 is specifically associated with inactivation of PKCζ. 
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Figure 5.2.2: Activation of Trop2 cleavage by shRNA-mediated PKCζ knockdown  
HEK293 cells were co-transfected with overexpression plasmids for AP-Trop2 and shRNA 
directed against PKCζ, or an expression vector for scrambled shRNA used as negative 
control (A) shPKCζ expression caused significantly higher AP-Trop2 release, compared to 
the scrambled shRNA control. Histogram bars shows fold of increase compared to the 
negative control, based on mean values of three independent experiments ± SD; * p < 0.05; 
n = 12. (B) Immunoblotting was used to detect full length AP-Trop2 and Trop2 fragments, 
with anti-V5 antibody. Knockdown of PKCζ caused a significant accumulation of the Trop2 
aMP fragment, when compared to the scrambled shRNA control. ImageJ software was used 
to quantify the band intensities by calculation of Trop2 aMP fragment to GAPDH ratio. The 
data is based on mean ratios of three independent experiments ± SD; ** p < 0.01; n = 3 (C) 
Immunoblotting with anti-PKCζ antibody confirmed the shPKCζ-induced knockdown of the 
atypical isoform. GAPDH was used as loading control. 
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5.2.3 Trop2 shedding in response to PKCζ inhibition over time  
Initially, cells were incubated with mPS for 3h, similar to stimulation with PMA, as 
described in chapter 4. In order to validate that this time frame is in the linear range, Trop2 
shedding in response to PKCζ inhibition was measured in a time course experiment. I was 
also interested to see whether mPS triggers Trop2 cleavage faster than PMA and therefore 
measured at three distinct time points of 30, 60 and 120 min. Most interestingly, I observed a 
significant reduction of AP-Trop2 release after 30 min. The signal went back up to the level 
of basal shedding after 60 min; and was significantly increased after 120 min of incubation 
(Figure 5.2.3A). Detection of V5 positive Trop2 species in the cell lysate showed a slight 
accumulation of the Trop2 45 kDa aMP fragment already at 30 min, which increased over 
the time course of 60 and 120 min (Figure 5.2.3B). The observation of cleavage product 
accumulation after 30 min contradicts the concurrent reduction of AP activity in the 
medium. However, this could indicate that either release of cleavage product is delayed, or 
that AP-Trop2 is internalised and that alternative cleavage takes place in the cell. 
Nonetheless, an incubation time of 3h for mPS treatment was used in all following 
experiments, as I could not detect significant loss of full length AP-Trop2 in the analysed 
time frame (Figure 5.2.3B).  
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Figure 5.2.3: PKCζ inhibition by mPS stimulates Trop2 shedding over a 2h time course 
Activation of Trop2 cleavage by mPS treatment was measured over a 2h time course. 
Distilled water was used as a solvent control. (A) mPS treatment led to a significant 
reduction of AP-Trop2 release at 30 min. A highly significant increase of AP-Trop2 release 
was observed at 120 min. Histogram shows fold of increase compared to the water control, 
based on mean values of three independent experiments ± SD; * p < 0.05, *** p < 0.001; n = 
12. (B) Trop2 was detected in the lysate by immunoblotting using anti-V5 antibody. 
Accumulation of the aMP fragment was observed in mPS treated cells after 30, 60 and 120 
min. GAPDH was used as loading control. 
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5.2.4 PKCζ inhibition results in the release of vesicles containing 
alternatively cleaved Trop2  
Next, I investigated how inhibition of PKCζ affects the release of extracellular Trop2 
fragments and AP-Trop2 containing vesicles into the medium. Similar to previous 
experiments with PMA, the conditioned medium of mPS-treated cells was ultracentrifugated 
at 100.000g, to separate extracellular vesicles in the pellet fraction from soluble proteins. 
Anti-V5 staining under reducing conditions revealed an mPS-induced increase of band 
intensity for the Trop2 45 kDa aMP fragment in the starting medium and pellet fraction, but 
not in the soluble fraction. This shows that PKCζ inhibition results in enhanced release of 
vesicles containing the cleaved aMP fragment, whereas the amount of full-length AP-Trop2 
containing vesicles, is not affected (Figure 5.2.4A). The 45 kDa band was not seen in non-
reduced medium samples, which makes it more than likely that the cleaved Trop2 aMP 
fragment is still connected to its N-terminal section, via an internal disulphide bond (Figure 
5.2.4A). Immunoblot detection with anti-Trop2 antibody, under non-reducing conditions, 
showed equal enrichment of Trop2-ECD dimers in the medium and soluble fraction of both 
mPS-treated and control cells. Interestingly, Trop2-ECD monomers in the medium were 
only seen in response to PKCζ inhibition (Figure 5.2.4B). The weak signals of Trop2-ECD 
dimers in the pellet fraction and full-length AP-Trop2 in the soluble fraction are most likely 
attributed to insufficient washing of the pellet. Sample lanes that were not relevant to this 
experiment were cut out of Figure 5.2.4A. The complete blots are displayed in the 
supplemental section (Supplement II Figure S2). 
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Figure 5.2.4: Identification of extracellular AP-Trop2, Trop2-ECD and Trop2-ECD 
dimers after mPS stimulation 
Detection of extracellular Trop2 in the medium of mPS treated cells. Distilled water was 
used as solvent control. The conditioned medium was collected and concentrated by using 
centrifugal filter units, with a 3kDa cut off. Samples were then analysed by 
ultracentrifugation to separate the released vesicles in the pellet fraction from soluble 
proteins. The samples were then analysed for full length AP-Trop2 and Trop2 fragments by 
immunoblotting. (A) V5 staining of the medium in reducing and non-reducing conditions 
revealed that mPS had no effect on full length AP-Trop2, but caused massive accumulation 
of the 45kDa aMP fragment. This increase of the aMP fragment was also seen for the pellet, 
but not in the soluble fraction. (B) Trop2-ECD monomers and dimers were enriched under 
non-reducing conditions in the soluble fraction when probed with anti-Trop2 antibody. 
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5.2.5 Quantification of vesicle release in response to PKCζ inhibition 
Due to the increase of V5 positive Trop2 aMP fragments in the medium I hypothesized that 
this was likely due to enhanced vesicle release. Therefore, I quantified the vesicle amount in 
the medium of mPS stimulated cells, using the NanoSight LM10 instrument. The vesicle 
size distribution was determined using NTA software and showed a minor peak shift 
between mPS-treated and control cells (Figure 5.2.5). Total vesicle concentration was 
slightly elevated in response to PKCζ inhibition, but statistically insignificant.  
 
Figure 5.2.5: mPS stimulation slightly increases vesicle release 
mPS stimulated medium from AP-Trop2 shedding assays was analysed for the presence of 
vesicles, using a NanoSight LM10 instrument. Particle size distribution for mPS treated and 
control cells show a peak at ~130nm. The bar graph presents the fold of increase of the 
vesicle concentration, compared to the distilled water control. PKCζ inhibition caused a 
slight, but insignificant, increase of vesicle release. The data is based on mean values of 
three independent experiments ± SD; n = 9.    
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5.2.6 Alternative cleavage of Trop2 generates two fragments which 
remain connected via internal disulphide bonds  
Earlier experiments showed that the Trop2 aMP fragment was only detected by 
immunoblotting, using media samples prepared with reducing sample buffer. As mentioned 
above, one explanation could be that the N-terminal Trop2 cleavage fragment is still 
attached to the protein, via internal disulphide bonds after shedding took place. This 
hypothesis is supported by similar observations describing that N-terminal cleavage 
fragments of EpCAM are only seen in HEK293T cells, when the lysates are reduced 
(Schnell et al. 2013). The N-terminal EpCAM cleavage site is located in its TY-domain 
between Arg-80/Arg-81; and although it was identified over 20 years ago its functions 
remains elusive (Thampoe et al. 1988; Schön et al. 1993). The results from Schnell et al. 
suggest that following cleavage, the domains stay bound together via a disulphide bridge in 
the EpCAM TY-like motif (Schnell et al. 2013). In order to determine whether this 
mechanism is also applicable for Trop2, we analysed the lysates of HEK293 cells stably 
expressing AP-Trop2 or Trop2 under reducing and non-reducing conditions. Prior to 
immunoblotting, cells were treated with mPS to ensure production of the Trop2 aMP 
fragment. The results confirmed that mPS-induced accumulation of the 45 kDa aMP 
fragment was only seen in reduced lysates, whereas the 45 kDa band disappeared in non-
reducing conditions (Figure 5.2.6.1A). As I have seen the same results for both AP-Trop2 
and Trop2, I can assume that the AP-tag does not influence N-terminal Trop2 cleavage. 
Based on the size difference between non-cleaved AP-Trop2 and the remaining 45 kDa aMP 
fragment, the corresponding alternative AP-ECD (aECD) fragment has a predicted size of 75 
kDa (Figure 5.2.6.1B).  
To identify the Trop2 75 kDa aECD fragment, I analysed lysates from HEK293 cells stably 
expressing AP-Trop2, because the N-terminally attached AP-tag facilitates the detection of 
the cleavage product, due to its increased size. Immunoblotting with anti-Trop2 antibody 
indeed revealed the presence of a 75 kDa band in response to PKCζ inhibition only (Figure 
5.6.2.2A). Next, I looked for signals of the N-terminal HA-tag, as staining for AP was 
inconclusive due to insufficient specificity of the antibody. Again, the 75 kDa aECD band 
was only observed in lysates of cells treated with mPS (Figure 5.6.2.2B) and was absent in 
both lanes when the blot was stained for V5 (Figure 5.6.2.2C). The identification of the 75 
kDa aECD fragment in the lysates confirmed that Trop2 is N-terminally cleaved and that 
both domains remain connected via internal disulphide bonds after cleavage.  
 
 131 
 
 
 
Figure 5.2.6.1: Cleavage products of alternative Trop2 shedding are linked by 
disulphide bonds  
HEK293 cells stably expressing either AP-Trop2 or Trop2 were treated with mPS, in order 
to enrich the Trop2 aMP fragment. Reduced and non-reduced cell lysates were analysed by 
Western blotting, using anti-V5 antibody. Under non-reducing conditions, mPS-induced 
accumulation of the aMP fragment disappeared for both AP-Trop2 (A) and Trop2 (B). 
Schematic of alternatively cleaved AP-Trop2 (C) being held together via disulphide bonds 
between the aMP and aECD fragment in a non-reducing environment.  
 
Figure 5.2.6.2: Intracellular identification of the Trop2 aECD fragment 
Detection of both alternative Trop2 cleavage products in the lysates of cells stimulated with 
mPS. Western blot analysis detected (A) AP-Trop2, aMP and aECD fragment with anti-
Trop2 antibody (B) AP-Trop2 and aECD fragment with anti-HA antibody and (C) AP-Trop2 
and aMP fragment with anti-V5 antibody. GAPDH was used as loading control. 
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5.2.7 Inhibition of classical and novel PKCs has no influence on mPS 
stimulated Trop2 shedding 
Various studies have associated PKCs to ADAM-mediated substrate cleavage and earlier 
experiments in this project have confirmed the involvement of classical and novel PKCs in 
PMA-induced Trop2 processing or vesicle release. Furthermore, I discovered a novel 
pathway, by which the inhibition of atypical PKCζ results in the N-terminal cleavage of 
Trop2. However, as it is possible that other PKC isoforms are also involved in this 
alternative Trop2 processing, I tested the effect of PKC inhibitors, Gö6976 and BIM-1, on 
mPS treated cells. The inhibitory effect of both compounds on classical and novel PKCs was 
previously described (Chapter 4.2.5).  
Treatment of mPS stimulated cells with either Gö6976 or BIM-1 resulted in a slight, but 
insignificant reduction of AP-Trop2 release (Figure 5.2.7A). Western blot analysis of cell 
lysates with anti-V5 antibody confirmed that production of the Trop2 45 kDa aMP fragment 
was not affected by inhibition of classical or novel PKCs (Figure 5.2.7B). Gö6976 treatment, 
however, induced loss of staining for the Trop2 11 kDa MP fragment, similar to earlier 
experiments (Figure 4.2.5B), which would explain the observed slight signal reduction in the 
AP-shedding assay. However, these results clearly show that classical and novel PKCs are 
not involved in PKCζ dependent N-terminal cleavage of Trop2. 
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Figure 5.2.7: PKC inhibitors Gö6976 and BIM-1 have no effect on mPS-induced Trop2 
shedding 
Involvement of other PKC isoforms in alternative Trop2 cleavage was analysed by mPS 
treatment together with cPKC inhibitor Gö6976 (1µM) or BIM-1 (1µM), an inhibitor against 
both cPKCs and nPKCs. DMSO was used as solvent control. (A) Both inhibitors cause a 
slight, but insignificant, reduction of AP-Trop2 release in stimulated cells. Histograms show 
fold of increase compared to the negative control, based on mean values of three 
independent experiments ± SD; n = 12 (B) Western blot analysis was used to detect Trop2, 
with anti-V5 antibody. Neither Gö6976 nor BIM-1 showed an effect on the aMP fragment. 
GAPDH was used as loading control. 
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5.2.8 mPS induced shedding is inhibited by metalloproteinase 
inhibitors 
So far, the protease responsible for alternative Trop2 shedding remains unknown. Earlier 
experiments indicate that ADAM10 and ADAM17 might be involved, as their inhibition 
caused the disappearance of the Trop2 45 kDa aMP fragment in conditioned media. The 
specific induction of N-terminal Trop2 cleavage in response to PKCζ inhibition, allowed me 
to investigate how it is affected by three different metalloproteinase inhibitors. In order to 
validate metalloproteinase-dependent cleavage, I chose GM6001 as one of the most common 
broad spectrum inhibitors of matrix metalloproteinases (Grobelny et al. 1992; Galardy et al. 
1994). Selective ADAM inhibition was achieved by ADAM17-specific GW64 and 
ADAM10-specific GI23, which were already used in previous experiments (Chapter 4.2.4).  
HEK293 cells were pre-incubated with the inhibitors overnight, before they were stimulated 
with mPS in the presence or absence of GM6001, GW64 or GI23. The AP-shedding assay 
revealed that all three inhibitors caused a massive and significant decrease of mPS-induced, 
AP-Trop2 release. Interestingly, the overall signal reduction to nearly basal shedding levels 
seemed to be slightly weaker for GI23, in comparison to GM6001 and GW64 (Figure 
5.2.8.1A). Staining with anti-V5 antibody showed that the mPS-induced production of the 
Trop2 45 kDa aMP fragment was completely blocked by GM6001 and GW64, whereas low 
amounts of the band were still detectable, following GI23 treatment (Figure 5.2.8.1B). These 
observations confirm that PKCζ inhibition results in metalloproteinase dependent, cleavage 
of Trop2. The strong effect of both GW64 and GI23 further suggests that both ADAM10 
and ADAM17 are capable to cleave Trop2 in its N-terminal region.  
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Figure 5.2.8.1: Influence of metalloproteinase inhibitors GW64, GI23 and GM6001 on 
mPS-mediated Trop2 shedding 
To investigate whether mPS-induced Trop2 shedding is metalloproteinase dependent, cells 
were inhibited with either ADAM17-specific GW64 (1µM), ADAM10-specific GI23 (1µM) 
or broad-spectrum matrix metalloproteinase inhibitor GM6001 (25µM). DMSO was used as 
solvent control. (A) Inhibition of mPS treated cells with each compound led to a significant 
reduction of AP-Trop2 release. Histogram shows fold of increase compared to the DMSO 
control, based on mean values of three independent experiments ± SD, ** p < 0.01; *** p < 
0.001; n = 12. (B) Cellular Trop2 levels were detected by Western blotting using anti-V5 
antibody. Treatment with GW64, GM6001 and less effective GI23 resulted in a strong 
reduction of mPS-induced 45 kDa aMP fragment accumulation, while the 11kDa MP 
fragment was not affected. GAPDH was used as loading control.  
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Next, I looked for extracellular Trop2 fragments in concentrated media of cells that were 
stimulated with mPS, in the absence or presence of ADAM inhibitors, GW64 and GI23. I 
described above that following N-terminal cleavage the Trop2 domains are still connected 
via an internal disulphide bridge and therefore, the samples were analysed under reducing 
and non-reducing conditions. The blots displayed in Figure 5.2.8.2 contain additional lanes 
which are not relevant to this experiment and were covered accordingly. Detection of 
reduced V5 positive Trop2 species revealed an accumulation of full length AP-Trop2 in 
response to PKCζ inhibition for all samples. The Trop2 45 kDa aMP fragment, however, 
was only seen in the medium of mPS treated cells, in the absence of the ADAM inhibitors 
(Figure 5.2.8.2A). V5 staining of non-reduced samples confirmed mPS-induced 
accumulation of full length AP-Trop2. Furthermore, we identified a V5 positive band 
running at ~60 kDa, which might represent a membrane-bound and dimerized form of the 
Trop2 aMP fragment. This conclusion is supported by the finding that ADAM inhibitor 
treatment caused disappearance of the 60 kDa band (Figure 5.2.8.2B). Western blotting with 
anti-Trop2 antibody under reducing conditions, showed that mPS caused a slight increase of 
Trop2-ECD in comparison to full length AP-Trop2. However, when cells were treated with 
either GW64 or GI23 both bands were detected with equal intensity. In addition, the 45 kDa 
aMP and the 75 kDa Trop2-ECD fragment were observed in the medium of mPS stimulated 
cells, but were absent in ADAM inhibitor samples (Figure 5.2.8.2C). Trop2 staining under 
non-reducing conditions showed that PKCζ inhibition resulted in a slight reduction of 
Trop2-ECD dimers and a strong accumulation of full length AP-Trop2 in comparison to the 
Trop2-ECD band. I also detected the 60 kDa band in mPS treated samples and similar to the 
results above the signal was not seen when the cells were incubated with either GW64 or 
GI23 (Figure 5.2.8.2D). 
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Figure 5.2.8.2: Influence of metalloproteinase inhibitors, GW64, GI23 and GM6001, on 
mPS-mediated Trop2 shedding 
To investigate whether mPS-induced release of extracellular Trop2 is mediated by ADAM10 
and ADAM17, I analysed the medium of cells that were inhibited with either ADAM17-
specific GW64 (1µM) or ADAM10-specific GI23 (1µM). DMSO was used as solvent 
control. (A) Immunoblot analysis of concentrated media under reducing conditions with 
anti-V5 antibody showed an overall accumulation of full length AP-Trop2 in response to 
mPS simulation. The Trop2 45 kDa aMP fragment was only seen in mPS treated samples in 
the absence of ADAM inhibitors. (B) Under non-reducing conditions, V5 positive full-
length AP-Trop2 also accumulated following mPS treatment, whereas Trop2 60 kDa aMP 
dimers were only detected in the absence of GW64 or GI23. (C) Staining with anti-Trop2 
antibody under reducing conditions revealed a slightly higher amount of Trop2-ECD, than 
full length AP-Trop2, in response to mPS stimulation. When cells were treated with 
inhibitors and mPS simultaneously full length AP-Trop2 and Trop2-ECD levels, were equal. 
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Inhibition of PKCζ induced, release of the Trop2 45 kDa aMP and 75 kDa aECD fragment, 
but only in cells that were not treated with GW64 or GI23. (D) Immunoblot detection using 
anti-Trop2 antibody, under non-reducing conditions, showed a slight reduction of Trop2-
ECD dimers in the medium of mPS stimulated cells, as wells as highly increased amounts of 
full length AP-Trop2 in comparison to Trop2-ECD. Furthermore, Trop2 60 kDa aMP dimers 
were only seen in the medium of mPS stimulated cells in the absence of metalloproteinase 
inhibitors.  
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5.2.9 Approximation of the Trop2 alternative cleavage site  
Like many other transmembrane proteins, Trop2 features several N-linked glycosylation 
sites in its extracellular domain; and is therefore heavily glycosylated. Due to the fact that 
un-glycosylated Trop2 has a molecular mass of 37 kDa, the 45 kDa aMP fragment must also 
be glycosylated. So in order to determine its actual size, I deglycosylated the fragment using 
Peptide-N-Glycosidase F (PNGase F). This glycoamidase cleaves specifically the link  
between N-acetylglucosamines and asparagine residues of high mannose, hybrid and 
complex oligosaccharides from N-linked glycoproteins (Maley et al. 1989). Therefore, we 
deglycosylated the lysates of mPS stimulated, HEK293 cells stably expressing AP-Trop2 or 
Trop2. PNGase F treatment resulted in a shift of full length AP-Trop2 from 130 to 100 kDa; 
and of full length Trop2 from 60 to 37 kDa. Moreover, it also revealed an equal shift of the 
Trop2 aMP fragment from 45 to 32 kDa for both AP-tagged and non-tagged Trop2 (Figure 
5.2.9), showing that the fragment has a molecular mass of approximately 32 kDa.  
 
Figure 5.2.9: Determination of the Trop2 aMP fragment size by deglycosylation  
HEK293 cells stably expressing AP-Trop2 or Trop2 were treated with mPS, in order to 
enrich the aMP fragment. Cell lysates (20µg) were subjected to treatment with PNGase F to 
remove all N-linked oligosaccharides from the peptides. Trop2 was detected by 
immunoblotting, using anti-V5 antibody. Deglycosylation resulted in AP-Trop running at 
~100 kDa and Trop2 at ~37 kDa. For both AP-Trop2 and Trop2, the deglycosylated aMP 
fragment shifted to 32 kDa, indicating that cleavage occurs in the region of the EGF-TY 
domain boundary.  
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5.2.10 Androgen-independent PC3 prostate cancer cells are positive 
for the 45kDa aMP Trop2 fragment in cell lysates 
Although its role in carcinogenesis remains ambiguous, PKCζ has been described to act as a 
potential tumour suppressor in prostate cancer (Sánchez et al. 2008; Y. J. Kim et al. 2013). 
Due to the findings that PKCζ inhibition stimulates the N-terminal cleavage of Trop2, we 
wanted to know whether this also happens in human prostate cancer cell lines. Therefore, I 
used PC3 and LNCaP cells which were a kind gift from Dr. Anne Collins and Prof. Norman 
Maitland, from the University of York. LNCaP is an androgen-dependent prostate cancer 
cell line isolated from lymph node metastases, whereas androgen-independent PC3 cells 
were isolated from bone metastases. Both represent the most commonly used in vitro models 
for prostate cancer studies, as they represent an indolent (LNCaP) and aggressive (PC3) 
form of the disease. The cells were stimulated with mPS and in order to distinguish full 
length Trop2 from the Trop2 aMP fragment, PNGase F was used to deglycosylate the 
lysates. Analysis of PNGase F free samples showed highly glycosylated Trop2 (~60 kDa) in 
both cell lines and less glycosylated Trop2 (~45 kDa) in LNCaP cells only (Figure 5.2.10A). 
This 45 kDa band could have represented the Trop2 aMP fragment but de-glycosylation of 
proteins in the LNCaP cell lysates, resulted in a shift of both bands to 37 kDa, which 
confirmed their identity as differentially glycosylated full length Trop2 molecules. In 
contrast, PNGase F treatment of PC3 cell lysates caused a shift to not only full length Trop2 
running at 37 kDa, but also the Trop2 aMP fragment with a molecular size of 32 kDa 
(Figure 5.2.10A). However, PKCζ inhibition had no effect on the observed band intensities 
for both PC3 and LNCaP cells.  
The finding that the Trop2 aMP fragment was only seen in more aggressive PC3 cells was 
rather interesting as it could imply a potential role of N-terminal Trop2 cleavage in 
carcinogenesis. Previous experiments have shown that the production of the aMP fragment 
can efficiently be blocked by metalloproteinase inhibitors. So to test whether I can observe 
the same effect in PC3 cells, I treated them with broad spectrum metalloproteinase inhibitor 
GM6001 and ADAM17-specific GW64. The cells were incubated overnight in presence or 
absence of the inhibitors, lysed, deglycosylated and then analysed by immunoblotting using 
anti-Trop2 antibody. However, both GM6001 and GW64 inhibition had no effect on the 
amount de-glycosylated full length AP-Trop2 or the Trop2 aMP fragment. It has to be 
pointed out though, that the data only represent one experiment and that in order to see an 
effect further optimization might be necessary.  
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Figure 5.2.10: Detection of the Trop2 aMP fragment in PC3, but not in LNCaP cells 
Investigation of alternative Trop2 cleavage in prostate cancer cell lines, LNCaP and PC3 (A) 
Cells were stimulated with mPS and their lysates (20µg) subjected to treatment with PNGase 
F, in order to remove all N-linked oligosaccharides. Western blot analysis was used to detect 
cellular Trop2 with anti-Trop2 antibody. Endogenous Trop2 was expressed in both LNCaP 
and PC3 cells. The Trop2 aMP fragment was only detected in PC3 cells regardless of mPS 
treatment. (B) PC3 cells were incubated with ADAM17 inhibitor GW64 (1µM) or broad-
spectrum matrix metalloproteinase inhibitor GM60011 (25µM) prior to PNGase F treatment. 
Trop2 was detected by immunoblotting, using anti-Trop2 antibody. GW64 and GM6001 
showed no effect on the deglycosylated Trop2 aMP fragment.  
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5.2.11 Trop2 expression in prostate cancer stem cells 
In the introduction (Chapter 1.2) it was described that the heterogeneous composition of 
tumour tissues has gained growing attention over the last few years. Subpopulations of 
cancer stem cells in tumours are a promising target for the development of novel anti-cancer 
therapies. Due to the collaboration with Dr. Anne Collins and Professor Norman Maitland 
from the University of York, I was provided with CD44
+/α2β1high/CD133+ prostate cancer 
stem cells. The cells were isolated from tissue samples of prostate cancer patients with 
varying Gleason (G) score; and a control sample from a patient with benign prostate 
hyperplasia (BPH). The cell pellets were lysed and then analyzed by Western blotting. 
Staining with anti-Trop2 antibody showed cancer stem cells with highly varying expression 
levels of endogenous Trop2 independent from Gleason score. The highest expression level 
was observed in a patient with G7, whereas another G7 patient showed only low Trop2 
expression. Cells isolated from BPH tissue lacked Trop2 expression. The second pellet of a 
G7 patient was also lacking signals of the GAPDH loading control (Figure 5.2.10). 
Unfortunately, the study was limited by the small sample size and therefore we were not 
able to investigate whether the 45 kDa alternative cleavage product was present.  
 
Figure 5.2.11: Trop2 expression levels in prostate cancer stem cells from different 
patients 
Trop2 expression levels in prostate cancer stem cells isolated from tumour tissue of different 
patient samples, were determined by Western blotting and staining with anti-Trop2 antibody. 
GAPDH was used as loading control and each lane was loaded with 50 µg protein. G = 
Gleason score; P = pellet; BPH = benign prostate hyperplasia. 
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5.2.12 mPS treatment does not induce binding of PKCs to Trop2 
Similar to PMA stimulation experiments in chapter 4 (Chapter 4.2.7), I wanted to know 
whether inhibition of PKCζ potentially induces binding of Trop2 to other PKC isoforms. 
Therefore, I performed co-immunoprecipitation in order to detect stable Trop2-PKC 
complexes following mPS stimulation. Lysates of HEK293 cells stably expressing Trop2-V5 
were immunoprecipitated with anti-Trop2, conjugated Protein G Sepharose beads; and 
analysed by Western blotting. Staining with anti-V5 and anti-Trop2 antibody showed Trop2 
signals in the precipitate, but not for the IgG control IP. PKCζ inhibition had no effect on the 
amount of precipitated Trop2 (Figure 5.11.1). Sample lanes that were not relevant to this 
experiment were cut out of Figure 5.11.1. The complete blots are displayed in the 
supplemental section (Supplement II Figure S3). 
 
Figure 5.2.12.1: Immunoprecipitation of Trop2  
HEK293 cells stably expressing Trop2-V5 treated with mPS and H2O as a solvent control 
were lysed and subjected to immunoprecipitation (IP) with anti-Trop2 antibody, followed by 
Western blotting using anti-Trop2 and anti-V5 antibodies. Anti-IgG antibody was used as 
negative control. Immunoblots show the efficiency of the Trop2 immunoprecipitation. 
Next, the precipitated lysates were immunoblotted and stained for classical, novel and 
atypical PKCs. Several of the antibodies caused unspecific background staining. Therefore, 
the position (height) of PKCs bands within the lanes was marked with an arrow according to 
their predicted molecular sizes. The IgG control lane was cut out from Figure 5.11.2 and the 
complete blots can be examined in in the supplemental section (Supplement II, Figure S4, 
S5, and S6). Staining for classical isoforms revealed expression of PKCα only, whereas 
PKCβ and PKCγ were either not expressed or below the detection limit. None of the 
isoforms was co-precipitated with Trop2 (Figure 5.11.2A). Novel PKCε, PKCδ, PKCη and 
PKCθ were observed in all input controls, but not in the precipitates (Figure 5.11.2B), as 
well as atypical PKCι and PKCζ (Figure 5.11.2C). In summary, PKCζ inhibition did not 
affect PKC expression levels or caused the formation of stable Trop2-PKC complexes. 
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Figure 5.2.12.2: mPS treatment does not induce PKC binding to Trop2 
HEK293 cells stably expressing Trop2-V5 treated with mPS and H2O as solvent control, 
were lysed and subjected to immunoprecipitation (IP) with an anti-Trop2 antibody, followed 
by Western blotting to detect co-precipitated PKC isoforms with antibodies specific for 
classical, novel and atypical PKCs. Anti-IgG antibody was used as negative control and the 
complete blots are shown in the supplemental section. Co-immunoprecipitation of PKC 
isoforms with Trop2 was not observed in either stimulated or unstimulated cell lysates. 
Respective blots show the input lysate and IP-lanes for Trop2 immunoprecipitation. (A) 
Blots were stained for classical PKC isoforms: PKCα, PKCβ and PKCγ. (B) Novel isoforms: 
PKCε, PKCδ, PKCη and PKCθ. (C) Atypical isoforms: PKCι and PKCζ. 
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5.2.13 Inhibition of endocytosis with Dynasore leads to a decrease of 
Trop2 shedding and vesicles in the medium after mPS 
treatment 
Data from the time course experiment (Chapter 5.2.3) revealed significant reduction in AP-
Trop2 release after 30 min of mPS treatment, which potentially indicates that Trop2 is 
internalized and cleaved in intracellular compartments at later time points. To test this 
hypothesis, I stimulated HEK293 cells stably expressing AP-Trop2 with mPS and treated 
them simultaneously with Dynasore, an effective inhibitor of clathrin-mediated endocytosis. 
Dynasore treatment of control cells caused a massive increase of AP-Trop2 release, as 
already seen previously (Chapter 4.2.8). Most surprisingly, the opposite effect was observed 
for mPS stimulated cells, where inhibition of endocytosis resulted in nearly complete 
abrogation of the signal (Figure 5.2.13.1A). When I analysed the lysates of cells treated with 
both mPS and Dynasore, a strong reduction of both Trop2 MP-fragments was seen, whereas 
full length AP-Trop2 was not affected. Dynasore treatment of the control cells had no effect 
on either full length AP-Trop2 or the 11 kDa MP fragment (Figure 5.2.13.1B).   
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Figure 5.2.13.1: Inhibition of clathrin-dependent endocytosis by Dynasore abolishes 
mPS mediated Trop2 processing 
Clathrin-mediated endocytosis was blocked by Dynasore (80µM), an inhibitor against 
dynamin, in order to investigate its effect on mPS-induced alternative Trop2 cleavage. 
DMSO was used as solvent control. (A) As observed in previous experiments, Dynasore 
treatment of unstimulated cells resulted in a huge signal increase in the AP shedding assay. 
In contrast, inhibition of endocytosis in mPS treated cells led to a nearly complete shutdown 
of AP Trop2 release. The histogram represent the fold of increase compared to the negative 
control based on mean values of three independent experiments ± SD; *** p < 0.001; n = 12  
(B) Cellular Trop2 levels were detected by immunoblotting using anti-V5 antibody. 
Dynasore inhibition caused a strong reduction of the Trop2 MP and aMP fragment, in mPS 
treated cells. GAPDH was used as loading control. 
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Next, I investigated how PKCζ inhibition affected the Trop2 medium content of cells that 
were treated with Dynasore. Western blot analysis of the concentrated media under reducing 
conditions showed a massive accumulation of V5 positive full length AP-Trop2 for 
Dynasore treated control cells. However, when cells were stimulated simultaneously with 
mPS the AP-Trop2 signal disappeared completely along with the Trop2 45 kDa aMP 
fragment (Figure 5.2.13.2A). The same was seen when non-reduced medium samples were 
stained with anti-Trop2 antibody, however, I also detected Trop2-ECD dimers in the 
medium of cells treated with both mPS and Dynasore (Figure 5.2.13.2B). This indicates that 
the observed reduction of AP-Trop2 in the medium is probably based on blockage of vesicle 
release and that cleavage is not completely ablated. 
As a consequence, I determined vesicle size and concentration in the medium using a 
NanoSight LM10 instrument. Similar to the experiments in Chapter 4, the data between 
Dynasore treated and DMSO control cells could not be compared, due to the fact that the 
inhibitor is only partially soluble and therefore we analysed the medium of Dynasore treated 
cells only. The acquired data showed that in terms of size there was no difference as vesicles 
from both mPS stimulated and DMSO control cells peaked at ~130nm. However, when we 
looked at vesicle concentration, a huge difference between the samples was seen. The 
number of vesicles in the medium of mPS stimulated cells was over 50% lower, when 
compared to the vesicles count of DMSO control cells (Figure 5.2.13.2C). This highly 
significant reduction in overall vesicle concentration is in accordance with the results above, 
which suggest that mPS-induced Trop2 processing is connected with internalization of the 
protein.  
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Figure 5.2.13.2: Inhibition of clathrin-mediated endocytosis in mPS treated cells, led to 
a reduction of extracellular Trop2- containing vesicles  
HEK293 cells stably expressing AP-Trop2 were treated with both mPS and Dynasore 
(80µM), an inhibitor against dynamin, to block clathrin-mediated endocytosis. DMSO was 
used as solvent control. The conditioned medium was collected, concentrated by spin down 
columns and analysed by immunoblotting. Dynasore inhibition of the control cells caused an 
accumulation of AP-Trop, which was detected with both (A) anti-V5 and (B) anti-Trop2 
antibodies. The medium of cells simultaneously treated with mPS and Dynasore only 
showed low amounts of Trop2-ECD dimers. (C) Nanoparticles in the medium of Dynasore 
treated cells were detected using a NanoSight LM10 instrument. Particle size distribution 
shows a peak at ~130nm in both samples. Dynasore inhibition caused a significant reduction 
of vesicle release in mPS stimulated cells. The histogram represents the fold of decrease of 
the vesicle concentration, compared to the negative DMSO control; and the data is based on 
mean values of three independent experiments ± SD; n = 9    
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5.2.14 Dynasore inhibition leads to an accumulation of Trop2 in the 
cell membrane of PKCζ inhibited cells 
The previous chapter outlined that inhibition of endocytosis in mPS stimulated cells resulted 
in a huge reduction of AP-Trop2 release into medium. Based on these findings, it was 
speculated that PKCζ inhibition might induce the internalization of Trop2 followed by its 
intracellular cleavage and the subsequent exosomal release of the protein. A similar course 
of action has been shown for cell adhesion molecule L1, which is endocytosed, cleaved by 
ADAM10 in MVBs and released by exocytosis (Stoeck et al. 2006). During endocytosis, the 
membrane buds inward until the formed vesicle is pinched off by the GTPase dynamin. 
Dynasore inhibition of dynamin led to accumulation of O-shaped, fully formed pit 
intermediates, that are captured at the inner membrane (Macia et al. 2006). So, if PKCζ 
inhibition triggers the internalization of Trop2, Dynasore treatment would trap the protein in 
inwardly budded vesicles that are stuck at the plasma membrane. In order to test this 
hypothesis, I determined cellular AP-Trop2 localization, in response to mPS and Dynasore 
treatment using Confocal Microscopy. HEK293 cells stably expressing AP-Trop2 were 
stimulated with mPS in the presence or absence of Dynasore followed by fixation, 
permeabilization and staining of the cells with mouse anti-V5 and goat anti-Trop2 
antibodies. Intra- and extracellular Trop2 domains were visualized with anti-mouse 
AlexaFluor
®
594 (red) and anti-goat AlexaFluor
®
488 (green) antibodies, whereas DAPI 
solution was used to stain cell nuclei (blue). Hence, full length AP-Trop2 is represented by 
co-localization (yellow) of green extracellular and red intracellular signals. 
For control cells, AP-Trop2 localization in the presence and absence of Dynasore was 
similar to the data from previous experiments (Chapter 4.2.9). Under normal conditions, AP-
Trop2 was evenly distributed in the plasma membrane (Figure 5.2.14A), whereas adding of 
Dynasore resulted in massive loss of cell surface AP-Trop2 and the accumulation of Trop2-
ICD fragments (red) in the cytoplasm (Figure 5.2.14B, white arrows). As I speculated that 
PKCζ inhibition induces endocytosis, I expected to see an increase of intracellular AP-Trop2 
containing vesicles. However, mPS stimulation did not alter the dominant membrane 
localization of AP-Trop2 and I did not detect any signals within the cell (Figure 5.2.14A). 
Despite this unexpected outcome, I saw the hypothesis confirmed when I looked at cells that 
were simultaneously treated with mPS and Dynasore. In contrast to unstimulated cells, AP-
Trop2 remained localized at the plasma membrane, along with partial accumulation of 
Trop2-ICD (red) in the cytoplasm of some of the cells (Figure 5.2.14B). These signals would 
concur with AP-Trop2 molecules in vesicles that cannot be released from the inner 
membrane. 
 150 
 
 
 
 
 151 
 
Figure 5.2.14: Sustained AP-Trop2 cell surface localisation in mPS-treated cells during 
Dynasore inhibition 
Analysis of AP-Trop2 cell surface localization after treatment with mPS and endocytosis 
inhibitor Dynasore (80µM), DMSO was used as solvent control. The cells were fixed, 
permeabilised and labelled using mouse anti-V5 and goat anti-Trop2 primary antibodies. 
Anti-mouse AlexaFluor
®
594 (red pseudocolour) and anti-goat AlexaFluor
®
488 (green 
pseudocolour) were used as secondary detection antibodies; and the cell nuclei were 
visualised with DAPI (blue pseudocolour). (A) Uninhibited control cells, as well as mPS 
stimulated cells, had evenly distributed AP-Trop2 in their plasma membranes. (B) Dynasore 
inhibition of unstimulated cells caused a massive loss of cell-surface AP-Trop2 and showed 
accumulation of V5-tagged, Trop2 fragments (red, white arrows) in the cytosplasm. This 
effect was reversed when cells were treated simultaneously with Dynasore and mPS. 
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5.2.15 Alternative Trop2 cleavage is not regulated by Ser
303
 
Although I showed that PKCζ inhibition leads to endocytosis of Trop2, it remains unclear 
how this process is regulated. A common endocytosis signal is the phosphorylation of serine 
residues, as it was shown for various GPCRs (Delom & Fessart 2011) or other 
transmembrane proteins, such as cell adhesion molecule L1 (Nakata & Kamiguchi 2007), or 
the FGF receptor (Nadratowska-Wesolowska et al. 2013). Due to the presence of a 
phosphorylatable serine residue at position 303 (Ser
303
) in the cytoplasmic tail of Trop2, it is 
possible that its internalization is regulated in a similar fashion. In order to determine the 
influence of Ser
303
 on Trop2 endocytosis, I investigated the shedding of two distinct Trop2 
serine mutants in response to PKCζ inhibition. Therefore, HEK293 cells were transiently 
transfected with overexpression plasmids for an either non-phosphorylatable alanine mutant 
(AP-Trop2 S303A), or a phosphor-mimicking aspartate mutant (AP-Trop2 S303D).  
Quantification of AP-Trop2 release using the AP-shedding assay, showed a significant 
increase for both mutants, with the signal being slightly higher for AP-Trop2 S303D (Figure 
5.2.15A). Detection of V5 positive Trop2 species, confirmed the accumulation of the Trop2 
45 kDa aMP in response to mPS for both mutants. The 11 kDa MP fragment was seen in 
lesser amounts for AP-Trop2 S303D, when compared to the S303A mutant and mPS 
treatment resulted in overall reduction of the 11 kDa band (Figure 5.2.15B). According to 
these results, Ser
303
 does not seem to play a role mPS-mediated alternative Trop2 processing. 
Next, I analysed the conditioned media for extracellular AP-Trop2 fragments. Interestingly, 
V5 positive full length AP-Trop2 S303A and S303D bands were detected in the reduced 
medium of control cells only, whereas PKCζ inhibition led to disappearance of these bands 
(Figure 5.2.15C). Anti-Trop2 antibody staining showed weak bands of full length AP-Trop2 
and high levels of Trop2-ECD dimers, for both mutants in non-reduced medium, 
independent of mPS treatment (Figure 5.2.15D). 
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Figure 5.2.15: mPS-induced alternative cleavage of Trop2 phosphoserine mutants, 
S303A and S303D  
HEK293 cells were transfected with S303A or S303D AP-Trop2 overexpression vectors, 
prior to stimulation with mPS. Distilled water was used as solvent control. (A) Activation of 
alternative cleavage by mPS led to a significant increase of AP-Trop2 release for both 
mutants. Histograms show fold of increase compared to the negative control, based on mean 
values of three independent experiments ± SD; n = 12 (B) Western blot analysis was used to 
detect Trop2 with anti-V5 antibody. Accumulation of the aMP fragment following mPS 
stimulation was observed for both S303A and S303D AP-Trop2. GAPDH was used as 
loading control. Trop2 fragments in conditioned media were detected using immunoblot 
analysis, with (C) anti-V5 and (D) anti-Trop2 antibodies, under reducing or non-reducing 
conditions. Reduced levels of full length AP-Trop2 were observed in the medium of mPS 
stimulated cells, whereas high levels of Trop2-ECD dimers were detected in all samples. 
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5.3 Discussion 
One of the major findings of this thesis was that PMA-induced Trop2 shedding is inhibited 
by classical and novel PKC inhibitors (Chapter 4.2.5). However, due to a study that showed 
that PKCζ inhibition enhanced NRG release upon PMA stimulation (Dang et al. 2011), I 
decided to scrutinize whether the atypical isoform is also involved in Trop2 processing. To 
do so, I tested a commonly used, commercially available myristoylated pseudosubstrate 
peptide inhibitor, with the ability to block PKCζ activity. To my surprise, preliminary 
experiments revealed that mPS was able to induce shedding on its own, in the absence of 
any other stimuli (data not shown). In order to validate the specificity of the observed effect, 
I used non-myristoylated pseudosubstrate (PS) and a myristoylated scrambled (mPS Scr.) 
peptide as negative controls. As the myristate-tag makes the peptide membrane-permeable, 
PS should exclude potential binding to cell surface receptors, whereas mPS Scr. was used to 
rule out unspecific intracellular interactions. Data from the AP-shedding assay showed an 
increase in AP-Trop2 release for both mPS and mPS Scr., but in direct comparison, the mPS 
signal was significantly higher than the one from mPS Scr. control (Figure 5.2.1A). 
However, there are reports that the myristate-tag of synthetic peptides can activate a variety 
of enzymes, such as eNOS and induce increased Ca
2+
 levels (Krotova et al. 2006; Lim et al. 
2008). Therefore, it is possible that the observed increase in AP-Trop2 release upon mPS 
Scr. treatment is caused by the myristate-tag, but shRNA mediated PKCζ knockdown 
confirmed mPS specificity (Chapter 5.2.2). Moreover, V5 staining of the lysates showed that 
only mPS treatment caused accumulation of the Trop2 45 kDa aMP fragment (Figure 
5.2.1B). So far, I was only able to detect a slight accumulation of the 45 kDa band as a side-
effect of PMA treatment, but the results show that N-terminal Trop2 cleavage can be 
specifically induced through PKCζ inhibition. Various studies, however, have shown that 
mPS blocks not only PKCζ, but also the second atypical isoform PKCι (Lee et al. 2013; Ren 
et al. 2013; Volk et al. 2013). Hence, at this point I could not exclude the possibility that the 
effect is PKCι-dependent. Nonetheless, this discovery gave a unique tool that allowed us to 
specifically investigate the alternative cleavage of Trop2.  
Before I proceeded, I wanted to be sure that N-terminal Trop2 cleavage is indeed PKCζ 
dependent. As both atypical PKCs share an overall amino acid identity of 72% (Nishizuka 
1995), I used shRNA directed against the 3’UTR of PKCζ in order to specifically inhibit 
synthesis of the isoenzyme. Knockdown of PKCζ resulted in significantly elevated AP-
Trop2 release (Figure 5.2.2A); and a 3-fold accumulation of the Trop2 45 kDa aMP 
fragment in the lysates (Figure 5.2.2B). Taken together, this confirms that N-terminal, Trop2 
cleavage and increased AP-Trop2 release is indeed associated with PKCζ.  
 155 
 
Based on my experience with PMA stimulation, I initially incubated the cells with mPS for 
3h. However, it was still necessary to verify that this time frame was in the linear range of 
mPS-induced Trop2 shedding; and to do so I measured cleavage after 30, 60 and 120 min in 
a time course experiment. To my surprise, the AP-shedding assay disclosed a significant 
signal reduction after 30 min of mPS treatment in the medium. After 60 min, AP-Trop2 
release went up to the level of baseline shedding and showed to be significantly elevated 
after 120 min (Figure 5.2.3A). Moreover, I saw a slight accumulation of the Trop2 45 kDa 
aMP fragment after 30 min, with increasing band intensity over the time course (Figure 
5.2.3B). The observed signal loss after 30 min was rather interesting, as it contradicted the 
immunoblot results showing increased Trop2 aMP fragment production at this time point. I 
saw in previous experiments that the 45 kDa fragment disappeared under non-reducing 
conditions (Figure 4.2.2A); and therefore, it might be that N-terminal cleavage does not led 
to immediate release of the alternative Trop2-ECD. It is possible that both fragments stay 
connected via internal disulphide bridges and that reduction of these bonds is delayed. This 
could explain the simultaneous reduction of AP-Trop2 release and accumulation of Trop2 
aMP fragment. However, another possibility might be that N-terminal Trop2 processing is 
performed in the endosomal compartment which would require internalization of Trop2 
prior to cleavage. Interestingly, a similar mechanism has been described for cell adhesion 
molecule L1 which can either be cleaved by ADAM17 on the cell surface or by ADAM10 in 
MVBs, following endocytosis (Stoeck et al. 2006). Endocytosis of AP-Trop2 would remove 
the molecule from the cell surface and result in decreased shedding assay signals. In this 
case, alternative Trop2 shedding would occur within the cell, leading to raised levels of the 
aMP Trop2 fragment. Due to the fact that we saw increased AP-Trop2 release after 120 min, 
I can also assume that at some point Trop2 fragments have to be released. This could happen 
either in soluble form or alternatively on the surface of exosomes. 
To follow up on this hypothesis, I separated vesicles from soluble proteins in the medium 
and stained for V5 positive Trop2 species. Under reducing conditions, I detected full-length 
AP-Trop2 and the Trop2 45 kDa aMP fragment in the pellet faction only. PKCζ inhibition 
caused strong accumulation of the aMP fragment whereas full length AP-Trop2 levels were 
unaltered. Furthermore, I saw that similar to previous experiments the Trop2 45 kDa band 
was not detectable in non-reduced samples (Figure 5.2.4A). These results indicate that PKCζ 
inhibition only affects the release of vesicles containing the aMP Trop2 fragment, which 
supports the hypothesis that alternative Trop2 shedding occurs inside the cell followed by 
exosomal release. It is likely that exosomal Trop2 is still connected to its N-terminal part via 
internal disulphide bonds.  When I stained non-reduced samples with anti-Trop2 antibody, I 
observed Trop2-ECD dimers in the soluble fraction that were unaltered by mPS treatment 
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(Figure 5.2.4B). This shows that basal Trop2 cleavage and subsequent dimer formation of 
the fragments is not affected by inhibition of PKCζ. 
As I saw an increase in vesicle release in response to mPS, I quantified vesicle numbers and 
sizes using NTA. Vesicle size distribution in the medium of control cells peaked at ~130 nm, 
whereas PKCζ inhibition caused discharge of slightly smaller vesicles (Figure 5.2.5). 
Although the size difference is rather small, the data point towards an increase in exosome 
numbers, as they are thought to be smaller than ectosomes (Cocucci et al. 2009). 
Comparison of vesicle concentrations showed increased numbers in response to mPS 
treatment, which however, were not statistically significant (Figure 5.2.5). Nonetheless, the 
data did not contradict the possibility of exosomal Trop2 release. 
So far, all the results indicated that the cleavage products of alternative Trop2 shedding stay 
connected, which is further supported by a study that reported a similar mechanism for 
Trop2 homologue, EpCAM. Schnell et al. described that the products of N-terminal EpCAM 
cleavage were only detectable in reduced lysates of HEK293 cells; and that this was due to 
internal disulphide bonds in the EpCAM TY-domain (Schnell et al. 2013). For both AP-
Trop2-V5 and Trop2-V5 expressing cells, mPS-induced accumulation of the Trop2 45 kDa 
aMP fragment was only detectable in reduced lysates. Nonetheless, to achieve a definite 
proof of an enduring connection via disulphide bonds, I still needed to identify the N-
terminal cleavage fragment, which has a predicted size of 75 kDa for AP-Trop2 (Figure 
5.2.6.1B). As predicted, PKCζ inhibition resulted in the production of a 75 kDa band, which 
was only detectable with anti-Trop2 and anti-HA antibodies (Figure 5.6.2.2). The positive 
staining of the N-terminal HA-tag, but not the C-terminal V5-tag, confirmed that the 75 kDa 
band is indeed the alternative Trop2 aECD fragment. The identification of the second 
cleavage product represents striking evidence that N-terminal Trop2 shedding occurs in 
response to PKCζ inhibition. Additionally, I clearly showed that both cellular and exosomal 
Trop2 is alternatively cleaved; and that both fragments stay connected via internal 
disulphide bonds. However, it remains unclear if the actual cleavage event occurs on the cell 
surface or within endosomal compartments.  
The primary aim of the following experiments was to determine how inhibition of ADAM 
metalloproteinases and other PKC isoforms affects mPS-induced shedding. Therefore, I 
looked into the potential involvement of novel and classical PKCs in N-terminal Trop2 
cleavage. The results showed that both cPKC and nPKCs inhibition had no significant effect 
on AP-Trop2 release and the amount of the Trop2 45 kDa aMP fragment generated (Figure 
5.2.7). This shows that PKCζ is likely to be the only member of the PKC family that is 
involved in the alternative Trop2 shedding pathway. General metalloproteinase inhibition 
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caused a massive reduction of AP-Trop2 release down to the level of basal shedding. The 
same effect was seen for specific inhibition of ADAM17; and to a lesser extent ADAM10 
(Figure 5.2.8.1A), which also blocked the production of the Trop2 45 kDa fragment (Figure 
5.2.8.1B). Taken together, these results demonstrate that N-terminal Trop2 cleavage is 
performed by either ADAM10 or ADAM17. The nearly complete reduction of the signal in 
response to ADAM10 and ADAM17 inhibition indicates that cleavage is not compensated 
by either one of them. This is interesting, as it known that many ADAM17 substrates, such 
as  TGF-α, TNF-α, HB-EGF or L-selectin are cleaved by ADAM10, in the absence of 
ADAM17 (Le Gall et al. 2009). It further shows that the mPS-induced increase in AP 
activity in the medium, solely depends on alternative processing of Trop2.  
V5 and Trop2 staining of the medium confirmed that mPS-induced accumulation of vesicles 
containing Trop2 45 kDa aMP fragment, was blocked by both ADAM inhibitors (Figure 
5.2.8.2A and C). Reduced samples also showed increased levels of full length AP-Trop2 and 
cleaved Trop2-ECD in response to PKCζ inhibition, which was already seen earlier but to a 
lesser extent (Figure 5.2.4A and B). This would indicate that the release of full length AP-
Trop2 containing vesicles and regular shedding of Trop2 might be at least partially 
influenced by mPS as well.  Under non-reducing conditions, anti-Trop2 staining clearly 
showed enhanced accumulation of full length AP-Trop2 in comparison to the Trop2-ECD 
band (Figure 5.2.8.2D). This was to be expected, as intact internal disulphide bridges would 
cause alternatively cleaved Trop2 to run at the same height as the full length protein. Both 
antibodies identified a novel band running at 60 kDa, which was only detectable in non-
reduced samples; and its generation was blocked by both ADAM inhibitors (Figure 5.2.8.2B 
and D). Given its molecular weight, the presence of disulphide bridges and the positive V5 
signal, I assume that it represents an intermediate product of aMP fragment dimerization. 
Such a Trop2 aMP dimer intermediate would consist of a V5-tagged 45 kDa aMP fragment, 
which is attached via disulphide bonds to a 15 kDa Trop2 TY-domain fragment (Figure 
5.3.1). So far, it remains elusive whether N-terminally cleaved Trop2 also undergoes regular 
shedding close to the membrane; and it is possible that this process is blocked due to 
conformational alterations in the molecule that make the cleavage site inaccessible to 
ADAM17. Interestingly, it was shown that isomerase mediated disulphide bond reshuffling 
of MICA induced conformational changes allowing proteolytic cleavage (Kaiser et al. 2007). 
Therefore, it cannot be ruled out that a similar mechanism applies to Trop2. Alternatively, 
cleaved AP-Trop2 molecules, in which both fragments are still attached via disulphide 
bonds, could be rearranged by an isomerase which would lead to the release of N-terminal 
aECD molecules and dimerization of two 45 kDa aMP fragments. This could induce a 
conformational change that enables ADAM17 to cleave the aMP dimer molecule close to the 
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cell surface; and the resulting Trop2 aMP dimer intermediate would match all previously 
described features of the 60 kDa band. Ongoing cleavage by ADAM17 would then result in 
the release of 30 kDa Trop2 TY-domain dimers, lacking the V5-tag and the N-terminal AP-
EGF domain (Figure 5.3.1).  
 
Figure 5.3.1: Schematic representation of hypothesized disulphide bond rearrangement 
and proteolytic processing of alternatively cleaved AP-Trop2 molecules 
Subsequent to N-terminal shedding of AP-Trop2, the cleavage products are being held 
together via internal disulphide bonds. Isomerase mediated re-structuring of these bonds 
potentially induces release of the AP-tagged 75 kDa N-terminal part, dimerization of two 
Trop2 45 kDa aMP fragments; and enables ADAM17 to cleave one of the dimer molecules 
close to the plasma membrane. The resulting 60 kDa aMP dimer intermediate consists of a 
V5-tagged 45 kDa aMP fragment that is connected via disulphide bridges to a twofold 
cleaved Trop2 fragment with a size of ~ 15 kDa. Ongoing ADAM17 activity liberates the 
intermediate from the cell surface as a Trop2 TY-domain dimer molecule, with a predicted 
size of ~30 kDa.  
In the next experiment, I de-glycosylated lysates of mPS treated cells in order to determine 
the actual size of the Trop2 45 kDa aMP fragment. This caused an equal shift of the Trop2 
aMP fragment from 45 to 32 kDa, for both AP-tagged and non-tagged Trop2 (Figure 5.2.9). 
The finding that the Trop2 aMP fragment has a molecular mass of approximately 32 kDa, 
allows the placement of the N-terminal cleavage at the EGF-TY domain boundary. This 
would be in accordance with Trop2 homologue EpCAM, where the N-terminal cleavage is 
located in the TY domain between Arg-80/Arg-81 (Thampoe et al. 1988; Schön et al. 1993). 
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As it was shown that Trop2 shedding is an important mechanism in prostate cancer 
progression (Stoyanova et al. 2012), I tested whether alternative Trop2 cleavage does occur 
in prostate cancer cell lines or in prostate cancer stem cells. Analysis of prostate cancer stem 
cells from tissue samples of prostate cancer patients showed highly varying expression 
levels of endogenous Trop2 (Figure 5.2.11). All samples showed Trop2 bands with low 
molecular weight, which could indicate that the peptide is only marginally glycosylated. Due 
to this, I was not able to distinguish Trop2 aMP fragments from full length Trop2; and the 
limited sample sized prevented me to use deglycosylation to separate both molecules. 
Therefore, I decided to analyse LNCaP and PC3 prostate cancer cell lines for alternative 
Trop2 cleavage products. Immunoblot detection revealed highly glycosylated Trop2 running 
at 60 kDa in both cell lines; and a less glycosylated form running at 45 kDa in LNCaP cells 
only (Figure 5.2.10A). Deglycosylation led to the identification of full length Trop2 running 
at 37 kDa in both cell lines, whereas the Trop2 32 kDa aMP fragment was only detected in 
PC3 cells. PKCζ inhibition had no effect on the 32 kDa band, although it was shown that 
PKCζ is expressed in LNCaP and PC3 cells (Sánchez et al. 2008). Due to reports that PKCζ 
acts as a tumour suppressor in prostate cancer (Kim et al. 2013), it is possible that the 
isozyme is deactivated in PC3 and LNCaP cells, which would render mPS ineffective. This 
is supported by the report that PKCζ activation through ceramides induced apoptosis in PC3 
and LNCaP cells (Sánchez et al. 2008). The fact that the Trop2 aMP fragment was not found 
in LNCaP cells is rather interesting, as this androgen-sensitive cell line represents an 
indolent form of the disease. In contrast, androgen-independent PC3 cells were isolated from 
aggressive bone metastases and the presence of the 32 kDa aMP fragment potentially 
suggests that N-terminal Trop2 cleavage is indicative of a more malicious form of the 
cancer. When I treated PC3 cells with an ADAM17 specific and a general metalloproteinase 
inhibitor, I did not see loss of the Trop2 aMP fragment (Figure 5.2.10B) as in previous 
experiments performed in HEK293 cells. It was shown that ADAM17 promotes 
invasiveness of PC3 cells (Xiao et al. 2012), so I can exclude that ADAM17 is inactive in 
our cells. However, it could be that inhibition of ADAM17 mediated alternative Trop2 
cleavage is compensated in PC3 cells, by another metalloproteinase insensitive to GM6001. 
It has to be taken into consideration though, that inhibitor dose and incubation time might 
need adjustment, in order to induce efficient inhibition of protease activity in PC3 cells and 
that further repeats are required to verify the outcome.  
Due to recent findings that Trop2 homologue EpCAM, is capable of binding novel PKCs via 
a pseudosubstrate sequence in its cytoplasmic tail (Maghzal et al. 2013), I investigated 
whether PKCζ inhibition is able to induce PKC binding to the Trop2 C-terminus. Therefore, 
I performed co-immunoprecipitation experiments to investigate the potential formation of 
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stable Trop2-PKC complexes. However, I did not detect any PKC isoform binding to Trop2 
in mPS treated or control cells (Figure 5.2.12.2A and B and C). The discussion about 
potential scenarios that could explain the lack of Trop2-PKC complexes can be found in 
Chapter 4.3.   
Based on this data, I hypothesized that PKCζ inhibition triggers internalization of Trop2, 
followed by N-terminal processing in the endosomal compartment. To further provide 
evidence for this theory, I treated cells with the endocytosis inhibitor Dynasore in the 
presence or absence of mPS. Dynasore caused a massive increase of AP-Trop2 release in 
control cells, which is due to blocked re-internalization of constitutively discharged vesicles 
containing full length AP-Trop2. However, when cells were simultaneously incubated with 
mPS and Dynasore, I saw abrogation of the signal in the AP-shedding assay (Figure 
5.2.13.1A). When I stained the lysates with anti-V5 antibody, I saw that Dynasore blocked 
not only the mPS-induced production of the Trop2 45 kDa aMP fragment, but also caused a 
strong reduction of the Trop2 11 kDa MP fragment band (Figure 5.2.13.1B). Taken together, 
these results strongly favour the assumption that PKCζ inhibition induces Trop2 
endocytosis, prior to alternative cleavage. Dynasore inhibition of dynamin has shown to 
cause  accumulation of O-shaped, fully formed pit intermediates that are captured at the 
inner membrane (Macia et al. 2006). Trapped in pit intermediates, Trop2 would be 
inaccessible to cell surface shedding, which could explain the observed reduction of the 
Trop2 11 kDa MP fragment, which could also be caused by increased γ-secretase 
processing. Furthermore, the massive loss of AP-Trop2 release indicates that interrupted 
endocytosis also interferes with the constitutive release of full length AP-Trop2 containing 
vesicles in the absence of PKCζ activity. I saw a complete loss of full length AP-Trop2 in 
the medium of mPS treated cells, in response to Dynasore treatment (Figure 5.2.13.2A and 
B). The additional loss of the Trop2 45 kDa band strongly suggests that release of vesicles 
containing the Trop2 aMP fragment is disrupted (Figure 5.2.13.2A); and conclude that 
intracellular Trop2 processing is blocked. Interestingly, the only Trop2 positive species 
detected were low amounts of dimerized Trop2-ECD molecules (Figure 5.2.13.2B), 
demonstrating that cell surface shedding is probably not directly affected, but does still 
occur to a certain degree. Quantification of vesicle numbers confirmed the Western blot 
results; and demonstrated a strongly significant reduction in extracellular vesicle 
concentration, when cells were simultaneously incubated with mPS and Dynasore (Figure 
5.2.13.2C), while vesicle release in control cells was not blocked by endocytosis inhibition.  
Next, I used Confocal Microscopy to determine cellular localization of AP-Trop2, in 
response to PKCζ inhibition. AP-Trop2 was detected pre-dominantly in the plasma 
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membrane, but comparison between mPS and control treated cells did not reveal any 
obvious differences (Figure 5.2.14A). It needs to be mentioned that AP-Trop2-ECD and –
ICD co-localization was not complete, which could be due to constitutive shedding resulting 
in local accumulation of C-terminal Trop2 fragments (red). Unfortunately, I did not detect 
any signals in the cytoplasm of mPS treated cells, which would support Trop2 endocytosis 
and intracellular processing. However, it could be that the amount of Trop2 in the 
endocytotic compartment is below the antibody detection limit, as I have so far no concrete 
indication of the magnitude of the internalization process. Dynasore treatment of control 
cells caused a massive loss of cell surface AP-Trop2 and intracellular clustering of Trop2-
ICD (Figure 5.2.14B), which was also observed in Chapter 4.2.9. PKCζ inhibition on the 
other hand, prevented Dynasore-induced loss of cell surface AP-Trop2 (Figure 5.2.14B). 
The retention of AP-Trop2 signals in the membrane concurs with the predicted accumulation 
in fully formed pit intermediates that are captured at the inner membrane in response to 
dynamin inhibition. Hereby, the data convincingly supports our hypothesis of mPS triggered 
Trop2 internalization, which is efficiently blocked by inhibition of clathrin-mediated 
endocytosis.  
To investigate the contribution of the phosphorylatable serine residue in the Trop2 
cytoplasmic tail in mPS-induced Trop2 processing, I investigated the effect of PKCζ 
inhibition on two AP-Trop2 Ser
303
 mutants. In contrast to PMA-induced shedding (Figure 
4.2.10A), mPS-induced alternative Trop2 processing was not affected by Ser
303
 mutations 
and resulted in significantly increased AP-Trop2 release for both mutants, with the signal 
being slightly higher for AP-Trop2 S303D (Figure 5.2.15A). I confirmed mPS-induced 
accumulation of the Trop2 45 kDa fragment, together with a slight reduction of the 11 kDa 
MP fragment for both AP-Trop2 S303A and S303D (Figure 5.2.15B). Taken together, the 
results demonstrate that mPS mediated Trop2 processing is not impaired by phosphoserine 
mutations. As a consequence, I can rule out that Trop2 is phosphorylated by PKCζ and that 
phosphorylation in general plays a role in the alternative pathway of Trop2 shedding. 
Analysis of Trop2 fragments in conditioned media showed for both mutants the 
disappearance of full length AP-Trop2 (Figure 5.2.15C). This implies that the observed mPS 
dependent increase in AP-Trop2 release is solely based on alternatively processed Trop2 
molecules. However, staining with anti-Trop2 antibody did not reveal any alterations in 
cleaved Trop2-ECD dimers (Figure 5.2.15C), indicating that basal shedding of the AP-
Trop2 mutants is not affected.  
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Figure 5.3.2: Schematic model of PKCζ regulated Trop2 endocytosis and subsequent 
alternative processing of Trop2 
Endocytosis of Trop2 is negatively regulated by PKCζ; and inhibition of the isozyme using 
mPS triggers Trop2 internalization and sorting through the endocytic pathway. Clathrin-
mediated endocytosis inhibitor Dynasore blocks this process, leading to accumulation of pit 
intermediates that are captured at the inner membrane. N-terminal Trop2 cleavage by either 
ADAM10 or ADAM17 is initiated in the endosomal compartment/MVB, with the cleavage 
products staying connected via internal disulphide bonds. These alternatively cleaved Trop2 
molecules are subsequently released from the cell in the form of exosomes.  
In summary, the results in this chapter demonstrate that N-terminal cleavage of Trop2 is 
negatively regulated by atypical PKCζ; and that PKCζ inhibition with a cell-permeable 
pseudo substrate inhibitor leads to alternative processing. Trop2 is initially internalized and 
sorted into the endocytic pathway. This mechanism was blocked by the endocytosis inhibitor 
Dynasore; and led to accumulation of Trop2 at the cell membrane, presumably trapped in 
fully formed pit intermediates (Figure 5.3.2). N-terminal cleavage of Trop2 occurs within 
the endosomal compartment (presumably in MVBs) by either ADAM10 or ADAM17; and I 
showed that both cleavage fragments remain connected via internal disulphide bonds. 
Eventually, alternatively cleaved Trop2 molecules are released from the cell on the surface 
of exosomes, probably together with ADAMs (Stoeck et al. 2006) (Figure 5.3.2). 
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6. Conclusion and future experiments 
6.1 Summary of the results 
The results presented in my thesis demonstrate for the first time that Trop2 cleavage can be 
stimulated through two different pathways. One pathway is activated by PMA and induces 
ADAM17 mediated cleavage of Trop2 close to the plasma membrane, leading to release and 
dimerization of extracellular Trop2-ECD molecules. I also showed that the phorbol ester 
triggers budding and release of full length Trop2 containing ectosomes, directly from the 
cell surface and that this process is used to exchange Trop2 molecules in between cells 
through vesicle transport. I further demonstrated that these two PMA mediated mechanisms 
are regulated by distinct members of the PKC family, Trop2 shedding by novel PKCs and 
ectosome discharge by classical PKCs. A second pathway is negatively regulated by atypical 
PKCζ and its activation leads to clathrin-dependent endocytosis of Trop2. Once internalized, 
Trop2 is sorted into the endocytic compartment, where it is N-terminally cleaved by either 
ADAM10 or ADAM17. The data showed that both cleavage fragments remained connected 
via internal disulphide bridges; and these alternatively cleaved Trop2 molecules are 
subsequently released from the cell on exosomes. In addition, I described that a 
phosphorylatable serine residue in the Trop2 cytoplasmic tail is involved in PMA-induced 
Trop2 shedding, but does not affect alternative Trop2 cleavage. 
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6.2 Conclusions 
Over the last decade, various studies have shown that Trop2 is a highly important molecule 
overexpressed in a variety of human cancers, conferring metastatic and invasive potential to 
tumor cells (reviewed by Cubas et al. 2009). The underlying mechanism was only recently 
described in a report that showed that regulated proteolysis of Trop2 drives epithelial 
hyperplasia and stem cell self-renewal, via β-catenin signaling (Stoyanova et al. 2012). 
However, the focus of the Stoyanova study focused on the intracellular release and nuclear 
translocation of Trop2-ICD/β-catenin complexes. The fate and function of Trop2-ECD on 
the other hand still remains largely unknown, although Stoyanova reported that recombinant 
Trop2-ECD was able to independently stimulate self-renewal and proliferation. Furthermore, 
their data suggested that soluble Trop2-ECD provides an auto- and paracrine activation 
signal for Trop2 shedding, similar to its homologue EpCAM (Maetzel et al. 2009). So, as it 
is undisputed that Trop2-ECD is involved in Trop2 signalling, the results raises the question 
about the nature of the extracellular fragments released. I showed that once released, Trop2-
ECD molecules dimerize (Figure 6.1A) in the extracellular space, which goes in accordance 
with another recent study describing dimerization of the Trop2 ectodomain in solution 
(Vidmar et al. 2013). Therefore, it would be interesting to know whether the effect observed 
by Stoyanova et al. was caused by Trop2-ECD monomers or dimers. Furthermore, the 
identification of a novel N-terminal Trop2 cleavage site indicates that Trop2-ECD molecules 
are not homogenous, but consist of different sized fragments with imaginably distinct 
functions in extracellular Trop2 signaling. Alternative cleavage of Trop2 generates two 
fragments which remain connected via internal disulphide bonds; and although it requires 
verification, it is easily conceivable that these molecules can be further cleaved close to the 
membrane. This could result in the release of a novel N-terminally cleaved Trop2-ECD 
species (Figure 6.1B), with different functions and the potential to dimerize. The results also 
suggest that two Trop2 aMP fragments can dimerize through re-arrangement of their 
disulphide bonds, which entails the loss of their N-terminus in form of Trop2 aECDs. 
Subsequent cleavage from the cell surface would then release a Trop2 TY-domain dimer 
molecule (Figure 6.1B), that might have different properties than untruncated Trop2-ECD 
dimers. However, it is also imaginable that alternatively processed Trop2 is firstly reduced 
and then cleaved by ADAM17 from the cell surface generating a Trop2 TY-domain 
monomer (Figure 6.1B). Taken together, it seems that extracellular Trop2 signaling is far 
more complex than assumed and that its regulation might occur through generation of 
multiple and differently sized Trop2-ECD molecules with potentially distinct functions. This 
is interesting, as I observed alternative Trop2 shedding in androgen-independent PC3 cells, 
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representing a more aggressive form of prostate cancer. Androgen-sensitive LNCaP cells on 
the other hand, were negative for the Trop2 aMP fragment. This invites speculation about a 
tumor promoting role of N-terminal Trop2 cleavage, especially as the mechanism is 
negatively regulated by PKCζ which has been shown to act as a tumor suppressor in prostate 
cancer (Powell, Gschwend, et al. 1996; Sánchez et al. 2008; Young et al. 2013). As it was 
already reported that recombinant Trop2-ECD can stimulate self-renewal and proliferation, 
it is not far-fetched to say that alternative Trop2 shedding might generate ECD fragments 
with properties that promote carcinogenesis. Alternatively generated Trop2-ECD molecules 
could, therefore, represent novel biological markers for more aggressive forms of prostate 
cancer and therefore, might allow the development of more precise diagnostic tools. For 
instance, specific antibodies could be used to validate the concentration of a particular 
Trop2-ECD fragment in serum or urine of patients, in order to determine disease 
progression.  
 
Figure 6.1: Schematic representation of known and hypothesized Trop2-ECD 
fragments generated by regular and alternative Trop2 cleavage 
(A) Regular Trop2 cleavage close to the membrane generates Trop2-ECD molecules which 
can dimerize in the extracellular space. (B) Alternative Trop2 cleavage generates two 
fragments which stay connected via internal disulphide bonds. These molecules might be 
further processed, leading to the release of N-terminally cleaved Trop2-ECD fragments or 
dimers. It is also possible, that re-arrangement or reduction of disulphide bindings releases 
N-terminal Trop2 aECD; and that subsequent processing generates Trop2 TY-domain 
monomers or dimers.  
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Full length Trop2 on microvesicles, likely ectosomes, was constitutively present in the 
medium of stably expressing HEK293 cells; and endocytosis inhibition resulted in strong 
accumulation of Trop2 containing vesicles. It has been shown that EpCAM (Rupp et al. 
2011), as well as cell adhesion molecule L1 and CD44 cleavage can occur on exosomes, 
conducted by ADAM10 in the latter cases (Stoeck et al. 2006). Therefore, it is likely that 
vesicle-bound Trop2 can be proteolytically processed as well. Hence, ectosomes may enable 
long distance transport of uncleaved Trop2 molecules, which could further be cleaved or act 
as ligands, thereby inducing downstream signalling events or interfering with cell-cell 
adhesions (Van Kilsdonk et al. 2010). Similar mechanisms are of course applicable to 
exosomes containing alternatively cleaved Trop2, although their function is likely to be 
different. Due to the observation that ectosomes and exosomes contain distinct Trop2 
molecules, one could hypothesize that the preferential release of either one of them could be 
linked to differential pathological phenotypes. As a consequence, qualitative and 
quantitative screening for Trop2 containing vesicles in body fluids might represent a novel 
diagnostic tool. One direct approach could be the extended analysis of urinary exosomes, 
which are already used to evaluate disease progression in prostate cancer patients, as they 
show higher exosome levels in their urine (Mitchell et al. 2009). I demonstrated that 
alternative Trop2 shedding is initiated by clathrin-mediated endocytosis; and that the actual 
cleavage event takes place in the endocytic compartment. Eventually, this leads to the 
release of exosomes containing N-terminally cleaved Trop2 fragments, which stay 
connected via internal disulphide bonds. Although the function of its exosomal release 
remains elusive, the Trop2 aMP fragment might represent a specific marker to look for in 
urinary exosomes of prostate cancer patients.  
However, the findings could not only lead to more sophisticated screening methods but to a 
better understanding of Trop2 regulation. It cannot be ruled out that there are even more 
Trop2 cleavage sites than the two described. So far, six different cleavage sites in the 
EpCAM ectodomain are known; and that all but one of the intermediate metalloproteinase 
products are further processed by intramembrane proteolysis (Schnell et al. 2013). The 
existence of five distinct cleavage sites within the EpCAM transmembrane domain allows 
the generation of a multitude of different ECD and ICD fragments, which might all vary in 
their individual function. The most famous example of competing RIP pathways is the 
processing of the amyloid precursor protein, where β-secretase and γ -secretase generates the 
Alzheimer’s disease causing amyloid β peptide, whereas cleavage by α-secretase ADAM10 
prevents its generation (Kuhn et al. 2010; Lichtenthaler et al. 2011). Therefore, it is possible 
that Trop2 is regulated in a similar manner and that differential processing generates not 
only various Trop2-ECDs, but also ICDs with different cancerogenous potential. However, 
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the high variety of potential fragments makes it unlikely that all of them promote 
tumourigenesis. Some of them could be involved in the regulation of Trop2 signalling in 
healthy tissue, i.e. during development and maintenance. So it is of utter importance to 
identify tumour promoting Trop2 cleavage events, in order to specifically target the involved 
pathways. 
Based on the data, I suggest atypical PKCζ as a potential therapeutic target, as it exclusively 
prevents N-terminal Trop2 cleavage with no other members of the PKC family involved. 
Under the assumption that downregulation or inactivation of PKCζ in prostate cancer results 
in increased alternative Trop2 processing, the effect might be reversed by activating PKCζ. 
It is worth mentioning that successful re-activation of PKCζ has already been shown to 
induce apoptosis in PC3 and LNCaP prostate cancer cell lines. Spisulosine, a novel anti-
cancer agent isolated from sea molluscs induced de novo synthesis of ceramides, which led 
to PKCζ activation and translocation to the membrane (Sánchez et al. 2008). Ceramides, 
which represent a subgroup of sphingolipids, have been long known to induce PKCζ 
activation (Galve-Roperh et al. 1997) and its recruitment to caveolin-enriched lipid 
microdomains (Fox et al. 2007). Therefore, stimulation of ceramide production might be a 
promising therapeutical approach in order to re-activate PKCζ and potentially block 
alternative processing of Trop2.   
I further showed that that mutation of Ser
303
 in the cytoplasmic tail of Trop2 had no effect on 
mPS-induced cleavage which showed convincingly that the particular serine residue has no 
role in alternative processing of Trop2. In contrast, PMA stimulated shedding was 
completely blocked, when I used a phosphor-mimicking aspartate mutant of Ser
303
. This is 
rather interesting, as one could expect that due to the PKC activating properties of the 
phorbol ester, phosphorylation of the serine residue might be a key signal to induce 
proteolytic processing of Trop2. Instead, Ser
303
 phosphorylation seems to protect Trop2 
against ADAM17 mediated cleavage close to the plasma membrane, which has been shown 
to drive self-renewal, proliferation and transformation of prostate tumour cells (Stoyanova et 
al. 2012). This demonstrates again that both pathways leading to differential Trop2 cleavage 
are regulated separately; and that this clear distinction can be utilized to specifically target 
either of them. The results indicate that Ser
303
 plays an important role in regular Trop2 
shedding and therefor the serine residue presents itself as a promising target to block Trop2 
processing and its associated promotion of tumourigenesis. Understanding the nature of this 
inhibitory mechanism and identification of potential interaction partners could help to 
develop strategies that aim for the specific deactivation of this process.  
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All in all, the data presented in this thesis showed for the first time that Trop2, a 
transmembrane protein expressed in normal prostate and prostate cancer cells is subject to 
differential proteolytic processing. Trop2 is shed by ADAM metalloproteinases at a cleavage 
site close to the cell surface or alternatively in its N-terminal domain somewhere in the 
region of the EGF-TY domain boundary. These two events are not only individually 
regulated, but which occur at different cellular locations. Regular Trop2 shedding takes 
place at the cell surface, can be stimulated by the phorbol ester PMA and is regulated by 
novel PKCs. On the other hand, atypical PKCζ negatively regulates Trop2 internalization 
and its subsequent alternative processing within the endocytic compartment. The 
identification of these separate pathways gives novel insight into Trop2 signalling, 
associated with prostate cancer and tumour aggressiveness. Consequently, further 
characterization and identification of the underlying mechanisms of Trop2 cleavage will 
eventually lead to the development of novel diagnostic and therapeutic approaches.  
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6.3 Future experiments 
To further investigate Trop2 shedding and its biological impact, I plan to perform 
experiments that help to achieve a deeper understanding of both pathways that lead to 
proteolytic processing of the peptide. However, I also want to verify previous experiments 
that were performed using inhibitory compounds, such as the involvement of ADAM17 in 
both pathways, as well as the role of ADAM10 in N-terminal cleavage of Trop2. These 
results should be reproducible with expression vectors of shRNA targeting both ADAMs. 
Another compound we used was Dynasore, an inhibitor against dynamin which is commonly 
used to block clathrin mediated endocytosis (Macia et al. 2006). However, there is growing 
evidence that dynamin-dependent and clathrin mediated endocytosis are not synonymous 
and it has been shown that some clathrin independent, dynamin-dependent endocytic 
pathways exist (Damke et al. 1995). As a consequence, it would be unnecessary to 
knockdown dynamin using short RNA oligonucleotides and more favorable to target another 
peptide with functions restricted to clathrin mediated endocytosis. One promising candidate 
is AP2, which is the second most abundant protein of clathrin-vesicles and has been shown 
to be crucial for clathrin-coated pit formation. An elegant approach is the “derouting” of 
AP2 to a location where it is not normally present. Robinson et al. described rapamycin-
induced heterodimerization as a fast way to relocate AP2 to mitochondria and effectively 
abolish clathrin mediated endocytosis (Robinson et al. 2010). Therefore, I might use this 
method to verify that Trop2 endocytosis is negatively regulated by PKCζ.  
Depending on the stimulus Trop2 is released on either exosomes or ectosomes. We want to 
find out more about their composition as the presence of ADAMs or small V5-tagged 
Trop2-ICD fragments might indicate that Trop2 is further processed on the vesicle surface. 
This could be tested by immunoaffinity-isolation of vesicle-bound ADAMs, followed by 
measurement of their proteolytic activity, as the feasibility of this method was already 
confirmed by showing ADAM10-mediated shedding of L1 and CD44 on exosomes (Stoeck 
et al. 2006). In addition, I plan to verify that PKCζ inhibition triggers exosomal Trop2 
release whereas PMA stimulation results in discharge of Trop2 containing ectosomes. Due 
to the fact that various ectosome or exosome associated marker proteins have been described 
(reviewed by Lee et al. 2011), I will use immunoblot detection to confirm the nature of the 
vesicles. In the previous chapter, I hypothesized the existence of soluble Trop2 aMP dimer 
molecules with a predicted size of 30 kDa (Chapter 6.3). Up to now, I only used low 
percentage gels to identify extracellular Trop2 species with a minimum size of ~40 kDa. In 
order to detect smaller Trop2 fragments, such as the potential soluble Trop2 aMP dimer, I 
will use high percentage gels in ofuture experiments. However, it has to be taken into 
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consideration that small Trop2-ECD molecules might lack epitopes that are required for the 
binding of the polyclonal Trop2 ectodomain antibody. To provide unambiguous 
identification of Trop2-ECD fragments, it could be useful to consider raising monoclonal 
antibodies that recognize specific motifs in the Trop2 ectodomain, such as the cysteine-free 
region close to the membrane or the region of the EGF-TY domain boundary.  
Another important future task is the identification of the Trop2 alternative cleavage site. In 
preliminary experiments, I tried to locate the cleavage site by N-terminal sequencing of the 
Trop2 aMP fragment (data not shown). Unfortunately, the Mass Spectroscopy results were 
inconclusive, most likely due to insufficient amounts of the fragment. In order to increase 
the yield, I plan to immunoprecipitate the V5-tagged Trop2 aMP fragment, to isolate enough 
protein for a successful Mass Spectroscopy analysis. Once I determined the actual cleavage 
site, the next step would be the creation of a Trop2 alternative cleavage site mutant. 
Investigating the effect of PKCζ inhibition on this mutant will be crucial to understand how 
regulation of this pathway works. For instance, it will be interesting to know whether the 
Trop2 cleavage site mutant is still endocytosed in response to mPS, or how the mutation 
affects regular Trop2 shedding close to the cell surface. Identification of the alternative 
cleavage site would further allow the generation of recombinant Trop2-aECD molecules and 
their testing for biological activity. This could reveal whether Trop2-aECD has different 
functions than Trop2-ECD and therefore, allow assessing the impact of alternative Trop2 
processing.  
It was recently shown that PKCζ represses prostate tumourigenesis through phosphorylation 
of c-myc (Y. J. Kim et al. 2013); and it is possible that this also leads to downstream 
deactivation of N-terminal Trop2 cleavage. To address the question of potential c-myc 
involvement in alternative Trop2 processing, I will test whether short RNA oligonucleotides 
targeted against c-myc are able to rescue full length Trop2 in response to PKCζ inhibition. 
Such an indirect regulation through PKCζ is supported by our findings that mutation of 
phosphorylatable Ser
303
 in the Trop2-ICD had no effect on N-terminal Trop2 cleavage. In 
contrast, the experiments with transiently transfected Trop2 Ser
303
 mutants demonstrated that 
the serine residue seems to be important for PMA-induced Trop2 shedding. Unfortunately, 
phorbol ester stimulation of Trop2 S303A turned out to be ambiguous as immunoblotting 
showed cleavage induction, whereas the increase of AP-Trop2 release in the AP shedding 
assay was insignificant. As this could be a result of low transfection efficiencies, I will 
create HEK293 cell lines stably expressing AP-Trop2 S303A and S303D.  With these cells, I 
will be able to confirm previous results and determine if AP-Trop2 S303A shedding can be 
induced by PMA.  
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Appendix I: Buffers & solutions 
Buffer Composition 
AP assay buffer  100 mM  Tris-HCl pH 9.5 
100 mM NaCl 
20 mM MgCl2 
Lysis buffer  50 mM  HEPES pH 7.5 
250 mM NaCl 
10 mM NEM 
2 mM EDTA 
100 µM benzamidine 
0.5 % Nonident P-40 
10 % (v/v) glycerol 
add freshly: 
1 mM sodium ortho-vanadate 
12.5 mM ortho-phenantroline 
1 x protease inhibitor cocktail 
TBS (Tris-buffered saline) pH 8.0 50 mM Tris-HCl 
150 mM NaCl 
Reducing sample buffer (2x) 65 mM Tris-HCl pH 6.8 
2 % SDS 
4 % glycerol 
0,01 % bromophenol blue 
5% β-mercaptoethanol 
Western blot transfer buffer 25 mM Tris 
190 mM glycine 
20 % methanol 
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TBS-T pH 8.0 TBS with 0.05% Tween-20 
Non-reducing sample buffer (2x) 65 mM Tris-HCl pH 6.8 
2 % SDS 
4 % glycerol 
0,01 % bromophenol blue 
Anode buffer 10x 1 M Tris-HCl pH 8.9 
Cathode buffer 10x 1 M Tris-HCl pH 8.9 
1 M Tricine 
1 % SDS 
Gel buffer 3x 3 M Tris-HCl pH 8.45 
0.3 % SDS 
Acrylamide-bisacrylamide (AB-3) solution 48 g acrylamide 
1.5 g bisacrylamide 
ECL solution A 0.1 M Tris-HCl pH 8.6 
50 mg Luminol 
ECL solution B 11 mg p-coumaric acid in DMSO 
Final ECL-solution 1 ml ECL solution A 
100 µl ECL solution B 
0.3 µl H2O2 (35 %) 
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Appendix II: Western blot antibodies 
Primary antibodies 
Antibody Working 
dilution 
Working 
concentration 
Manufacturer 
Mouse anti-V5 1:2000 50 ng/ml Invitrogen 
Mouse anti-GAPDH 1:2000 25 ng/ml Sigma-Aldrich 
Goat anti-Trop2 1:2000 50 ng/ml R&D 
Rabbit anti-ADAM9 1:2000 50 ng/ml Abcam 
Rabbit anti-ADAM15 1:2000 50 ng/ml Abcam 
Rabbit anti-ADAM17 1:2000 50 ng/ml Abcam 
Rabbit anti-HA 1:2000 50 ng/ml Sigma-Aldrich 
Mouse anti-PKCα 1:1000 25 ng/ml BD Bioscience 
Mouse anti-PKCβ 1:1000 25 ng/ml BD Bioscience 
Mouse anti-PKCγ 1:1000 25 ng/ml BD Bioscience 
Mouse anti-PKCδ 1:1000 25 ng/ml BD Bioscience 
Mouse anti-PKCε 1:1000 25 ng/ml BD Bioscience 
Mouse anti-PKCη 1:1000 25 ng/ml BD Bioscience 
Mouse anti-PKCθ 1:1000 25 ng/ml BD Bioscience 
Mouse anti-PKCι 1:1000 25 ng/ml BD Bioscience 
Rabbit anti-PKCζ 1:1000 25 ng/ml New England Biolabs 
Secondary antibodies 
Antibody 
Working 
dilution 
Working 
concentration 
Manufacturer 
Donkey anti-mouse-HRP 1:10.000 20 ng/ml Jackson ImmunoResearch 
Donkey anti-goat-HRP 1:10.000 20 ng/ml Jackson ImmunoResearch 
Donkey anti-rabbit-HRP 1:10.000 20 ng/ml Jackson ImmunoResearch 
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Appendix III: Overexpression plasmids 
Plasmid Protein tags 
ADAM9 overexpression plasmid non-tagged 
ADAM10 overexpression plasmid non-tagged 
ADAM12 overexpression plasmid V5-tagged 
ADAM17 overexpression plasmid Flag-tagged 
ADAM15b E/A overexpression plasmid V5-tagged 
Trop2 overexpression plasmid V5-tagged 
AP-Trop2 overexpression plasmid AP-tagged, V5-tagged 
Δ254-271 AP-Trop2 overexpression plasmid AP-tagged, V5-tagged 
Δ247-273 AP-Trop2 overexpression plasmid AP-tagged, V5-tagged 
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Appendix IV: Chemicals 
Chemical Manufacturer 
Acrylamide powder Geneflow Ltd., Staffordshire, UK 
Ammonium persulphate Sigma-Aldrich Ltd., Gillingham, UK 
Bis-acrylamide powder Geneflow Ltd., Staffordshire, UK 
Benzamidine Sigma-Aldrich Ltd., Gillingham, UK 
Bromphenol blue Sigma-Aldrich Ltd., Gillingham, UK 
BSA Promega, Southhampton, UK 
β-mercaptoethanol Sigma-Aldrich Ltd., Gillingham, UK 
Dimethylsulfoxide (DMSO) Sigma-Aldrich Ltd., Gillingham, UK 
Ethanol Fisher Scientific, Loughborough, UK 
Glycerol Fisher Scientific, Loughborough, UK 
Glycine Fisher Scientific, Loughborough, UK 
H2O2 Sigma-Aldrich Ltd., Gillingham, UK 
HCl Fisher Scientific, Loughborough, UK 
HEPES Fisher Scientific, Loughborough, UK 
Isopropanol Fisher Scientific, Loughborough, UK 
Luminol Sigma-Aldrich Ltd., Gillingham, UK 
Magnesium chloride Sigma-Aldrich Ltd., Gillingham, UK 
Methanol Fisher Scientific, Loughborough, UK 
N-ethylmaleimide (NEM) Sigma-Aldrich Ltd., Gillingham, UK 
Nonident P-40 Sigma-Aldrich Ltd., Gillingham, UK 
Ortho-phenantroline Sigma-Aldrich Ltd., Gillingham, UK 
p-coumaric acid Sigma-Aldrich Ltd., Gillingham, UK 
Paraformaldehyde Fisher Scientific, Loughborough, UK 
Protease inhibitor cocktail Roche Diagnostic Ltd. West Sussex, UK 
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Saponin from quillaja bark Sigma-Aldrich Ltd., Gillingham, UK 
Skimmed milk powder Milbona, Lidl, UK 
Sodium ortho-vanadate  Sigma-Aldrich Ltd., Gillingham, UK 
Sodium chloride Fisher Scientific, Loughborough, UK 
Sodium dodecyl sulphate Sigma-Aldrich Ltd., Gillingham, UK 
Tetramethylethylendiamine (TEMED) Sigma-Aldrich Ltd., Gillingham, UK 
Tricine Fisher Scientific, Loughborough, UK 
Tris Base  Fisher Scientific, Loughborough, UK 
Tris HCl Sigma-Aldrich Ltd., Gillingham, UK 
Tween-20 Sigma-Aldrich Ltd., Gillingham, UK 
Vectashield mounting medium Vector Laboratories, Burlingame, UK 
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Appendix V: Consumables & laboratory equipment 
Consumable Manufacturer 
Developer G153 Agfa, Mortsel, Belgium 
Fixer G354 Agfa, Mortsel, Belgium 
Cryo vials Greiner Bio-One Ltd. Stonehouse, UK 
Pipette tips (10, 100, 200, 1000 µl) Elkay Laboratory Products Ltd. Hampshire, UK 
Foams Bio-Rad Laboratories Ltd., Hertfordshire, UK 
Whatman filter paper Fisher Scientific, Loughborough, UK 
BLUeye prestained protein ladder Geneflow Ltd., Staffordshire, UK 
 
Equipment  Manufacturer  
Balance MXX-212 Denver Instrument GmbH, Göttingen, Germany 
Combs (1 or 1.5 mm) Bio-Rad Laboratories Ltd., Hertfordshire, UK 
Glass coverslips VWR International Inc., Chicago, USA 
Glass plates (1 or 1.5 mm) VWR International Inc., Chicago, USA 
Freezing container Nalgene Labware, Thermo Fisher Scientific, 
Basingstoke, UK 
Gel electrophoresis tank, Mini-proteanII Bio-Rad Laboratories Ltd., Hertfordshire, UK 
Incubator Binder GmbH, Tuttlingen, Germany 
Labofuge H100 R Heraeus Thermo Fisher Scientific, Basingstoke, UK 
Magnetic stirrer  Falc Instruments, Tremglio, Italy  
Microcentrifuge (Centrifuge 5415 R) Eppendorf UK Limited, Cambridge, UK 
Microscopy slides Carl Zeiss AG, Oberkochen, Germany 
Mini Trans-Blot cell  Bio-Rad Laboratories Ltd., Hertfordshire, UK 
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Neubauer counting chamber VWR International Inc., Chicago, USA 
OMEGA plate reader BMG Labtech, Offenburg, Germany 
Pipettes Starlab, Milton Keynes, UK and Gilson 
Scientific Ltd., Bedfordshire, UK 
Shaker plate (IKA-VIBRAX-VXR) IKA-Werke GmbH & Co KG, Staufen, 
Germany 
Pipette boy Integra Biosciences AG, Zizers, Switzerland 
Power supply (Power Pac HC) Bio-Rad Laboratories Ltd., Hertfordshire, UK 
Rotator plate (Luckham 802 suspension 
mixer) 
Luckham Ltd. Sussex, UK 
pH meter (pH209) Hanna Instruments 
Tweezers VWR International Inc., Chicago, USA 
X-ray hypercassettes  Amersham Bioscience, GE Healthcare Ltd., 
Buckinghamshire, UK 
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Supplement I: AP shedding assay data 
 
 
Figure S1: Analysis of AP-Trop2 shedding in response to different concentrations of 
IngM and EBC46  
AP-Trop2 expressing cells were stimulated with PKC activators IngM and EBC46 using 
concentrations in the range of 50-1000 ng/ml. PMA (100 ng/ml) was used as positive control 
and DMSO as solvent control. The highest increase in AP-Trop2 release was observed for 
(A) IngM at 100 ng/ml and for (B) EBC46 at 500 ng/ml. Histogram shows fold of increase 
compared to the negative control based on one experiment. 
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Supplement II: Western blots 
 
Figure S2: Identification of extracellular AP-Trop2, Trop2-ECD and Trop2-ECD 
Dimers after PMA and mPS stimulation 
Detection of extracellular Trop2 in the conditioned medium of PMA and mPS treated cells. 
The conditioned medium was collected and concentrated by using centrifugal filter units 
with a 3kDa cutoff. Samples were then analysed by ultracentrifugation to separate the 
released vesicles in the pellet fraction from soluble proteins. The samples were then 
analysed for AP-Trop2 and Trop2 fragments by immunoblotting. Western blot analysis of 
the medium was performed in reducing (A) and non-reducing (B) conditions. Full length 
AP-Trop2 and the Trop2 45 kDa aMP fragment were detected in starting medium and the 
pellet but not in the soluble fraction.  
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Figure S3: Immunoprecipitation of Trop2  
HEK293 cells stably expressing Trop2-V5 treated with PMA and mPS were lysed and 
subjected to immunoprecipitation (IP) with an anti-hTrop2 antibody followed by Western 
blotting using anti-hTrop2 and anti-V5 antibodies. Anti-IgG antibody was used as negative 
control. Immunoblots show the efficiency of the Trop2 immunoprecipitation. 
 
 
 
 
 
 
 
 
 
 
 231 
 
 
Figure S4: PMA and mPS stimulation does not induce classical PKC binding to Trop2 
HEK293 cells stably expressing Trop2-V5 were treated with PMA or mPS, subjected to 
immunoprecipitation (IP) with an anti-hTrop2 antibody followed by Western blotting to 
detect bound PKC isoforms using antibodies against classical PKCs. Anti-IgG antibody was 
used as negative control. Co-immunoprecipitation of PKC isoforms with Trop2 was not 
observed in either stimulated or control cell lysates. Respective blots show the input lysate 
and IP-lanes for Trop2 immunoprecipitation. Blots are stained for classical PKC isoforms: 
(A) PKCα, (B) PKCβ and (C) PKCγ.  
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Figure S5: PMA and mPS stimulation does not induce novel PKC binding to Trop2 
HEK293 cells stably expressing Trop2-V5 were treated with PMA or mPS, subjected to 
immunoprecipitation (IP) with an anti-hTrop2 antibody followed by Western blotting to 
detect bound PKC isoforms using antibodies against novel PKCs. Anti-IgG antibody was 
used as negative control. Co-immunoprecipitation of PKC isoforms with Trop2 was not 
observed in either stimulated or control cell lysates. Respective blots show the input lysate 
and IP-lanes for Trop2 immunoprecipitation. Blots are stained for novel isoforms: (A) 
PKCε, (B) PKCδ, (C) PKCη and (D) PKCθ. 
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Figure S6: PMA and mPS stimulation does not induce atypical PKC binding to Trop2 
HEK293 cells stably expressing Trop2-V5 were treated with PMA or mPS, subjected to 
immunoprecipitation (IP) with an anti-hTrop2 antibody followed by Western blotting to 
detect bound PKC isoforms using antibodies against atypical PKCs. Anti-IgG antibody was 
used as negative control. Co-immunoprecipitation of PKC isoforms with Trop2 was not 
observed in either stimulated or control cell lysates. Respective blots show the input lysate 
and IP-lanes for Trop2 immunoprecipitation. Blots are stained for atypical isoforms: (A) 
PKCι and (B) PKCζ. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
